Proteomic and metabolomic profiling in the stroke-prone spontaneously hypertensive rat and chromosome 2 congenic strains by Tsiropoulou, Sofia
Glasgow Theses Service 
http://theses.gla.ac.uk/ 
theses@gla.ac.uk 
 
 
 
 
 
Tsiropoulou, Sofia (2013) Proteomic and metabolomic profiling in the 
stroke-prone spontaneously hypertensive rat and chromosome 2 congenic 
strains. PhD thesis. 
 
 
http://theses.gla.ac.uk/5284/ 
 
 
 
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or 
study, without prior permission or charge 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the 
author, title, awarding institution and date of the thesis must be given 
 
Proteomic and Metabolomic Profiling in the 
Stroke-Prone Spontaneously Hypertensive Rat 
and Chromosome 2 Congenic Strains 
 
 
 
 
Thesis submitted for the degree of Doctor of Philosophy (Ph.D.) 
in the College of Medical, Veterinary and Life Sciences 
November 2013 
 
 
 
Sofia Tsiropoulou, M.Res. 
 
 
 
 
 
BHF Glasgow Cardiovascular Research Centre 
Institute of Cardiovascular and Medical Sciences 
College of Medical, Veterinary and Life Sciences 
University of Glasgow 
 
© S. Tsiropoulou 2013 
Sofia Tsiropoulou  2 
Declaration 
I declare that this thesis has been written entirely by myself and is a record of research 
performed by myself, unless otherwise acknowledged. Liquid chromatography / mass 
spectrometry was conducted by Mr William Mullen for the proteomics experiments and Dr. 
Karl Burgess for the metabolomics experiments. Processing of proteomics data on 
MaxQuant was conducted by Dr. David Sumpton. Collection of plasma and urine samples 
used for metabolomics screening was performed by researchers at the BHF/GCRC. Setting up 
of wire and pressure myographs, vessel mounting and normalisations for the myography 
experiments were done by Mrs Elisabeth Beattie. This work has not been submitted 
previously for a higher degree and was carried out under the supervision of Dr. Martin W. 
McBride, Professor Anna F. Dominiczak and Dr. Richard J. Burchmore.  
 
 
------------------------ 
Sofia Tsiropoulou 
 
 
Sofia Tsiropoulou  3 
Acknowledgements 
Firstly, I wish to acknowledge my supervisors, Dr. Martin W. McBride, Professor Anna F. 
Dominiczak and Dr. Richard J. Burchmore for their support and advice. In particular, I would 
like to thank Dr. McBride for his supervision and guidance over the past four years and 
during the production of this thesis. Thanks also to Dr. Delyth Graham, Dr. John D. McClure 
and Miss Elisabeth Beattie for their advice and technical assistance.  
I would like to express my appreciation to several people in the Glasgow Polyomics and the 
Beatson Institute for their help in the 'omics' studies. Prof. Reiner Breitling, for his vital input 
and constructive criticism. Dr. Andris Jankevics, not only for his constant assistance in the 
bioinformatic analyses, but also for our adventurous trips and bike-service sessions. Dr David 
Sumpton and Dr Sergio Lilla for their help in the proteomics analysis.   
A very big thank you to my closest friends for being there when their support was most 
needed. Dimi, thank you for the inspirational conversations over our daily coffee breaks. 
Aurelie and Guto, thank you for all your help and encouragement. Louise, Dashti and Scott, 
thank you for the great fun in and out of the office. My dearest Finola, I am extremely 
grateful to you for all your kindness and invaluable support and for putting up with me till 
the end of this task. 
Finally, I cannot express enough my gratitude towards my family, especially my parents, 
Aleka and Niko, for their un-wavering support and constant encouragement throughout my 
studies. I could not have achieved any of this without them. Μαμά, μπαμπά, σας ευχαριστώ 
που πιστέψατε σε μένα και πάντα στεκόσαστε πλάι μου σε κάθε μου προσπάθεια, έστω κι 
εξ αποστάσεως. 
Thank you 
Σας ευχαριστώ 
 
Funding for this project was provided by the Scottish Universities Life Sciences Alliance 
(SULSA). 
Sofia Tsiropoulou  4 
 Table of Contents 
DECLARATION ...........................................................................................................................................................2 
ACKNOWLEDGEMENTS ................................................................................................................................................3 
TABLE OF CONTENTS...................................................................................................................................................4 
LIST OF FIGURES ........................................................................................................................................................8 
LIST OF FIGURES ........................................................................................................................................................8 
LIST OF TABLES ........................................................................................................................................................12 
LIST OF ACCOMPANYING MATERIAL (CD) .....................................................................................................................13 
Chapter 3 - Urine, Plasma metabolomics ......................................................................................................13 
Chapter 5 - SILAC proteomics ........................................................................................................................13 
Chapter 6 - S1P stimulated VSMC metabolomics ..........................................................................................14 
ABBREVIATIONS, ACRONYMS & SYMBOLS.....................................................................................................................15 
THESIS SUMMARY ....................................................................................................................................................18 
1 INTRODUCTION......................................................................................................................................... 21 
1.1 CARDIOVASCULAR DISEASE ................................................................................................................................22 
1.1.1 Hypertension: Causality and Classification ........................................................................................22 
1.1.2  Essential Hypertension ......................................................................................................................23 
1.1.2.1 Genetic Regulation of EH........................................................................................................................... 23 
1.1.2.2 Salt-Sensitivity ........................................................................................................................................... 27 
1.2 BLOOD PRESSURE REGULATION..........................................................................................................................28 
1.2.1 Small Resistance Arteries in HTN........................................................................................................30 
1.2.1.1 Vascular Smooth Muscle and Remodelling in HTN.................................................................................... 30 
1.2.1.2 Vascular Endothelium and Endothelial Dysfunction in HTN ...................................................................... 32 
1.2.2 Treatments in HTN .............................................................................................................................36 
1.3 HTN IN RATS..................................................................................................................................................37 
1.3.1 Rat Models of HTN and Salt Disease ..................................................................................................37 
1.3.2 The Stroke-Prone Spontaneously Hypertensive Rat (SHRSP)..............................................................39 
1.3.3 Congenic Strains in Genetic Screenings..............................................................................................40 
1.3.4 Candidate Genes for BP Regulation and Salt Sensitivity in SHRSP .....................................................41 
1.3.4.1 Glutathione S-transferase Mu Type 1 (Gstm1) .......................................................................................... 41 
1.3.4.2 Sphingosine-1-Phosphate Receptor 1 (S1pr1) and Vascular Cell Adhesion Molecule (Vcam1) ................. 43 
1.4 SYSTEMS BIOLOGY ...........................................................................................................................................48 
1.4.1 Proteomics .........................................................................................................................................50 
1.4.1.1 Mass Spectrometry-Based Quantitative Proteomics................................................................................. 50 
1.4.1.2 Proteomics Instrumentation and Bioinformatic Analysis .......................................................................... 51 
1.4.2 Metabolomics.....................................................................................................................................53 
1.4.2.1 Metabolomics Analytical Platforms and Applications ............................................................................... 53 
1.4.2.2 Metabolomics Bioinformatic Analysis ....................................................................................................... 56 
1.5 AIMS.............................................................................................................................................................57 
Sofia Tsiropoulou  5 
2 MATERIALS AND METHODS ...................................................................................................................... 58 
2.1 MATERIALS ....................................................................................................................................................59 
2.1.1 Biological Material .............................................................................................................................59 
2.1.2 Reagents ............................................................................................................................................59 
2.1.3 Kits......................................................................................................................................................61 
2.1.4 Solutions & Media ..............................................................................................................................61 
2.1.5 Primary Antibodies.............................................................................................................................63 
2.1.6 Secondary Antibodies.........................................................................................................................65 
2.1.7 Software .............................................................................................................................................65 
2.2 GENERAL PRIMARY CELL CULTURE METHODS .......................................................................................................66 
2.2.1 Isolation of Mesenteric Primary Rat VSMCs.......................................................................................66 
2.2.2 Culture and Passage of Primary Rat VSMCs.......................................................................................66 
2.2.3 Cryo-preservation of Primary Rat VSMCs...........................................................................................67 
2.2.4 Characterisation of Mesenteric Primary Rat VSMCs ..........................................................................67 
2.2.5 S1P-stimulation of Mesenteric Primary Rat VSMCs ...........................................................................68 
2.2.6 SILAC Labelling of Mesenteric Primary Rat VSMCs ............................................................................68 
2.2.7 Preparation of Whole Cell Lysates .....................................................................................................69 
2.2.8 Compartmental Protein Extraction from Cells ...................................................................................69 
2.3 GENERAL PROTEIN METHODS ............................................................................................................................70 
2.3.1 Determination of Protein Concentration............................................................................................70 
2.3.2 SDS-PAGE ...........................................................................................................................................70 
2.3.3 Coomassie Staining / De-staining ......................................................................................................71 
2.3.4 In-gel Trypsin Digestion of Coomassie-stained proteins ....................................................................71 
2.3.5 Semi-dry Protein Transfer ..................................................................................................................72 
2.3.6 Western Immunoblotting...................................................................................................................72 
2.3.7 Membrane Re-probing .......................................................................................................................72 
2.4 IMMUNOHISTOCHEMISTRY ................................................................................................................................73 
2.5 EX-VIVO TECHNIQUES.......................................................................................................................................74 
2.5.1 Wire Myography ................................................................................................................................74 
2.5.2 Pressure Myography ..........................................................................................................................75 
2.6 PROTEOMIC PROFILING.....................................................................................................................................76 
2.6.1 Sample Preparation............................................................................................................................76 
2.6.2 Liquid Chromatography – Tandem Mass Spectrometry Analysis.......................................................77 
2.6.3 Proteomic Data Processing ................................................................................................................77 
2.7 METABOLOMIC PROFILING ................................................................................................................................80 
2.7.1 Sample Preparation............................................................................................................................80 
2.7.2 Hydrophilic Interaction Liquid Chromatography – Mass Spectrometry .............................................80 
2.7.3 Metabolomic Data Processing ...........................................................................................................81 
2.8 STATISTICAL ANALYSIS ......................................................................................................................................82 
Sofia Tsiropoulou  6 
3 EFFECTS OF SALT LOADING ON S1PR1 EXPRESSION AND SIGNALLING AND ON BP REGULATION IN SALT-
SENSITIVE RATS......................................................................................................................................... 84 
3.1 INTRODUCTION ...............................................................................................................................................85 
3.1.1 Aims....................................................................................................................................................87 
3.2 RESULTS ........................................................................................................................................................88 
3.2.1 S1PR1 expression in tissues from salt-loaded rats .............................................................................88 
3.2.1.1 S1PR1 renal expression in salt-loaded WKY, SHRSP and congenic strains................................................. 88 
3.2.1.2 S1PR1 vascular expression in salt-loaded WKY and SHRSP........................................................................ 90 
3.2.2 Urine and Plasma Metabolomics and Bioinformatics Analysis ..........................................................91 
3.2.2.1 Urine metabolomic profiling at baseline and upon salt-loading................................................................ 96 
3.2.2.2 Plasma metabolomic profiling at baseline and upon salt-loading ........................................................... 102 
3.3 DISCUSSION..................................................................................................................................................110 
4 FUNCTIONAL AND MOLECULAR CHARACTERISATION OF MESENTERIC RESISTANCE ARTERIES FROM WKY, 
SHRSP AND CHROMOSOME 2 CONGENIC STRAINS ................................................................................. 114 
4.1 INTRODUCTION .............................................................................................................................................115 
4.2 RESULTS ......................................................................................................................................................118 
4.2.1 Structural and mechanical properties of MRAs from WKY, SHRSP and 2a congenic strains............119 
4.2.2 Vascular reactivity and endothelial function of MRAs from WKY, SHRSP and 2a congenic strains .123 
4.2.3 Isolation of primary VSMCs from MRAs and culture establishment ................................................130 
4.2.4 S1P-Receptors expression in primary VSMCs from MRAs ................................................................131 
4.2.5 S1PR1 signalling in primary VSMCs from MRAs...............................................................................133 
4.3 DISCUSSION..................................................................................................................................................137 
5 PROTEOME PROFILING IN S1P-STIMULATED MESENTERIC PRIMARY VSMCS .......................................... 142 
5.1 INTRODUCTION .............................................................................................................................................144 
5.1.1 MS-based quantitative proteomics: SILAC .......................................................................................144 
5.1.2 Quantitative proteomics sample preparation and instrumentation ................................................145 
5.1.3 Proteomic data processing and analysis:  MaxQuant - Perseus.......................................................147 
5.1.4 Aims..................................................................................................................................................148 
5.2 RESULTS ......................................................................................................................................................149 
5.2.1 Proteomics and bioinformatics analysis...........................................................................................149 
5.2.2 Immunoblotting validation ..............................................................................................................167 
5.3 DISCUSSION..................................................................................................................................................170 
6 METABOLOME PROFILING IN S1P-STIMULATED MESENTERIC PRIMARY VSMCS ..................................... 176 
6.1 INTRODUCTION .............................................................................................................................................177 
6.1.1 Aims..................................................................................................................................................177 
6.2 RESULTS ......................................................................................................................................................179 
6.2.1 Metabolic differences across strains at basal conditions.................................................................183 
6.2.2 Metabolic differences across strains upon S1P-stimulation.............................................................187 
Sofia Tsiropoulou  7 
6.2.3 Metabolic effects of S1P-stimulation within strains.........................................................................191 
6.3 DISCUSSION..................................................................................................................................................196 
7 GENERAL DISCUSSION............................................................................................................................. 200 
8 REFERENCES............................................................................................................................................ 211 
 
 
 
Sofia Tsiropoulou  8 
List of Figures 
Figure 1-1 - Systolic and diastolic blood pressures in the vascular system..............................29 
Figure 1-2 - Vascular remodelling.............................................................................................31 
Figure 1-3 - Endothelium-mediated contraction and relaxation in the smooth muscle..........33 
Figure 1-4 - Phylogenetic tree of inbred experimental rat models used in studies of complex 
human diseases, including hypertension, diabetes and insulin resistance..............................38 
Figure 1-5 - Identification of congenic interval and candidate genes for salt sensitivity and BP 
regulation..................................................................................................................................42 
Figure 1-6 - Overview of signalling pathways of S1P receptors (S1PR) and regulated cellular 
responses. .................................................................................................................................44 
Figure 1-7 - Differential renal expression of S1pr1 and Vcam1 candidate genes, and altered 
vascular S1P/S1PR1 signalling, in hypertension.. .....................................................................46 
Figure 1-8 - Transcriptional networks of S1pr1 and Vcam1 positional candidate genes.........47 
Figure 1-9 - The 'omics' information universe..........................................................................49 
Figure 1-10 – Quantitative shotgun proteomics. .....................................................................52 
Figure 1-11 – Metabolite diversity ...........................................................................................54 
Figure 2-1. Myography systems................................................................................................75 
Figure 2-2 - SILAC proteome profiling of parental and congenic primary S1P-stimulated 
VSMC.........................................................................................................................................79 
Figure 2-3 - Metabolomic analysis: sample processing and MS data analysis pipeline...........82 
Figure 2-4 - IPA annotations. ....................................................................................................83 
Figure 3-1 - Chromosome 2 congenic and transgenic strains generated by WKY (donor) and 
SHRSP (recipient) mating ..........................................................................................................86 
Figure 3-2 - Metabolomics analysis of urine and plasma from parental, SW2k-congenic and 
Gstm1-transgenic rats...............................................................................................................87 
Figure 3-3 - Characterisation of S1PR1 expression in kidney (medulla and cortex) from 21 
week-old, salt-loaded WKY and SHRSP rats, by IHC .................................................................88 
Figure 3-4 - S1PR1 expression in protein enriched, cellular compartments of whole kidney 
homogenate, from 21 week-old, salt-loaded parental and SW2a and SW2k congenic strains
..................................................................................................................................................89 
Figure 3-5 - Characterisation of S1PR1 expression in thoracic aorta from 21 week-old, salt-
loaded WKY and SHRSP rats, by IHC .........................................................................................90 
Sofia Tsiropoulou  9 
Figure 3-6 - Orbitrap Exactive MS-data filtering and visualisation on IDEOM v18 ..................92 
Figure 3-7 - Comparisons of interest between WKY, SHRSP, SW2k congenic and Gstm1-
transgenic strains, at baseline and salt-loading, in plasma and urine......................................94 
Figure 3-8 - Comparisons of interest across baseline and salt-loaded conditions in plasma and 
urine from WKY, SHRSP, SW2k congenic and Gstm1-transgenic strains .................................95 
Figure 3-9 - Ingenuity Pathway Analysis (IPA) network associating urine N-acetyl-L-cysteine 
with GSTM1 and GSTM5 (glutathione S-transferase mu 1/5)..................................................98 
Figure 3-10 - IPA network of urine metabolites significantly changing in the salt-sensitive 
versus the salt-resistant strains, upon salt-loading............................................................... 100 
Figure 3-11 - PeakML chromatograms of metabolites of interest identified in urine 
comparisons across WKY, SHRSP, SW2k and Gstm-1 transgenic strains, at baseline or salt-
loaded conditions .................................................................................................................. 101 
Figure 3-12 - IPA network associating plasma metabolites, which significantly change at 
baseline in SHRSP versus WKY, SW2k and Gstm1-transgenic, with GSTM1 and GSTM5...... 104 
Figure 3-13 - 'Disease and function' analysis on IPA for significantly changing metabolites 
upon salt-loading, in salt-sensitive strains............................................................................. 108 
Figure 3-14 - PeakML chromatograms of metabolites of interest identified in plasma 
comparisons across WKY, SHRSP, SW2k and Gstm-1 transgenic strains, at baseline or salt-
loaded conditions. ................................................................................................................. 109 
Figure 4-1 - Chromosome 2 reciprocal congenic strains generated by WKY and SHRSP  
mating. ................................................................................................................................... 118 
Figure 4-2 - Comparison of structural properties of MRAs from 16 week old parental WKY 
and SHRSP and congenic WKY.SPGla2a and SP.WKYGla2a strains ........................................... 120 
Figure 4-3 - Comparison of mechanical parameters of MRAs from 16 week old parental WKY 
and SHRSP and congenic WKY.SPGla2a and SP.WKYGla2a strains. ...................................... 122 
Figure 4-4 - Contractile responses to noradrenaline (NA) in MRAs from 16 week old parental 
WKY and SHRSP and congenic WKY.SPGla2a and SP.WKYGla2a strains................................... 125 
Figure 4-5 - Endothelium-dependent relaxation to carbachol, in fully (100%) pre-contracted 
MRAs with noradrenaline, from 16 week old parental WKY and SHRSP and congenic 
WKY.SPGla2a and SP.WKYGla2a strains.................................................................................... 126 
Figure 4-6 - Endothelium-dependent vasodilatation responses to carbachol, in 80% NA pre-
contracted MRAs from 16 weeks old parental WKY and SHRSP and congenic WKY.SPGla2a and 
SP.WKYGla2a strains................................................................................................................ 128 
Sofia Tsiropoulou  10 
Figure 4-7 - Endothelium-independent vasodilatation responses to the external nitric oxide 
donor, sodium nitroprusside (SNP) in noradrenaline pre-contracted (80%) MRAs.............. 129 
Figure 4-8 - Characterisation of mesenteric VSMC cultures from 16 week old rats, by 
immunocytochemistry........................................................................................................... 130 
Figure 4-9 - S1P-Receptors expression in whole cell lysates of primary VSMCs from 16 week 
old WKY, SHRSP and 2a congenic strains............................................................................... 132 
Figure 4-10 - Effect of S1PR1 receptor stimulation and antagonism on S1P-induced SAPK/JNK 
phosphorylation in VSMCs from WKY, SHRSP and the 2a congenics. ................................... 134 
Figure 4-11 - Effect of S1PR1 receptor stimulation and antagonism on S1P-induced p38MAPK 
phosphorylation in VSMCs from WKY, SHRSP and the 2a congenics. ................................... 135 
Figure 4-12 - Effect of S1PR1 receptor stimulation and antagonism on S1P-induced ERK 1/2 
phosphorylation in VSMCs from WKY, SHRSP and the 2a congenics.................................... 136 
Figure 5-1 - Stable isotope labelling by amino acids in cell culture (SILAC) .......................... 146 
Figure 5-2 – Proteomics analysis pipeline. ............................................................................ 150 
Figure 5-3 - List of phosphorylated proteins identified at 95% probability, or higher, in 
Scaffold3 proteome software ................................................................................................ 151 
Figure 5-4 - Distribution histograms of all proteins quantified per comparison in experiments 
A and B ................................................................................................................................... 152 
Figure 5-5 – Quantitative scatterplots of all proteins quantified per comparison in 
experiments A and B.............................................................................................................. 154 
Figure 5-6 - Software and version comparison...................................................................... 155 
Figure 5-7 - Bioinformatics analysis of data produced on MaxQuant v1.2.2.6..................... 157 
Figure 5-8 - Correlation analysis in IPA.................................................................................. 160 
Figure 5-9 - Schematic representation of RhoA signalling and mapping of differentially 
expressed proteins identified in SHRSP vs WKY (H/L) comparison ....................................... 163 
Figure 5-10 - Schematic representation of top canonical pathways of caveolin-1 (CAV1)... 164 
Figure 5-11 - Schematic representation of sphingosine-1 phosphate (S1P) signalling and 
mapping of differentially expressed proteins identified in SHRSP vs WKY (H/L) comparison
............................................................................................................................................... 166 
Figure 5-12 - Western blot analysis of selected proteins identified in the SILAC study ....... 169 
Figure 6-1 - Metabolomics analysis in S1P-stimulated mesenteric primary VSMCs isolated 
from 16-week-old WKY, SHRSP and SP.WKYGla2a-congenic strains ...................................... 178 
Figure 6-2 - Orbitrap Exactive MS-data filtering and visualisation on IDEOM v18 ............... 180 
Sofia Tsiropoulou  11 
Figure 6-3 - Comparisons of interest across WKY, SHRSP and SW2a-congenic strains, under 
control and S1P-treated conditions....................................................................................... 182 
Figure 6-4 - Levels of significantly changing metabolites in the comparisons across WKY, 
SHRSP and SW2a, at basal conditions (vehicle)..................................................................... 185 
Figure 6-5 - Ingenuity Pathway Analysis (IPA) network of metabolic changes in SHRSP versus 
WKY and SW2a, in VSMCs under basal conditions................................................................ 186 
Figure 6-6 - Levels of significantly changing metabolites in the comparisons across S1P-
stimulated VSMCs from WKY, SHRSP and SW2a. .................................................................. 189 
Figure 6-7 - IPA comparison of S1P-network across S1P-stimulated VSMCs from SHRSP, WKY 
and SW2a ............................................................................................................................... 190 
Figure 6-8 - Levels of significantly changing metabolites upon S1P-stimulation of the three 
strains, illustrated as peakML chromatograms ..................................................................... 194 
Figure 6-9 - Metabolic changes induced by S1P-stimulation of VSMCs in SHRSP, WKY and 
SW2a and mapping to S1P-network. ..................................................................................... 195 
Figure 7-1 - Data integration across the various layers of information ................................ 208 
Sofia Tsiropoulou  12 
List of Tables 
Table 1-1. Mendelian / monogenic forms of hypertension. ............................................... 24 
Table 1-2. Genetic loci associated with BP and/or hypertension identified in genome-wide 
association studies (GWAS).......................................................................................... 26 
Table 2-1. List of primary antibodies used in the experiments........................................... 63 
Table 2-2. List of secondary antibodies used in the experiments....................................... 65 
Table 3-1. Subset of the 41 'in common' urine metabolites exhibiting consistent, significant 
change across the comparisons of SHRSP versus WKY, SW2k and Gstm1-transgenic, at 
baseline. ....................................................................................................................... 97 
Table 3-2. Subset of the 21 'in common' urine metabolites exhibiting significant change 
across the comparisons of SHRSP and Gstm1-transgenic versus WKY and SW2k, under 
salt loading. .................................................................................................................. 99 
Table 3-3. Subset of the 19 'in common' plasma metabolites exhibiting significant change in 
SHRSP compared to WKY, SW2k and Gstm1-transgenic, at baseline. ....................... 103 
Table 3-4. Subset of the 44 'in common' plasma metabolites exhibiting significant change 
across the comparisons of SHRSP and Gstm1-transgenic versus WKY and SW2k, under 
salt loading. ................................................................................................................ 106 
Table 3-5. Subset of the plasma metabolites exhibiting significant change in SHRSP and 
Gstm1-transgenic or in the transgenic alone (unique), upon salt-loading. ............... 107 
Table 4-1. Morphometric parameters of pressurised MRAs. ........................................... 119 
Table 4-2. Mechanical parameters of pressurised MRAs.................................................. 121 
Table 4-3. Contractile responses to noradrenalin in untreated and fasudil-treated MRAs.
.................................................................................................................................... 124 
Table 4-4. Relaxation responses of MRAs ......................................................................... 127 
Table 5-1. Differentially expressed proteins in SHRSP vs WKY (H/L) comparison, ‘common’ 
across experiments A and B, encoded by genes mapping to rat chromosome 2...... 158 
Table 5-2. List of highly regulated proteins identified on IPA to be related to processes and 
pathways implicated in hypertension. ....................................................................... 162 
Table 5-3. List of proteins selected for immunoblotting validation.................................. 168 
Table 6-1. Subset of metabolites exhibiting significant change in the comparisons across 
WKY, SHRSP and SW2a, under basal conditions. ....................................................... 184 
Table 6-2. Subset of metabolites exhibiting significant change in comparisons across S1P-
stimulated VSMCs from WKY, SHRSP and SW2a........................................................ 188 
Table 6-3. Subsets of metabolites exhibiting significant change upon S1P-stimulation in 
VSMCs from WKY, SHRSP and SW2a.......................................................................... 192 
Sofia Tsiropoulou  13 
List of Accompanying Material (CD) 
The list-level of the contents represents the folders, subfolders and documents 
included in the supplemented hard copy (CD). 
Chapter 3 - Urine / Plasma metabolomics 
• Plasma 
o Baseline 
 Plasma_base_IC3_19_IPA 
 IDEOM_v18_Plasma_POSNEG__baseline_comparions 
o Salt 
 Plasma_salt_IC4_44_IPA 
 IDEOM_v18_plasma_POSNEG_salt_comparisons 
o Salt_v_Baseline 
 Plasma_salt_v_base_SHRSP_IC_Trans_(13)+Trans unique_(28)_IPA 
 IDEOM_v18_plasma_POSNEG_salt_v_baseline_comparisons 
• Urine 
o Baseline 
 Urine_base_IC3_41_IPA 
 IDEOM_v18_urine_POSNEG_baseline_comparisons 
o Salt 
 Urine_salt_IC4_21_IPA 
 IDEOM_v18_urine_POSNEG_salt_comparisons 
o Salt_v_Baseline 
 IDEOM_v18_urine_POSNEG_salt_v_baseline_comparisons 
Chapter 5 - SILAC proteomics 
• MaxQuant Parameters Summary 
• Common_HLA_HLB_1056 
• Common_HLA_HLB_Fold change significant_203 
• HLA_analysis ready_340 
• HLB_analysis ready_289 
• PerseusDataTable_Expanded_MajorityIDs_1998 
Sofia Tsiropoulou  14 
Chapter 6 - S1P stimulated VSMC metabolomics 
• S1P_v_vehicle_comparisons 
• S1P comparisons 
• vehicle comparisons 
 
  
Sofia Tsiropoulou  15 
Abbreviations, Acronyms & Symbols 
  Intersection 
~   Approximately 
˚C  Degrees Celcius   
µ   Micro (prefix) 
ACTA2   Alpha Smooth Muscle Actin 2 
ADP    Adenosine Diphosphate 
ANP   Atrial Natriuretic Peptide 
ATP   Adenosine Triphosphate 
AngII  Angiotensin II  
ANOVA   Analysis of Variance  
APS   Ammonium Persulphate 
AQP2    Aquaporin 2 
ATP   Adenosine Triphosphate 
BCA   Bicinchoninic Acid 
BP   Blood Pressure 
BSA   Bovine Serum Albumin 
CAD    Coronary Artery Disease 
Chr   Chromosome 
CO   Cardiac Output 
cAMP   Cyclic AMP 
CVD    Cardiovascular Disease 
DAB   Diaminobenzidine Tetrahydrochloride 
DAPI   4'-6-Diamidino-2-Phenylindol 
DMEM    Dulbecco’s Modified Eagle’s Medium 
DMSO    Dimethyl Sulphoxide 
DTT   Dithiothreitol 
EC    Endothelial Cell 
ECL    Enhanced Chemiluminescence 
ECM   Extracellular Matrix 
EDG    Endothelial Differentiation Gene 
EDHF  Endothelium-Derived Hyperpolarisation Factor 
EDRF  Endothelium-Derived Relaxation Factor 
EDTA   Ethylene Diamine Tetra-Acetic Acid 
EGTA  Ethylene Glycol Tetra-Acetic Acid 
eNOS   Endothelial Nitric Oxide Synthase 
ERK   Extracellular Signal-Regulated Kinase 
ESI   Electrospray Ionisation 
ET-1  Endothelin I 
FCS   Fetal Calf Serum 
FITC   Fluorescein Isothiocyanate 
g   Gram(s) 
Sofia Tsiropoulou  16 
g   Gravitational force 
GAPDH    Glyceraldehyde 3-Phosphate Dehydrogenase  
GPCR    G-protein-Coupled Receptor 
GRK   G-protein-Coupled Receptor Kinase 
GSTM1  Glutathione S-Transferase Mu 1 
GTP     Guanosine Triphosphate 
GWAS  Genome Wide Assossiation Studies 
dH2O   Distilled Water 
h   Hours 
H2O2    Hydrogen Peroxide 
HEPES    4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid 
HILIC   Hydrophilic Interaction Liquid Chromatography 
HRP   Horseradish Peroxidase 
HTN   Hypertension 
ICC  Immunocytochemistry 
IF  Immunofluorescence 
IgG   Immunoglobulin G 
IHC   Immunohistochemistry 
IP   Immunoprecipitation 
IPA   Ingenuity Pathway Analysis 
IPI  International Protein Index 
kDa  Kilodalton(s) 
KEGG  Kyoto Encyclopedia of Genes and Genomes 
L   Litre(s) 
LC  Liquid Chromatography 
L-NAME  N-Nitro-L-Arginine Methyl Ester 
m   Milli (prefix) 
M   Molar(s) 
mA  Milliamp(s) 
MAPK     Mitogen-Activated Protein Kinase 
min   Minute(s) 
ml   Millilitre(s) 
mmHg  Millimetres of Mercury 
MLC   Myosin Light Chan 
MLCK   Myosin Light Chain Kinase 
MRA  Mesenteric Resistance Artery 
MS   Mass Spectrometry 
n   Nano (prefix) 
NO   Nitric Oxide 
OD   Optical Density 
PBS    Phosphate-Buffered Saline 
PCA   Principal Component Analysis 
PDGF   Platelet Derived Growth Factor 
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PGI2  Prostacyclin 
Pen/strep   Penicillin / Streptomycin 
PFA    Paraformaldehyde 
Pi   Inorganic Phosphate 
PI3K    Phosphatidylinositol 3-Kinase 
PKC  Protein Kinase C 
PMSF   Phenylmethylsulphonyl Fluoride 
PTM  Post Translational Modifications 
QTL   Quantitative Trait Loci 
QC  Quality Control 
rcf   Relative Centrifugal Force  
RhoA   Ras Homolog Gene Family, Member A 
Rock   Rho Kinase 
ROS  Reactive Oxygen Species 
PRLC   Reverse Phase Liquid Chromatography 
rpm    Revolutions per Minute 
RT   Retention Time 
r.t   room temperature 
SAPK / JNK  Stress-Activated Protein Kinase / c-Jun N-Terminal Kinase 
S1P   Sphingosine-1-Phosphate 
S1PR1 / S1P1  Sphingosine-1-Phosphate Receptor 
SBP   Systolic Blood Pressure 
SDS     Sodium Dodecyl Sulphate 
SDS-PAGE   Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
SEM    Standard Error of the Mean 
SHR   Spontaneously Hypertensive Rat 
SHRSP    Stroke-Prone Spontaneously Hypertensive Rat 
SP  Short for SHRSP  
SW2a  SP.WKYGla2a Congenic Strain 
SW2k  SP.WKYGla2k Congenic Strain 
TBS   Tris - Buffered Saline 
TBST   0.1% Tween-20 in TBS 
TPR   Total Peripheral Resistance 
v (vs)  Versus 
v/v   Units volume per unit volume 
VCAM-1    Vascular Cell Adhesion Molecule-1 
VEGF   Vascular Endothelial Growth Factror 
VSMC    Vascular Smooth Muscle Cell 
w/v  Units weight per unit weight 
WB   Western Blot 
WHO  World Health Organisation 
WKY   Wistar Kyoto  
WS2a  WKY.SPGla2a Congenic Stain 
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Thesis Summary 
Essential hypertension (EH) is considered one of the major contributors to the present 
pandemic of cardiovascular disease (CVD). EH has a largely obscure aetiology, which lies 
upon both environmental risk factors and underlying genetic traits. The stroke-prone 
spontaneously hypertensive rat (SHRSP) is an excellent model of human EH and exhibits salt 
sensitivity. Two quantitative trait loci (QTL) for blood pressure (BP) regulation have been 
identified on rat chromosome 2 (chr.2). On this basis, previous work in our laboratory 
focused on construction of chr.2 congenic strains, on both the SHRSP and Wistar-Kyoto 
(WKY) genetic backgrounds. In combination with microarray gene expression profiling in 
kidney from salt-loaded rats, two positional candidate genes for salt-sensitive hypertension 
were identified. Sphingosine-1-phosphate receptor 1 (S1pr1) and vascular adhesion 
molecule (Vcam1) lie on the chr.2 congenic interval implicated in salt-sensitivity. 
Additionally, studies on vascular smooth muscle cells (VSMC) demonstrated enhanced 
S1PR1-mediated sphingosine signalling in SHRSP compared to WKY. Finally, glutathione S-
transferase mu 1 (Gstm1) was identified as another chr.2 candidate gene for BP regulation, 
lying outside the region implicated in salt-sensitivity.  
This project attempts to comprehensively investigate the potential role of altered 
S1PR1 signalling in BP regulation and salt-sensitivity, through comparative proteomic and 
metabolomic profiling in WKY, SHRSP and chromosome 2 congenic and transgenic stains 
(WKY.SPGla2a, SP.WKYGla2a, SP.WKYGla2k and Gstm1-transgenic).  
Characterisation of S1PR1 expression in renal and vascular tissue from 21 week-old 
salt-loaded rats, demonstrated below detection protein levels across parental and congenic 
strains. To further investigate the effect of the congenic interval and Gstm1 on salt-
sensitivity and BP regulation and identify putative biomarkers, high-throughput metabolomic 
screening of urine and plasma was conducted in parental, SP.WKYGla2k congenic and Gstm1-
transgenic strains, on a normal-salt and high-salt diet. In both urine and plasma, salt-loading 
affected processes implicated in CVD, including inflammatory response, free radical 
scavenging and lipid metabolism. In urine, oleic acid, implicated in regulation of renin levels, 
was increased in the SHRSP and transgenic salt-sensitive strains compared to the WKY and 
2k congenic salt-resistant strains, upon salt-loading. In plasma, known biomarkers of CVD 
were altered in SHRSP compared to the other three strains, at normal-salt, including L-
proline and linoleic acid. Upon salt-loading, glutathione disulfide and sphingosine-1-
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phosphate (S1P) were identified in high levels in the salt-sensitive strains. However, at 
normal-salt S1P was decreased in SHRSP compared to WKY and 2k congenic strains. 
Therefore, characterisation of the impact of S1P/S1PR1 signalling in the vasculature across 
the different strains was further investigated.  
 Initially, structure, mechanical properties and vascular reactivity of mesenteric 
resistance arteries (MRA) were studied in 16 week-old parental and reciprocal 2a congenic 
strains (WKY.SPGla2a and SP.WKYGla2a). There was no significant remodelling observed across 
the strains. However, SHRSP vessels were stiffer and this phenotype was under the control 
of the congenic segment. SHRSP exhibited hypercontractility, which was mediated by 
RhoA/Rock signalling pathway and was corrected by the transfer of the congenic interval in 
SP.WKYGla2a. SHRSP also displayed endothelial dysfunction, which was related to reduced 
nitric oxide (NO) bioavailability and was not improved by the congenic interval. The 
predominant regulatory mechanisms of contraction and relaxation in MRAs from WKY and 
WKY.SPGla2a were demonstrated to be different compared to SHRSP.  
Subsequently, representation of these physiological differences in MRAs, at the 
molecular level, was investigated along with the effect of S1P-signalling in HTN. 
Comprehensive, high-throughput proteome profiling of S1P-stimulated primary mesenteric 
VSMCs from parental and 2a-reciprocal congenic strains, was achieved through triple stable 
isotope labelling (SILAC), LC-MS/MS analysis and MaxQuant quantification. Detection of few 
abundant phosphorylated proteins was attributed to lack of enrichment for 
phosphoproteome. Therefore, focus was placed on proteins whose differential expression 
between SHRSP and WKY was genetically regulated. These proteins mapped to pathways 
implicated in BP-regulation, including oxidative stress, vascular tone regulation and vascular 
remodelling. Glutathione S-transferase mu 1 (GSTM1) was upregulated in SHRSP, as opposed 
to down-regulated NAD(P)H oxidase quinone 1 (NQO1) and heme oxygenase 1 (HMOX1), 
suggesting different antioxidant mechanisms in health and disease. Natriuretic peptide 
receptor C (NPR3) which is implicated in vascular relaxation was increased in SHRSP, along 
with activators of RhoA contractile mechanism, such as caveolin1 (CAV1). Furthermore, 
RhoA/Rock signalling pathway was highly altered in SHRSP. Finally, differentially expressed 
proteins were related to sphingosine signalling, including superoxide dismutase 2 (SOD2) 
and collagen type III, alpha 1 (COL3A1). 
To further investigate the metabolic effect of sphingosine signalling across the strains, 
and assess the contribution of the congenic interval, metabolomic profiling of primary 
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mesenteric VSMCs from parental and SP.WKYGla2a congenic strains, was performed at basal 
conditions and upon S1P-stimulation. A labelling-free, untargeted approach was employed, 
using HILIC-MS analysis and data processing through IDEOM. The effect of the congenic 
interval on the metabolic profile of SP.WKYGla2a was more profound under basal conditions. 
S1P-stimulation induced greater responses in SHRSP than WKY, indicating altered signalling. 
Furthermore the responses were different in each strain, suggesting a combined effect of 
the genetic background and the congenic interval on S1P signalling regulation. Inosine, 
which is implicated in purine metabolism, was significantly decreased in SHRSP compared to 
SP.WKYGla2a, at basal conditions, but was increased upon-S1P stimulation, implying that this 
S1P effect depends on the congenic interval. Moreover, tyramine, which has vasodilatory 
properties, was increased in stimulated SHRSP compared to basal conditions, indicating 
potential relation of sphingosine signalling with BP-regulation.  
This study has combined high-throughput proteomic and metabolomic screenings with 
congenic and transgenic strains to capture a clearer picture of the pathophysiological 
processes that underlie HTN in SHRSP. Individual metabolites and proteins or pathways and 
processes identified to be altered in HTN, through this work, can be used for generation of 
new testable hypothesis towards the development of new therapeutic approaches against 
HTN. 
1 Introduction 
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1.1 Cardiovascular Disease 
 Cardiovascular disease (CVD) refers to a class of disorders associated with the heart 
and vascular system, including coronary artery disease (CAD), cerebrovascular disease, 
hypertension, peripheral vascular disease, heart and renal failure. In the modern world, it 
represents a major cause of morbidity and mortality. In 2008, CVD was the leading cause of 
deaths attributed to non-communicable diseases (NCD), accounting for 17.3 million deaths 
or approximately 47% of the NCD deaths, according to the World Health Organisation (WHO, 
2012). The rapid rise in the mortality of CVD over the last decades can be attributed 
primarily to modifiable environmental risk factors, such as poor diet, tobacco use and 
physical inactivity (Yusuf et al., 2001). However, CVD is also known to have a large heritable 
component, classifying it as a complex and multifactorial disease (Kathiresan and Srivastava, 
2012). 
Hypertension (HTN) is considered one of the major contributors to the present 
pandemic of CVD (Levenson et al., 2002a, Carretero and Oparil, 2000). The WHO 2012 
statistics-report highlights the growing problem of raised blood pressure, which exhibits a 
high frequency affecting almost one in three adults (WHO, 2012). The actual prevalence and 
absolute burden of HTN was 26.4% (972 million) in 2000 and was predicted to increase by 
60% (1.56 billion) by 2025. Although the relative numbers of hypertensive adults were 
greater in economically developed countries, the rate of increase in incidence of HTN was 
almost 7 times higher in the developing world. Moreover, prevalence was similar between 
men and women and increased with age, consistently in all regions (Kearney et al., 2005). 
Despite advances in the prognosis and primary prevention of HTN, treatment remains poor 
(Vidt and Borazanian, 2003, Kumar et al., 2013). Therefore, there is a pressing need for 
better understanding of the pathophysiological mechanisms and genetics of HTN towards 
the improvement of public health and socioeconomic conditions. 
1.1.1 Hypertension: Causality and Classification 
Hypertension is a disease of large phenotypic variance, characterised by elevated 
blood pressure (BP). Diagnosis of HTN is made when patient’s average systolic/diastolic 
blood pressure (SBP/DBP) is consistently 140/90 mmHg or greater, although risk varies even 
at levels below 140/90 mmHg (pre-hypertensive; 120-139/80-89 mmHg) (Kshirsagar et al., 
2006). BP is a complex trait because of interplay between heritable components and 
environmental factors. Modifiable risk factors for increased BP include elevated body mass 
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index (obesity), insulin resistance, high alcohol / salt intake, smoking, sedentary lifestyle, 
stress and low potassium / calcium intake. Conversely, age, family history of CVD, gender 
and ethnicity belong to non-modifiable risk factors (Poulter, 2003). The prevalence of HTN 
increases with age, and above the age of 50 years systolic HTN represents the most common 
form of HTN (Chobanian et al., 2003). The occurrence of the disease changes with race, age, 
geographic patterns, gender and socioeconomic status. Critically, there is a strong positive 
and continuous correlation between systolic BP (SBP) and the risk of cardiovascular disease 
(CVD) (stroke, myocardial infarction, and heart failure), renal failure and mortality 
(Chobanian et al., 2003, Carretero and Oparil, 2000).  
According to the causality, HTN is classified in primary and secondary. Primary or 
essential hypertension (EH) is the dominant form, which accounts for 90-95% of cases of 
HTN (Carretero and Oparil, 2000). It is a disorder of largely obscure aetiology with lifestyle, 
environmental and genetic (Pickering, 1955, Marteau et al., 2005) components implicated in 
the occurrence. On the other hand, secondary hypertension is the least common form of 
HTN and is caused by another pre-existing medical condition, such as renovascular disease, 
renal failure, aldosteronism or tumours (Carretero and Oparil, 2000). 
1.1.2 Essential Hypertension 
1.1.2.1 Genetic Regulation of EH 
EH is a heterogeneous disorder, with different patients having different causal factors 
that lead to high BP. However, in most of EH cases the causes are not clear. Since its 
description as a polygenic trait (Pickering, 1955), EH genetic predisposition has been 
extensively reviewed (Franceschini and Le, 2013, Padmanabhan et al., 2012). There are also 
preliminary studies on epigenetic regulation of EH by DNA methylation, histone 
modifications and microRNAs (Udali et al., 2013).  
Early mechanistic insights into pathways altered in BP homeostasis came from studies 
on human Mendelian forms of HTN. These syndromes are caused by mutations in single 
genes which have large effects on BP and exhibit an early onset hypertension. Most of the 
mutated genes identified, correspond to rare variants which are associated with impaired 
sodium re-absorption (Table  1-1) (Munroe et al., 2013). 
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Table  1-1. Mendelian / monogenic forms of hypertension.
1
 
 
                                                      
1
 Table 1-1 summarises main features of Mendelian forms of HTN, causative genes and processes 
affected. WNK1/4: lysine deficient protein kinase 1/4; KLHL3: Kelch-like protein 3; CUL3: cullin 3; 
PPARγ: peroxisome proliferator-activated receptor gamma; NR3C2: mineralocorticoid receptor; 
CYP11B1: 11β hydroxylase; CYP11B2: aldosterone synthase; CYP17A1: 17α hydroxylase; HSD11B2: 
11β-hydroxysteroid dehydrogenase; SCNN1B/G: sodium channel nonvoltage-gated 1, β and γ 
subunits; IR: insulin resistance; T2DM: Type II diabetes mellitus; Chr: chromosome. 
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Recent advances in high-throughput genomic approaches have allowed more robust 
identification of genetic determinants of EH and BP. Human candidate genes studies have 
identified more than 110 genes to be potentially implicated in EH, such as angiotensin I 
converting enzyme (ACE), and nitric oxide synthase 3 (NOS3) genes (Benjafield and Morris, 
2000, Bedir et al., 1999). However, the results were difficult to replicate, frequently due to 
poor study design or SNP (single nucleotide polymorphisms) coverage. Such studies analyse 
allelic frequencies of genetic markers (SNPs), tandem oligo-nucleotide repeats or gene copy 
number on a set of potential candidate genes, in patients and healthy individuals. Further, 
genetic linkage studies have identified susceptibility loci for EH and BP in every human 
chromosome so far (Cowley, 2006). This approach analyses the frequency by which adjacent 
SNPs/alleles are inherited with the trait of interest, while further fine mapping narrows 
down the genomic region of interest and identifies new genetic biomarkers. Several genetic 
linkage studies on human populations of different ethnicities have repeatedly associated the 
long arm of chromosome 2 (Chr.2q) with BP/EH regulation (Caulfield et al., 2003, Mocci et 
al., 2009, Rao et al., 2003). However, such approaches have been challenging due to the 
polygenic nature of BP regulation. This issue has been tackled by large-scale, genome-wide 
association studies (GWAS) (Table  1-2), which, over the past few years, have accelerated the 
current understanding of the genetic architecture of BP and EH. GWAS investigate dense 
sets of single nucleotide polymorphisms (SNP) with allele frequency greater than 5% in a 
population, located throughout the genome and their association with complex polygenic 
traits. In humans, common genetic biomarkers for EH/BP have been reported in 29 loci, by 
identifying SNPs within or between genes as in the case of ATP2B1 (intron; (Levy et al., 
2009)), NPR3 - C5orf23 (intergenic; (Ehret, 2011)) and in regulatory regions as in the 
promoter region of UMOD (Padmanabhan et al., 2010) and NOS3 (Salvi et al., 2012).  
However, the reported genetic biomarkers represent, collectively, only a small fraction 
of BP heritability and have small size effects that do not explain BP phenotypic variance. 
Molecular and functional dissection of novel variants, using more detailed low-throughput 
analytical methods along with pathway analysis and in combination with advanced mapping 
(genome exon sequencing) and epigenetic studies may shed light into the aetiology of 
human EH (Padmanabhan et al., 2012). For example, in the case of UMOD, studies in 
transgenic mice homozygous for UMOD promoter risk variants demonstrated salt-sensitive 
hypertension and renal lesions, similar to those observed in homozygous individuals (Trudu 
et al., 2013). 
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Table  1-2. Genetic loci associated with BP and/or hypertension identified in genome-wide 
association studies (GWAS). The loci are listed in chromosomal order. 
2
  
 
                                                      
2
  GWAS studies: CHARGE (Levy et al., 2009); GBPG (Newton-Cheh et al., 2009); AGEN-BP (Kato et al., 
2011); ICBP (Ehret et al., 2011); Gene-centric (Johnson et al., 2011); BP-extremes (Padmanabhan et 
aal. 2010). MTHFR: methylene-tetrahydrofolate reductase; NPPA: atrial natriuretic peptide; NPPB: 
brain natriuretic peptide; AGT: angiotensinogen; ULK4: serine/threonine-protein kinase ULK4; 
MECOM (MDS1): myelodysplasia syndrome protein 1; FGF5: fibroblast growth factor 5; NPR3: 
natriuretic peptide clearance receptor; HFE: human hemochromatosis protein; NOS3: nitric oxide 
synthase 3; CACNB2: voltage-dependent calcium channel B2 subunit; CYP17A1: cytochrome p450; 
PLEKHA7: plextrin-homology domain-containing family A member 7; SOX6: sex determining region y 
(SRY)-box 6; LSP1/TNNT3: leukocyte-specific protein 1 / troponin T type 3; ATP2B1: 
calcium/calmodulin-dependent ATPase isoform 1; SH2B3: lymphocyte-spesific adapter protein; TBX5, 
TBX3: T-box family genes; CSK: cytoplasmic tyrosine kinase; UMOD: uromodulin; ZNF652: zinc-finger 
protein 652; GNAS: guanine nucleotide binding protein, a-subunit stimulating; EDN3: endothelin 3.  
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1.1.2.2 Salt Sensitivity 
High salt intake is a major dietary risk factor contributing to EH with approximately one 
half of essential hypertensive patients demonstrating salt sensitivity. This chronic condition 
is characterised by exaggerated responses to changes in salt balance due to alteration of 
kidney function. Sodium retention, extracellular volume (ECV) expansion, increase of cardiac 
output and increased peripheral vascular resistance are some of the characteristic high salt-
intake phenotypes that lead to elevation of SBP.  
Salt sensitivity was arbitrarily classified by Weinberger et al. (Weinberger et al., 1986) 
as a difference of ≥10 mmHg in SBP between salt-loaded (2L of saline over 4h) and salt-
depleted (10mmol sodium diet per day, plus oral furosemide) states and salt-resistance as a 
difference of ≤5 mmHg. Salt-sensitive patients exhibit a significantly reduced capacity to 
restore sodium balance, after increased salt intake, due to impaired pressure-natriuresis 
relationship (Luft et al., 1986, Rodriguez-Iturbe and Vaziri, 2007). The implication of genetic 
factors has been demonstrated in humans (Mei et al., 2012, Svetkey et al., 1996). A number 
of mutations have been found in genes implicated in BP regulation, by encoding for proteins 
that alter renal salt re-absorption in kidney. Specifically, the mutations affected circulation of 
mineralocorticoid hormones, renal ion channels and transporters and the mineralocorticoid 
receptor, causing Mendelian forms of hypertension and hypotension (Lifton et al., 2001). In 
addition, several genetic polymorphisms (SNPs) related to impaired sodium excretion, have 
been localised in quantitative trait loci (QTL) for salt sensitivity in genetic rat models 
(Johnson et al., 2009, Yagil et al., 2003). Other processes which have been associated with 
salt sensitivity include altered activity of neurohormonal systems, renal inflammation and 
oxidative stress (Laffer et al., 2006, Manning et al., 2005, Beeks et al., 2004). Salt sensitivity, 
apart from enhancing susceptibility to renal damage, is considered a major contributor to 
overall cardiovascular risk.  
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1.2 Blood Pressure Regulation 
Circulation is a vital and highly regulated physiological function responsible for 
transportation of molecules (e.g. gases, nutrients and metabolism (by-)products) in the 
organism, across cells and organ tissues. The heart must pump against a variety of vascular 
beds (blood vessels) to transport blood to the organs, before it eventually returns to the 
heart via the veins, by flowing from areas of high to areas of low hydrostatic pressure. The 
force driving blood flow in the circulatory system is the mean arterial pressure (MAP), which 
is the result of the cardiac output (CO) multiplied by the total peripheral vascular resistance 
(TPR). CO represents the blood volume pumped by each heart ventricle per minute (~5.0 
L/min) and depends on the heart rate and the amount of blood pumped from each ventricle 
per pulse (stroke volume). TPR is influenced by the individual resistance in each vessel, 
which is predominantly determined by the lumen diameter (Di). The Di is controlled by a 
number of physiological and neurohormonal mechanisms to maintain a normal MAP in the 
system (Vander, 2001a). 
 The kidney is a major organ involved in MAP regulation by controlling the blood 
volume and the myogenic tone (the vessel's physiological contractile tension relative to 
maximally dilated state) in the circulatory system. In response to decreases in sodium or BP, 
kidney produces renin, which acts through the renin-angiotensin-aldosterone system (RAAS) 
to cause sodium re-absorption, water retention and vasoconstriction, promoting an increase 
in BP (Vander, 2001b). 
The autonomic nervous system can also regulate MAP through rapid activation of the 
sympathetic nervous system. Changes in BP are sensed by the baroreceptors in the vessels, 
which via signals to the vasomotor centre trigger secretion of hormones that affect the 
myogenic tone (a adrenoreceptors) and heart rate (β adrenoreceptors) to restore normal 
MAP (Julius, 1993). 
Large vessels do not play significant role in TPR, and therefore MAP regulation, due to 
increased diameter and elasticity (compliance; δV/δP). On the contrary, TPR is primarily 
controlled by the microcirculation, the part of vasculature that is more sensitive to pressure-
dependent diameter regulation, and consists of small arteries, pre-capillary arterioles, 
capillaries and venules, as well as elements of the lymphatic system (lymphatic capillaries 
and thoracic ducts). Increased resistance of these vessels, due to narrow Di and slow blood 
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flow as a result of the high total cross sectional area (CSA), lowers the MAP, under normal 
conditions (Figure  1-1) (Vander, 2001a).  
In pathological conditions, including HTN, there is normally a disturbance in the CO 
or/and TPR. 
 
Figure  1-1 - Systolic and diastolic blood pressures in the vascular system. The large drop in blood 
pressure is caused by the resistance vasculature (microcirculation), characterised by narrow lumen 
diameter and slow blood flow as a result of increased total cross sectional area (Adapted from 
Purves et al., Life: The Science of Biology, 4th Edition). 
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1.2.1 Small Resistance Arteries in HTN 
HTN is characterised by sustained increase in TPR, caused predominantly by 
pathological narrowing of small arteries (Di: 100-300µm) and precapillary arterioles (Di 
<100µm), which are considered a continuum rather distinct sites of resistance control (le 
Noble et al., 1998). This is evidenced by a large drop in BP across these vessels, which 
predicts a high resistance during HTN (Borders and Granger, 1986, Bohlen, 1986) (Figure 
 1-1). The lumen narrowing, observed in small arteries of both hypertensive animals (Briones 
et al., 2003, Arribas et al., 1997, Mulvany, 1988) and humans (Schiffrin, 1999, Rizzoni et al., 
2003), is attributed to structural and functional alterations (Mulvany and Aalkjaer, 1990). 
Changes in structure of small resistance arteries, known as vascular remodelling, seem to be 
the result of abnormal organisation of extracellular material and have been significantly 
associated with the occurrence of cardiovascular events, including EH (Aalkjaer et al., 1987, 
Mathiassen et al., 2007, Muiesan et al., 2002). They have also been suggested to represent 
the most common and early form of target organ damage in human (Park and Schiffrin, 
2001). 
In addition, functional alterations refer, mainly, to impaired endothelial function and 
subsequent changes in the myogenic tone and Di, which are tonically modulated by 
endothelium-derived factors. Impaired endothelium-dependent responses in the resistance 
vasculature have been well documented in EH patients (Panza et al., 1990, Rossi et al., 1997, 
Taddei et al., 1992) and animal models (Ito and Carretero, 1992, Tuncer and Vanhoutte, 
1993). 
1.2.1.1 Vascular Smooth Muscle and Remodelling in HTN 
In the arterial wall, the smooth muscle (SM) layer consists of vascular smooth muscle 
cells (VSMCs) in a matrix of collagen and elastin fibres and is known as tunica media. 
Depending on the vessel type, SM appears to be of variable thickness with the exception of 
capillary vessels, which consist only from endothelium. In response to physiological or 
chemical signals, SM can rapidly adapt its structural design to regulate the lumen diameter 
(Di) and meet vessel's functional demands.  
It has been demonstrated that in EH patients and animal models the structure of small 
resistance arteries is abnormal, characterised by reduced Di and increased wall thickness to 
Di ratio (wall : lumen ratio), without change in wall mass (Aalkjaer et al., 1987, Rizzoni et al., 
2003, Briones et al., 2003, Arribas et al., 1997). The mechanisms leading to such 
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abnormalities are not fully understood. Wall stress-induced changes in extracellular matrix 
proteins and neurohormonal environment as well as ROS have been suggested as potential 
mechanisms playing an important role (Lee et al., 1995, Touyz et al., 2003). The altered 
structure is considered to be the result of abnormal elastin and collagen re-arrangement in 
the vessel wall, rather than SM growth, known as inward eutrophic remodelling (Briones et 
al., 2003, Arribas et al., 1997, Mulvany, 1988). 
Although structural changes in small arteries have been related to long-term elevated 
BP (Folkow, 1958), it is unclear whether remodelling is the cause or consequence of 
increased BP. Experiments in rats made hypertensive (Goldblatt technique) suggest that the 
remodelling is adaptive to increased BP (Deng and Schiffrin, 1991). On the contrary, 
increased media:lumen ratio has been observed in mesenteric resistance arteries (MRA) 
from rats (SHR) at a pre-hypertensive stage (Rizzoni et al., 1994). However, recent studies in 
humans show strong correlation between small artery remodelling and TPR, proposing that 
the structural changes are the result of myogenic tone rather than of pressure (Mathiassen 
et al., 2007). Such changes have, in turn, a positive feedback on TPR and BP.  
 
Figure  1-2 - Vascular remodelling. Structural changes in the vascular smooth muscle are reflected 
as changes in the cross sectional area (CSA) and lumen diameter (Di) of the vessel. The relationship 
between CSA - Di determines the type of remodelling in small and large arteries. (Adapted 
from Mulvany et al., 1996) 
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1.2.1.2 Vascular Endothelium and Endothelial Dysfunction in HTN 
The luminal surface of the entire cardiovascular system, from heart to capillary vessels, 
is lined by a monolayer of endothelial cells, the vascular endothelium or tunica intima. Apart 
from being a natural semi-selective barrier between circulating blood and tissue, the role of 
endothelium further expands into maintaining the balance between vasodilatation and 
vasoconstriction (myogenic tone), proliferation and migration of VSMCs (angiogenesis, SM 
growth, vascular remodelling) and thrombogenesis and fibrinolysis (inflammatory responses, 
coagulation) (Davignon and Ganz, 2004).  
Upon exposure to mechanical or chemical stimuli, endothelial cells synthesise and 
secrete a variety of vasoactive factors (Félétou and Vanhoutte, 2006), which act primarily on 
the underlying SM to modulate myogenic tone and thereby vascular resistance. Vasodilators 
such as nitric oxide (NO), endothelium-derived hyper-polarisation factors (EDHF) and 
prostacyclin (PGI2) increase vessel diameter and decrease resistance. The exact opposite 
effect is introduced by vasoconstrictors, including endothelin-1 (ET-1), angiotensin II (Ang II), 
prostanoids and reactive oxygen species (ROS) (Félétou and Vanhoutte, 2006, Vanhoutte et 
al., 2005). The relative contribution of each vasoactive mediator to endothelium-dependent 
responses varies according to the vessel size, the specific vascular bed, and the animal 
species. The mechanisms of action of these factors are discussed below and illustrated in 
Figure  1-3. 
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Figure  1-3 - Endothelium-mediated contraction and relaxation in the smooth muscle. 
Vasoconstrictors and vasodilators released from endothelium upon stimulation, act on the smooth 
muscle through G-protein coupled receptors (GPCR), diffusion or membrane hyperpolarisation to 
cause contractile or vasodilatory responses, respectively. AngII, angiotensin II; ET-1, endothelin-1; 
O2
.- 
, superoxide; ONOO
.-
, peroxynitrate; NO, nitric oxide; PGl2, prostacyclin; EDHF, endothelium-
derived hyperpolarisation factor; PLC, phospholipase C; IP3, inositol triphosphate; DAG, 
diacyloglycerol; Ca
+2
, calcium; p-MLC, phosphorylated myosin light chain; Rock, Rho kinase; sGC, 
soluble guanyl cyclase; AC, adenyl cyclase; cGMP, cyclic guanosine monophosphate; cAMP, cyclic 
adenosin monophosphate; arrows indicate increased / decreased levels.  
The major regulator of cardiovascular homeostasis is considered to be NO, since apart 
from mediating vascular relaxation it also protects vascular wall from coagulation of blood 
and inflammatory responses leading to atherosclerosis (Harrison et al., 2010, Kubo-Inoue et 
al., 2002). Moreover, NO is known as the gate-keeper of endothelial function since it 
controls the production/action of other endothelium-derived mediators, including EDHF and 
ET-1 (Feletou et al., 2008). Its vasodilatory effects are predominantly exerted through 
stimulation of the soluble guanylyl cyclase (sGC) in the VSMCs and subsequent production of 
cyclic-GMP (Hobbs, 1997). In a similar manner, PGI2 promotes SM relaxation by activating 
adenyl cyclase (AC) in the VSMCs, followed by generation of cyclic-AMP (Holzmann et al., 
1980). On the contrary, the identity of EDHF is still not known. Several molecules have been 
proposed to complement the vasodilatory actions of NO and PGI2, by causing membrane 
hyperpolarisation (opening of potassium channels) of VSMCs resulting in closure of voltage-
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gated calcium channels (Feletou and Vanhoutte, 2009). C-type natriuretic peptide (CNP) has 
been identified as a potential EDHF, highly associated with regulation of relaxation in small 
resistance arteries (Barton et al., 1998, Chauhan et al., 2003, Steinmetz et al., 2004).  
In the case of vasoconstrictors, peptides such as AngII and ET-1 exert their effects upon 
binding to a G-protein coupled receptor (GPCR) on the VSMC membrane. Regardless of the 
stimuli, the cellular mechanism leading to constriction involves initial elevation of cytosolic 
Ca2+ levels, through efflux of extracellular Ca2+ and release of intracellular Ca2+ from 
sarcoplasmic reticulum. Subsequently, Ca2+/calmodulin complex induces activation of 
myosin by the myosin light chain kinase (MLCK), to promote contraction. Contraction is 
further maintained by Ca2+-sensitisation signalling, in which RhoA small G protein and its 
downstream effector, Rho kinase (RhoA/Rock) prevent activation of myosin light chain 
phosphatase (MLCP) (Webb, 2003, Wynne et al., 2009). On the other hand, ROS, superoxide 
anion (O2
-) in particular, induce contraction mainly by increasing Ca2+ mobilisation or 
sensitisation, direct depolarisation of the cell membrane or activation of endothelial 
enzymes which produce endothelium-derived contracting factors (EDCFs) (Jin et al., 1991, 
Tang et al., 2004, Vanhoutte et al., 2005). 
1.2.1.2.1 Endothelial Dysfunction 
Under physiological conditions release of endothelium-derived vasodilators 
predominate to maintain a normal vascular tone. Sustained shift of the equilibrium towards 
generation of endothelium-derived contracting factors (EDCF) results in endothelial 
dysfunction (Abdel-Sayed et al., 2003). In general, endothelial dysfunction is characterised 
by impaired endothelium-dependent relaxation of the SM to vasodilators such as 
acetylcholine, bradykinin and calcium ionophore. The reduced sensitivity of the vessel to 
such factors results from altered production and/or action of endothelium-derived 
vasodilators. Altered endothelial function is considered the hallmark in almost all forms of 
CVD (Félétou and Vanhoutte, 2006, Widlansky et al., 2003), including hypertension (Grunfeld 
et al., 1995, Potenza et al., 2005, Treasure et al., 1993), atherosclerosis (Ludmer et al., 1986, 
Kawashima and Yokoyama, 2004), CAD (Chan et al., 2003) and heart failure (Heitzer et al., 
2005). Endothelial dysfunction has been shown to occur in small resistance arteries from 
both EH patients and animal models of HTN.  
The mechanisms underlying endothelial dysfunction vary, depending on pathological, 
physiological and non-modifiable risk factors such as age and gender. In HTN, the 
impairment has been attributed to reduced synthesis and release of NO (Taddei et al., 1999, 
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Panza et al., 1993), and EDHF (Goto et al., 2004, Onaka et al., 1998) , or increased release of 
EDCFs (Luscher and Vanhoutte, 1986, Vanhoutte and Tang, 2008). It is still unclear whether 
endothelial dysfunction is a predictor, a risk factor or an end point of HTN, although it has 
been shown to precede establishment of high BP in young normotensive offspring of EH 
parents (Taddei et al., 1996). Moreover, inconsistent effects of antihypertensive drugs on 
endothelial function, despite correction of BP levels (Ghiadoni et al., 2012), further support 
the notion that endothelial dysfunction may be a primary event to BP increase.  
An increasing body of evidence reveals oxidative stress as the common denominator of 
endothelial dysfunction in CVD, including EH (Griendling and FitzGerald, 2003a, Griendling 
and FitzGerald, 2003b). Oxidative stress occurs upon increased ROS production or reduced 
ability to scavenge ROS and/or impaired antioxidant activity (Touyz and Schiffrin, 2004). ROS 
have been involved in the inhibition of the three major endothelium-dependent 
vasodilatation pathways, i.e. NO, EDHF and PGI2, by reducing NO bioavailability, inactivating 
NO and PGI2 synthases or inhibiting sGC and decreasing the activity of channels implicated in 
the EDHF-mediated relaxation (Münzel et al., 2005, Zou et al., 2004, Liu et al., 2006, Kusama 
et al., 2005). Furthermore, ROS are known to induce VSMC contraction, as mentioned above 
(Félétou and Vanhoutte, 2006). It is still not clear whether vascular oxidative stress causes 
HTN in human, as only few antioxidant approaches have demonstrated improvement of 
endothelial function (Mistry et al., 2008, Duffy et al., 2001, Hamilton et al., 2002) as opposed 
to rat models of HTN (Hamilton et al., 2002, Graham et al., 2009, Savoia et al., 2006, Fennell 
et al., 2002). Furthermore, oxidative stress has been shown to precede the establishment of 
high BP in SHR rats (Nabha et al., 2005).  
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1.2.2 Treatments in HTN 
Despite the extensive research in the battle against HTN, no treatment able to correct 
for all of the increased BP levels, oxidative stress and endothelial dysfunction has been 
found, to date. For improvement of HTN a selection of antihypertensive drugs is being used 
according to the individual's cardiovascular profile (BP readings, cardiovascular risk) and 
their response to the therapy (Mathiassen et al., 2007).  
Traditionally, diuretics have been used as first line treatment to increase water and 
sodium excretion with subsequent reduction in CO and minor change of TPR (Shah, Littler 
2004). Likewise, antagonists of β-adrenergic receptors (β-blockers) exert their therapeutic 
effects by lowering CO, but have no effect on endothelial function (Taddei et al., 2001). 
Calcium channel blockers improve endothelial function (Taddei et al., 2001), decrease 
contraction of the SM and consequently the TPR, however, they have been related to high 
risk of myocardial infarction. Blockers of AngII II receptors (ARB) or of its converting enzyme 
(ACE) increase dilatation of small arteries, leading to reduced TPR, without improving 
endothelial function (Schiffrin, 1998, Taddei et al., 1998). Antagonists of α-adrenergic 
receptors (α-blockers), which are less commonly used, decrease contraction of muscle fibres 
in the small arteries and hence the TPR. Finally, combination therapies, using more than one, 
are applied in the majority of cases, such as renin–angiotensin system inhibitors and calcium 
channel blockers, or renin–angiotensin system inhibitors and diuretics (Daskalopoulou et al., 
2012, Frank, 2008). However, none of the modern therapies seem to have consistently long-
term effects in lowering the pressure of EH patients. Unfortunately, their effects have not 
been assessed on TPR or small artery structure (Mulvany, 2012). It has been shown that 
therapies using substances with vasodilatory effects (Ca antagonists, ACE inhibitors, and 
receptor blockers (ARB)) can normalise small vessel structure, whereas beta-blocker 
treatments do not reduce TPR (Buus et al., 2004) and therefore do not correct the abnormal 
structure (Mathiassen et al., 2007, Agabiti-Rosei et al., 2009). Hence, treatment of HTN 
which focuses only on BP regulation could correct large artery and LV morphology, whereas 
for the normalisation of the crucial small resistance vessels structure vasodilator therapies 
are required (Mulvany, 2005, Mulvany, 2012, Schiffrin, 2010).  
Apart from prescription of antihypertensive drugs, preventative lifestyles changes are 
essential in order to control BP levels and lower the risk of CVD and renal damage 
(Daskalopoulou et al., 2012). 
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1.3 HTN in Rats 
The use of experimental animal models in studies of human diseases has been vital to 
the understanding of their pathophysiology. Using in-bred animal models ensures increased 
genetic homogeneity, reduced environmental effect through standardised housing criteria, 
and allows for controlled mating between diseased and healthy animals for linkage analysis 
(Graham et al., 2005). 
Due to clear pathogenic (genetic, biochemical and physiological) similarity with 
humans, rodent models are extensively used in the investigation of the genetic, cellular and 
molecular basis of CVD in order to gain a better understanding of the long-term BP 
regulation. The rat, mouse and human genomes encode for a similar number of genes and 
almost all human genes have corresponding orthologues in the rat genome (Rat Genome 
Sequencing Project Consortium; 2004). Moreover, rodents are ideal experimental models in 
the drug research and testing due to their small size, short breeding time and simple 
husbandry.  
Despite mice being the major model for mammalian genetic studies and 
manipulations, it is not the most appropriate model of human CVD, due to their small size 
and increased heart rate. On the contrary, rats have been widely bred to provide an animal 
model of human EH, due to their higher pathophysiological similarity to the human 
condition, as well as their bigger size which makes them more amenable to handling (Rapp, 
2000). 
1.3.1  Rat Models of HTN and Salt Disease 
Most of the rat experimental models of HTN were developed from either Wistar-
related or Sprague-Dawley stock, which share a common origin, using selective inbreeding, 
surgery, diet or drug treatment to induce HTN. A phylogenetic tree of 28  inbred laboratory 
rat strains used in the study of complex diseases, including HTN, has been generated 
recently, following their genome sequencing (Figure  1-4) (Atanur et al., 2013). 
An example of a genetic model of HTN is the Dahl salt-sensitive (S) and salt-resistant 
(R) rats, which were bred on the basis of their BP after being fed a high salt diet (8% NaCl). 
On the other hand, genetically hypertensive rats (GH) and spontaneously hypertensive rats 
(SHR) are two models developed by rats selectively bred for high BP without any dietary or 
environmental stimuli. Rats with surgery-induced HTN include the Goldblatt model of 
renovascular HTN, in which one or both renal arteries have been constricted by use of a 
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small adjustable clamp (Goldblatt et al., 1934). Sabra HTN prone (SBH) and resistant (SBN) 
strains were selectively bred according to the response of BP to unilateral nephrectomy, 
treatment with deoxycorticosterone acetate and 1% NaCl to drink. Several rat hypertensive 
models have been generated using specific diet or drug treatments, such as high salt / fat / 
sugar diets, chronic inhibition of NO and chronic infusion of AngII. Despite the common 
genetic origin of the above strains, the genetic diversity amongst them is substantial and 
comparable to the divergence between unrelated humans (Doggrell and Brown, 1998, 
Dornas and Silva, 2011). 
 
Figure  1-4 - Phylogenetic tree of inbred experimental rat models used in studies of complex human 
diseases, including hypertension, diabetes and insulin resistance. The scale represents genetic 
distance based on whole genome comparisons, using Brown Norway (BN/Mcwi) as the reference 
strain (Atanur et al., 2013). 
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1.3.2 The Stroke-Prone Spontaneously Hypertensive Rat (SHRSP) 
The most commonly studied SHR is a breed established in the early ‘60s (1963), at the 
University of Kyoto, from Wistar-Kyoto (WKY) normotensive male with elevated BP mated to 
female with slightly elevated BP (Okamoto and Aoki, 1963). Further selective inbreeding of 
SHR more susceptible to stroke led to development of an SHR sub-strain, the stroke-prone 
SHR (SHRSP) (1974) (Yamori and Okamoto, 1974). The SHRSP spontaneously develops 
cerebral stroke as well as severe hypertension (>200 mmHg) early in life. The onset of 
spontaneous HTN is between 8 and 12 weeks of age and its magnitude is closely related to 
the incidence of stroke. SHRSP also exhibit sexual dimorphism, characterised by more 
pronounced HTN in male than in female animals. At 16 weeks of age, SBP reaches 
approximately 180 mmHg in male compared to 150 mmHg in females. Divergence in SBP 
between individual SHRSP colonies is observed, considering different husbandry regimes and 
criteria for selecting breeding pairs. Further hypertensive phenotypes and end organ 
damage exhibited by SHRSP include salt-sensitivity, proteinuria, left ventricular hypertrophy, 
and endothelial dysfunction (Yamori and Okamoto, 1974, Ohtaka, 1980, Tesfamariam and 
Halpern, 1988).  
Because of the similarity in the pathophysiolology of stroke and EH between this strain 
and humans (Rapp, 2000), SHRSP is one of the most utilised experimental models for 
studying development, prognosis and treatment of EH, as well as interactions between 
genetics and environment. Its wide use in the genetic study of HTN involves genetic 
manipulations via generation of congenic (chromosomal segment replacement) and 
consomic (whole chromosome replacement) strains. Hilbert et al. (Hilbert et al., 1991)  at 
the same time with Jacob et al. (Jacob et al., 1991) were the first to generate congenic 
strains of crosses between SHRSP and the normotensive control Wistar-Kyoto (WKY) in 
genetic linkage studies, aiming to locate candidate genes that regulate the quantitative trait 
of EH. However, SHRSP fail to display every phenotype of human EH. It is known that this 
strain do not exhibit spontaneous heart failure. Moreover, rats do not develop spontaneous 
atherosclerosis due to their plasma profile of high HDL levels (Fernandez et al., 1999) and 
absence of cholesteryl ester transfer protein (CETP) (Guyard-Dangremont et al., 1998), as 
well as their increased ability to convert cholesterol to bile acids (Horton et al., 1995).  
SHRSP and WKY rats have been bred in Glasgow since September 1991. Integrity of 
colonies and hypertensive phenotype are ensured through selective mating of male SHRSP 
with SBP of 170-190 mmHg and female animals with SBP of 130-150 mmHg, measured by 
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tail cuff.  Offspring start to develop HTN at 6-8 weeks of age and by 12-16 weeks they exhibit 
baseline SBP of 187 mmHg, compared to 134 mmHg for age-matched WKY (Figure  1-5A) 
(Graham et al., 2007, Koh-Tan et al., 2009). Consomic and congenic strains have been 
constructed and utilised in genome-wide linkage studies to identify candidate genes for BP 
regulation and salt-sensitivity, in SHRSP (Clark et al., 1996, McBride et al., 2003). 
1.3.3 Congenic Strains in Genetic Screenings 
Congenic strains are constructed by selective replacement of a chromosomal region 
closely linked to genes and other genetic elements, underlying a particular polygenic trait 
(e.g. EH) in the recipient strain, with the homologous region from the donor strain. Such 
regions of interest are known as quantitative trait loci (QTL). For identification of candidate 
genes underlying a trait, QTLs are the first to be determined via genome wide linkage scan 
by use of microsatellite markers. Subsequent generation of congenic and consomic strains 
verifies the existence of the QTL. Further breeding produces smaller congenic substrains, 
carrying a reduced size of the implicated chromosomal region for gene identification (Zhang 
et al., 1997). Finally genome-wide microarray expression profiling allows for identification of 
differentially expressed, candidate genes. In SHRSP, QTLs associated with BP regulation and 
salt-sensitivity have been identified on chromosomes 2, 3 and 14 (Clark et al., 1996, McBride 
et al., 2005, McBride et al., 2003). Moreover, construction of reciprocal congenic stains has 
previously been used in the genetic dissection of a BP QTL on rat chromosomes 1, 8, 9 and 
13  (Clemitson et al., 2007, Zhang et al., 1997, Kumarasamy et al., 2011, Ariyarajah et al., 
2004) 
Previous work in our laboratory has led to construction of chr.2 congenic animals by 
mating of WKY (donor) and SHRSP (recipient) rats (Jeffs et al., 2000). A 'speed congenic' 
strategy was used, by combining a marker-directed breeding programme with genetic 
linkage maps, to achieve the congenic strains in 3-4 backcross generations (Jeffs et al., 2000). 
The strains were confirmed through genotyping. These animals exhibit significant reduction 
in SBP at baseline, when compared to SHRSP (Figure  1-5A). Total genome screening in the 
congenic strains (F2 generation) confirmed findings of Clark et al. (Clark et al., 1996) on the 
two QTLs for BP and salt-sensitivity identified on rat chr.2 (Jeffs et al., 2000, McBride et al., 
2003). Further exclusion mapping studies on this chromosome, by use of the congenic 
animals, identified a potential 6-Mbp region harbouring candidate genes for salt sensitivity 
(Figure  1-5B). Subsequent microarray expression profiling carried out in whole kidneys from 
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salt-loaded parental and chr.2 congenic strains revealed differential expression of 
physiological candidate genes for BP and salt-sensitivity in HTN (Graham et al., 2007, 
McBride et al., 2003). 
1.3.4 Candidate Genes for BP Regulation and Salt Sensitivity in SHRSP 
1.3.4.1 Glutathione S-transferase Mu Type 1 (Gstm1) 
One of the first positional and functional candidate genes for BP regulation identified 
in our laboratory on rat chr.2 was glutathione S-transferase mu type 1 (Gstm1) (Figure  1-5B) 
(McBride et al., 2003). Gstm1 encodes for an enzyme belonging to the superfamily of 
glutathione S-transferases (GST), which catalyses ROS scavenging by conjugation to the 
reduced form of glutathione (GSH), and therefore participates in the endogenous defence 
against oxidative stress (Hayes and Pulford, 1995). Studies in the absence of salt loading  
demonstrated reduced renal mRNA and protein levels in young SHRSP (5 week old) and 
adult (16 week old) compared to SP.WKYGla2c* and WKY. Gene sequencing identified SNPs in 
coding and non-coding (promoter) regions (McBride et al., 2005). Moreover, combination 
antihypertensive treatment, using an ARB and a diuretic/vasodilator, did not restore Gstm1 
expression levels in young SHRSP, despite improvement of renal histopathological damages 
caused by sustained high BP (Koh-Tan et al., 2009). The above findings suggest involvement 
of Gstm1 in the pathogenesis of HTN and occurrence of endothelial dysfunction, potentially 
via an oxidative stress pathway.   
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Figure  1-5 - Identification of congenic interval and candidate genes for salt sensitivity and BP 
regulation. (A) Averaged weekly radiotelemetry recordings of night-time and day-time SBP in male 
WKY and SHRSP parental, SP.WKYGla2k, SP.WKYGla2a and SP.WKYGla2c* congenic strains. The 
animals were put on high-salt diet at 18 weeks of age. (B) Middle: Schematic map of chromosome 
2 from congenic strains SP.WKYGla2a, 2k and 2c*. Blue bars: regions of WKY homozygosity, red 
bars: regions of SHRSP homozygosity, hatched bar: region of recombination and heterozygosity. 
Right: Physical map of a 6-Mbp congenic interval harbouring physiological candidate genes for salt 
sensitivity including S1pr1 and Vcam1. Left: Genetic map. The location of Gstm1 is indicated 
outside of the region implicated in salt-sensitivity (McBride et al., 2003). A and B edited from 
Graham et al., 2007. 
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1.3.4.2 Sphingosine-1-Phosphate Receptor 1 (S1pr1) and Vascular Cell Adhesion 
Molecule (Vcam1) 
Sphingosine-1-phosphate receptor 1 (S1pr1) and vascular cell adhesion molecule 
(Vcam1) were identified as two positional candidates for salt-sensitivity, lying on the 6-Mbp 
congenic interval of rat chr.2 (Graham et al., 2007). The proteins produced by the two genes 
are known to lie on a number of common and functionally important molecular pathways 
(Graham et al., 2007, Yogi et al., 2011, Bolick et al., 2005). 
S1pr1, previously known as “endothelial differentiation gene 1” (Edg1), encodes for a 
G-protein coupled receptor (GPCR). It belongs to the family of receptors for sphingosine-1 
phosphate (S1P), a lysophospholipid released mainly from platelets at sites of tissue injury or 
inflammation to promote angiogenesis (Sano et al., 2002, Lee et al., 1999). The S1P receptor 
family consists of five members: S1PR1/EDG1, S1PR2/EDG5, S1PR3/EDG3, S1PR4/EDG6, and 
S1PR5/EDG8 (Pyne and Pyne, 2000a). Upon activation by S1P, the receptors couple to 
heterotrimeric G-proteins (exchange of GDP for GTP: Gi, Gq, and G12,13), which promote 
generation of second messengers to regulate a variety of cellular responses (Figure  1-6). 
Second messengers include phospholipase C (PLC), phospholipase D (PLD), adenylate cyclase 
(AC), intracellular Ca2+ levels, ERK, and many others (Van Brocklyn et al., 1998, Pyne and 
Pyne, 2000b). Regulated responses include survival, proliferation, migration, angiogenesis, 
and actin cytoskeletal rearrangements (Spiegel and Milstien, 2003a). The expression profile 
of each member changes across the different tissues and cell types. S1PR1, S1PR2, and 
S1PR3 are the most widely expressed and therefore most studied, whereas S1PR4, and 
S1PR5 are expressed in limited tissues and their function is less clearly understood. S1PR1 is 
highly abundant in endothelial cells and has been shown to signal exclusively through 
coupling with Gi (Windh et al., 1999). Its key role is the regulation of endothelial barrier 
functions, cell proliferation and migration, differentiation and vascular maturation (Kimura 
et al., 2000, Lee et al., 1998). Altered S1PR1 signalling has been implicated in the aetiology of 
cardiovascular disorders, including cardiac hypertrophy and inflammation (Yogi et al., 2011, 
Robert et al., 2001). Although the effects of S1P have been well documented, a major 
limitation in studying the role and signalling of discrete endogenous receptor subtypes has 
been the lack of subtype-selective agonists and antagonists, as well as poor receptor 
antibodies. Use of subtype-specific knockout mice has provided a powerful tool to overcome 
such challenges (Ishii et al., 2002, Liu et al., 2000). However, the S1pr1 knock-out mouse 
shows embryonic lethality and the cardiac specific knock-out is not yet available. In recent 
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years, however, a number of such ligands (fingolimond - FTY720, SEW2871) have emerged 
and are undergoing clinical trials to determine their efficiency in treating acute kidney injury 
and autoimmune disorders such as multiple sclerosis by inducing lymphopenia (Kim et al., 
2011, Lien et al., 2006).  
 
Figure  1-6 - Overview of signalling pathways of S1P receptors (S1PR) and regulated cellular 
responses. Upon activation, all S1PR can couple to Gi proteins, all except S1PR1 couple to G12-13 and 
finally the S1PR2 and S1PR3 receptors can also couple to Gq. Subsequently, the signal can be 
transduced through several second messengers to regulate different processes. S1PR1 couples 
exclusively to Gi, which then can activate either phospholipase C (PLC) to increase intracellular Ca
2+
 
levels, or Ras (small GTPases family) to promote proliferation, or phosphatidylinositol 3-kinase 
(PI3K) to induce survival and migration. It can also block adenylate cyclase (AC) to inhibit 
migration. Edg, endothelial differentiation gene; G, heterotrimeric G-proteins; Rac, subfamily of 
Rho GTPases ; Rho, small GTPases family;  DG, diacylglycerol; IP3, inositol triphosphate; JNK, C-Jun 
N-terminal kinase; cAMP, cyclic AMP; AKT, protein kinase B ; ERK, extracellular signal-regulated 
kinase; PKC, protein kinase C. 
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Vcam1 is mainly expressed in endothelial cells after stimulation by cytokines, encoding 
for an adhesion molecule which functions as a pro-inflammatory marker. Alternative splicing 
results into two different transcripts encoding for two isoforms of VCAM1. The membrane-
bound form allows adhesion of leukocytes (lymphocytes, monocytes, eosinophils, basophils) 
to vascular endothelium and subsequent trans-endothelial migration into arterial intima, 
and it also functions in signal transduction (Jager et al., 2000). The soluble isoform is used to 
monitor the membrane-bound VCAM1 expression and high levels are indicative of 
progressive formation of atherosclerotic lesions in human (Jager et al., 2000, Jang et al., 
1994). Although hypertensive rat models, are not readily susceptible to atherosclerosis, due 
to a different lipoprotein profile from that of humans (i.e. low plasma levels of pro-
atherogenic LDL and VLDL), increased expression of the soluble VCAM1 indicate potential 
kidney inflammation and low grade arterial stenosis. 
Previous gene expression profiling in our laboratory, demonstrated differential 
expression of the two positional candidate genes, S1pr1 and Vcam1, in kidneys from salt-
loaded rats, and identified a number of SNPs in their promoter regions. mRNA expression of 
both genes was up-regulated in SHRSP compared to WKY and the SP.WKYGla2a and 
SP.WKYGla2k congenic strains. However, protein expression analysis in the salt-loaded 
kidneys showed reduced S1PR1 as opposed to increased VCAM1 in SHRSP relative to WKY 
and the congenic strains (Figure  1-7A and B). This lack of concordance in S1pr1 mRNA and 
protein levels was suggestive of abnormal post-transcriptional regulation or protein turnover 
and subsequent altered S1PR1 signalling in HTN (Graham et al., 2007). Reduced protein 
levels could imply reduced renoprotection according to studies in rodents, which 
demonstrated a protective role of S1PR1 activation on renal function, characterised by 
suppression of pro-inflammatory molecules (Awad et al., 2006, Lien et al., 2006). Moreover, 
the renal levels of the pro-inflammatory marker VCAM1 were up-regulated in our SHRSP, 
indicating progressive kidney inflammation, a known key mechanism for inducing salt 
sensitivity (Rodriguez-Iturbe et al., 2002). However, recent studies on mesenteric primary 
VSMCs from WKY and SHRSP demonstrated that S1P-mediated S1PR1 activation up-
regulated mitogenic and pro-inflammatory signalling, including induction of VCAM1 
expression (Figure  1-7C and D). S1P/S1PR1 signalling was found to be altered in HTN, with 
related responses amplified in SHRSP, including activation of receptor tyrosine kinases 
(EGFR, PDGFR) and mitogenic kinases (MAPKs, SAPK/JNK) (Figure  1-7C), as well as expression 
of pro-inflammatory markers (ICAM1, VCAM1) and VSMC migration (Yogi et al., 2011). 
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Figure  1-7 - Differential renal expression of S1pr1 and Vcam1 candidate genes, and altered vascular 
S1P/S1PR1 signalling, in hypertension. (A) and (B): Differential mRNA (qRT-PCR; top graphs) and 
protein (WB; bottom graphs) expression levels of S1pr1 and Vcam1 in kidney from salt-loaded 
SHRSP compared to WKY and the SP.WKYGla2a, SP.WKYGla2k congenic strains. Statistical analysis 
was performed using 1-way ANOVA with Dunnett’s posthoc test for multiple comparisons. 
Adapted from Graham et al., 2007. (C) and (D): Up-regulated mitogenic (SAPK/JNK 
phosphorylation) and pro-inflammatory (VCAM1 expression) responses upon S1P-stimulation in 
mesenteric primary VSMCs from WKY and SHRSP. Responses were mediated through S1PR1 and 
were augmented in SHRSP compared to WKY. *P< 0.05, ***P< 0.001 indicate statistical 
significance. Adapted from Yogi et al., 2011. 
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To better comprehend / visualise the relationship between the two candidate genes 
and the pathways they are involved in, a hypothetical signalling network with S1PR1 (EDG1) 
at the apex, has been previously proposed using systems biology approaches (Graham et al., 
2007). In this static model there is no concept of dynamic behaviour as it merely depicts 
protein-protein interactions, post-translational modifications (PTMs) and protein-DNA 
interactions (Figure  1-8). The rising argument is whether phenotypic differences between 
health and disease are driven exclusively by S1PR1 receptor via VCAM1 or by both candidate 
genes, which could be answered through enrichment of the pathway with dynamic data on 
the connectivities. 
 
Figure  1-8 - Transcriptional networks of S1pr1 and Vcam1 positional candidate genes. Static model 
of direct connections between S1PR1 and VCAM1 (generated by Ingenuity Pathway Analysis (IPA) 
software, Ingenuity Systems). The network is displayed graphically as nodes (gene products) and 
edges (the biological relationship between the nodes). Adapted from Graham et al., 2007. 
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1.4 Systems Biology 
Dynamic living systems sense their environment and respond to changes through 
complex cellular processes. Signal transduction and metabolic pathways are involved in 
every cellular response and are organized as highly interconnected networks, in which 
molecules participate in more than one reaction and there are several feedbacks. Therefore, 
any genetic alteration or exogenous perturbation results in a series of changes in the 
dynamic proteome and metabolome, which can be generally translated into phenotypic 
alterations. Thus, it becomes challenging to distinguish which metabolic processes / 
pathways are modified in each system, under different conditions.  
Systems biology aims to interpret experimental evidence by reconstructing 
interconnected networks with increasing reliability, which would further allow rigorous 
predictions of cellular responses to specific perturbations. Crosstalk between networks 
provides holistic information on living systems for subsequent studies on diagnosis or 
prognosis of diseases. The emphasis is on the shift from working on individual molecules to 
work on networks which constitute the functional processes that link genetic and 
biochemical networks with biological phenotypes. To achieve this, mathematical modelling is 
combined with experimental validation, generating dynamic network maps with models 
describing their behaviour.  
The use of mass spectrometry (MS)-based, high-throughput strategies permits precise 
and rapid proteome and metabolome screenings, which can capture changes in protein and 
metabolite profiles, as well as transient interactions between molecules. These approaches 
contribute to systematic mapping of cellular responses and the enrichment of static network 
maps obtained from genetic screens with dynamic data on their connectivity. Such 
combination of highly complementary network topology maps with inter-dependent 
dynamic data enables the study of cellular networks' function, from the physiological to the 
molecular level, and allows comparison of health and disease states.  
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Figure  1-9 - The 'omics' information universe. Systems biology aims to describe what can happen 
(genomics), what appears to be happening (transcriptomics), what makes it happen (proteomics) 
and what has happened and is happening (metabolomics) in a living system. Combination of this 
diverse yet complimentary information provides better understanding of the phenotype and 
function of the biological system. 
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1.4.1 Proteomics 
1.4.1.1 Mass Spectrometry-Based Quantitative Proteomics  
Proteomics is the science often described as the next step after the sequencing of the 
human genome, as it is supported that there are many more proteins than there are 
corresponding genes in the genome. Proteomics focus on the study of protein structure and 
function and the ways they are produced and interact under different conditions within 
cells, in a system-wide manner. This highly sensitive and accurate 'omics' strategy provides a 
means towards a global view of cellular proteomes, which will improve our understanding of 
fundamental biological processes underlying a wide range of diseases and may facilitate 
discovery of new drugs. To date, the only global proteome (interactome) 
screening/quantification has been completed in Saccharomyces cerevisiae (Krogan et al., 
2006, Gavin et al., 2006). 
In highly complex dynamic systems, such as cells, proteins comprise the principal 
components of every cellular response to genomic changes or exogenous perturbations. 
Such responses involve the interplay of multiple protein modifications, interactions and 
signalling networks. Therefore, comprehensive protein characterisation is vital in revealing 
the mechanisms and underlying principles of biological processes, as well as in detecting 
unpredictable events. The complexity of proteomic changes has made their identification 
and characterisation quite challenging in modern cell biology.  
Traditionally, techniques such as affinity purification of proteins and conventional 
column chromatography, combined with immunobloting, microscopy and mass 
spectrometry (MS), have been employed to measure abundance, modifications and 
interactions of proteins and have permitted extensive characterisation of many signalling 
pathways and cellular responses (Gingras et al., 2007, Kocher and Superti-Furga, 2007). 
However, limitations of such approaches include the need for specific antibodies or epitope-
tagged proteins, the false-positive interactions difficult to distinguish from true specific 
signals, the need for extensive protein purification resulting in loss of weak binders and of 
course the restricted throughput (small-scale) which sheds light into a small part of the large 
interconnected protein networks in the cell. Therefore, such approaches were not suitable 
for large-scale interaction mapping.  
Recent development of high-throughput, MS-based quantitative proteomics, highly 
sensitive and accurate, circumvents the above limitations, offering the potential to compare 
global proteomic outputs and gain molecular insights into cellular function and physiology, in 
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situations of health and disease. Large-scale, unbiased profiling of protein abundance 
(Andersen et al., 2005) and dynamics (Blagoev et al., 2003, de Hoog et al., 2004) provides 
data to improve characterisation of mechanisms of action and prediction of biomarkers. 
Monitoring of quantitative differences in proteomes and dynamic properties of proteins, 
including sub-cellular distribution, protein-protein interactions, turnover rates and PTMs 
(Mann, 2006, Ong et al., 2002), can be achieved by in vitro labelling of proteins. Labelling can 
be introduced either as chemical modifications (ICAT, iTRAQ) (Gygi et al., 1999, Ross et al., 
2004), or as metabolic tags of peptides (Ong et al., 2004). Direct comparison of intensity 
signals between differentially labelled isotopes correspond to peptide and protein ratios. 
Metabolic labelling with stable heavy amino acid isotopes (SILAC) is proving to be a state-of-
the-art, important tool for systems biology applicable from cell lines to primary cells, tissues 
(Ishihama et al., 2005) and animal models (Krüger et al., 2008, Sury et al., 2010). In 
combination with high-resolution MS-instruments and specialised data-processing 
bioinformatics tools, this powerful technique has led to a spectacular progress in rapid and 
accurate proteome screening of large proportions of mammalian proteomes (Graumann et 
al., 2008). 
1.4.1.2 Proteomics Instrumentation and Bioinformatic Analysis  
Routine MS-screening of hundreds of proteins in complex sample mixtures, within few 
hours, has been mainly permitted due to continuous development of the instrumentation 
and bioinformatics tools for sample processing and data analysis (Makarov et al., 2006, 
Domon and Aebersold, 2006, Mueller et al., 2008).  
Powerful mass spectrometers, such as the LTQ-Orbitraps, have become widespread in 
shotgun proteomics due to their high-mass precision and high-resolution in the rapid 
analysis of highly complex proteomes (Makarov et al., 2006, Olsen et al., 2005). Gigabytes of 
high-resolution MS data generated by proteomic analyses are processed through advanced 
computational software packages, essential for extraction, filtering, identification and 
quantification of such datasets. MaxQuant is a high-accuracy protein quantification platform 
developed by Cox et al. (Cox et al., 2009), which supports LTQ-Orbitrap instruments and 
enables high peptide identification rates. Combined with advanced modules for extensive 
bioinformatics and statistical analysis, these platforms represent powerful, unified 
computational analysis pipelines for quantitative proteomics. Perseus (http://www.perseus-
framework.org), is such a module separately developed to complement MaxQuant 
workflow. Finally, pathway/network analysis performed on relevant databases, such as 
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Ingenuity Pathway Analysis (IPA; http://www.ingenuity.com), allows for biological 
interpretation and generation of new testable hypotheses. 
However, such sensitive and automated technologies have the disadvantage of 
identifying a large number of contaminants. Additionally, during protein identification, 
partial overlap of the results from different quantification algorithms reflects imperfect 
overlap of different search engines (Searle et al., 2008, Yu et al., 2010). Because of this 
complexity, validating these events in vitro is difficult, despite the fact that they can provide 
a first step in establishing predictive models.  
 
 
Figure  1-10 – Quantitative shotgun proteomics. Differentially labelled protein samples (SILAC) are 
mixed in equal amounts and digested enzymatically into mixtures of chemically identical but 
isotopically distinct peptides. Peptides are then separated by high performance liquid 
chromatography (HPLC) and transferred into a mass spectrometer by electrospray ionisation (ESI). 
The mass spectra (MS) reveal intensity ratios of labelled peptide pairs/triplets, which assist relative 
quantification. Fragmentation spectra (MS/MS) of individual peptides contain information about 
peptide identity and are matched to protein sequence databases. Further bioinformatics analysis 
requires use of advanced algorithms, which enable protein identification and quantification, data 
visualisation and biological interpretation.  
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1.4.2 Metabolomics 
1.4.2.1 Metabolomics Analytical Platforms and Applications 
Metabolomics is a rapidly growing field of post-genomic systems biology, 
complementary to the other 'omics' areas, focusing on comprehensive characterisation of 
living systems biochemistry (Arita, 2009). The metabolome of a biological system refers to its 
complete set of small molecules (metabolites). In contrast to genome and transcriptome 
which describe the potential of a cell, tissue or organism, metabolome represents the 
fingerprint of dynamic states that reflect the actual phenotypic status of the system 
(Breitling et al., 2008, Kell, 2006). Hence, metabolome screening offers an un-biased strategy 
towards characterisation of metabolic signatures/patterns driving phenotypic changes in 
disease and biomarker identification. Moreover, construction of dynamic metabolic maps 
would permit insights into physiological stress responses and pathological processes 
involved in disease development. 
However, due to the highly diverse chemical nature of metabolites, a truly holistic 
metabolomics approach is not possible on a single analytical platform (Moco et al., 2007, 
Garcia et al., 2008). Therefore, current metabolomic studies are either targeted, focusing on 
specific metabolites or metabolic pathways of interest (Scalbert et al., 2009, Olszewski et al., 
2010), or untargeted, aiming to identification of the most significant detectable changes in a 
system, but exhaustive coverage is not the goal (De Vos et al., 2007, Dunn et al., 2011). 
Normally, the latter approach is used in hypothesis-generating and biomarker identification 
studies (Sreekumar et al., 2009).  
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Figure  1-11 – Metabolite diversity. The highly diverse chemical nature of metabolites requires use 
of multiple analytical platforms in order to achieve comprehensive characterisation of the 
metabolome. Gas chromatography (GC) and hydrophilic interaction liquid chromatography (HILIC) 
are the two most commonly used platforms in metabolomics analysis, coupled to MS. Adapted 
from Gratzfeld-Husgen and Schuster, 1996; Agilent Technologies.  
To sidestep limitations of individual analytical methods in global metabolic profiling, a 
multi-platform approach is required (Mandal et al., 2012, Naz et al., 2013, Suhre et al., 
2010). However, recent advances in HPLC technologies and mass spectrometers, have made 
liquid chromatography coupled to mass spectrometry (LC-MS) increasingly popular in the 
field of metabolomics (Cubbon et al., 2010, Scalbert et al., 2009, Kamleh et al., 2008). 
Traditional reversed phase (RP) LC-MS, which is used for separation of hydrophobic small 
molecules on a non-polar stationary phase, is now complemented by the hydrophilic 
interaction LC (HILIC) approach which separates highly polar analytes on a hydrophilic 
stationary phase (Cubbon et al., 2010, Dunn et al., 2011, Scalbert et al., 2009). Therefore 
separation of a broader spectrum of metabolites is achieved. In combination with high-
resolution mass analysers, such as the Orbitraps which offer accurate mass detection within 
1ppm (Breitling et al., 2006, Moco et al., 2007) and much greater sensitivity over nuclear 
magnetic resonance (NMR) spectrometers, significantly improve metabolite identification. 
Moreover, quantitative changes are monitored simultaneously in hundreds of metabolites. 
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Nevertheless, presence of numerous structural isomers in biological systems makes 
confirmation of identifications extremely crucial. The two parameters most extensively used 
in identification are the LC retention time (RT) and MS/MS fragmentation spectra (Scalbert 
et al., 2009), which are normally compared to authentic standards or matched to public 
MS/MS databases. Despite all improvements in technologies and instrumentation, high 
technical and biological variability during robust characterisation of the extremely dynamic 
metabolome makes the use of large number of replicates (biological, technical, analytical) 
indispensable, to avoid inconsistent findings and increase confidence (Jankevics et al., 2011).  
One of the major goals of metabolomics is the discovery of metabolic biomarkers, 
which are essential tools in clinical diagnostics as well as in monitoring progression of 
chronic diseases and responses to pharmacological treatments (Robertson, 2005, Rosner, 
2009). Chronic diseases, such as CVD, are typically multifactorial, characterised by systemic 
pathological changes, which influence numerous metabolic processes. Therefore, 
identification of a single biomarker cannot, normally, display the disease complex status and 
is insufficiently powerful to provide a clinically useful diagnosis. High-throughput, 
quantitative metabolic profiling offers the advantage of detecting several biomarkers or 
characteristic metabolite patterns, either genetically controlled or being the result of drug 
interventions. This way, a more accurate representation of the condition is provided and 
understanding of metabolism disorders and their underlying mechanisms is improved.  
The application of metabolomics in cardiovascular pathophysiology and genetics is a 
rapidly growing field, aiming to define a clearer metabolic picture for CVD prediction and 
progression. Accurate non-invasive techniques, carried out primarily on preparations of 
serum, plasma or urine (Giovane et al., 2008, Barderas et al., 2011, Waterman et al., 2010), 
have been combined with pattern-recognition algorithms to diagnose the presence and 
severity of the disease, as in the case of CAD (Brindle et al., 2002). A number of studies have 
focused and succeeded on establishing direct functional links between disease risk-genetic 
variants previously identified in GWAS, quantitative metabolic traits and an end-point of 
cardiovascular diseases. By integrating genomics with serum and urine metabolomics, such 
studies have allowed identification of new underlying biological processes and pathways in 
CVD (Illig et al., 2010, Suhre et al., 2011, Kettunen et al., 2012). Moreover, recent 
metabolomic studies are pointing at intestinal microbiota metabolism of nutrients as a 
potential risk factor for atherosclerosis pathogenesis (Koeth et al., 2013). 
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Therefore, data integration from high-throughput 'omics' studies will not only give 
insights into CVD pathophysiology, but will stress even more the importance of human 
metabolic individuality towards the development of new therapeutic strategies on a 
personalised medicine approach (Suhre et al., 2011).  
1.4.2.2 Metabolomics Bioinformatic Analysis  
In order to extract valuable information from gigabyte-large LC-MS datasets, the use of 
automated and reliable bioinformatics algorithms is essential. A number of freely available 
applications has been developed to aid conversion, quantification and identification of LC-
MS signals (Blekherman et al., 2011), complemented by advanced statistical software which 
extract significant features from such datasets (Madsen et al., 2010). IDEOM is a data 
processing pipeline developed for analysis of metabolomic LC/MS data from untargeted 
metabolomics studies (Creek et al., 2012). Its Excel graphical user interface (GUI) enables 
fast and easy conversion of raw LC-MS data into lists of putative metabolites, as well as 
advanced removal of noise and false identifications. This is achieved by implemented 
powerful processing tools, which perform automated filtering, peak annotation and 
metabolite identification with confidence levels and intensities (Smith et al., 2006b, 
Scheltema et al., 2011). Improved metabolite identification is based on mass and retention 
time matching to integrated databases. In addition, development of the PeakML.Viewer 
provides an environment for rapid inspection of peak quality (Scheltema et al., 2011). 
Subsequent interpretation of significant data through association with metabolic 
processes/networks and biomarker search, on web-servers such as IPA 
(http://www.ingenuity.com), allows for generation of new testable hypotheses and drug 
development.  
However, sensitivity of automated technologies on metabolite identification is 
particularly challenged by the highly unstable nature of metabolome, artefact peaks (Moco 
et al., 2007, Neumann and Bocker, 2010, Scheltema et al., 2009) and the large number of 
structural isomers in biological samples. Confidence of the results is greater when observed 
metabolic changes can be related to each other or to processes/pathways known to be 
deregulated or lastly to gene and protein networks of other 'omic' studies (Loscalzo et al., 
2007). Nonetheless, verification/validation of findings is vital before proceeding to 
generation of testable hypothesis and it minimally involves confirmation of the metabolite 
identity by further fractionation. In biomarker studies the result is usually validated in a 
different cohort of samples.  
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Aims 
Previously, microarray gene expression profiling in kidneys of salt-loaded WKY, SHRSP 
and chr.2 congenic strains, identified S1pr1 and Vcam1 as candidate genes predisposing to 
salt-sensitive HTN. In addition, studies in primary VSMCs from MRAs demonstrated 
association of S1P/S1PR1 signalling to specific pro-inflammatory pathways (VCAM1) through 
receptor tyrosine kinases, a process which was more pronounced in SHRSP compared to 
WKY. Moreover Gstm1 was identified as a chr.2 positional and functional candidate for BP 
regulation, mapping outside the region implicated in salt-sensitivity. 
The overall aim of this study is to dissect the functional role of these genes and of the 
chr.2 congenic interval in EH and salt-sensitivity in the SHRSP. A combination of chr.2 
congenic and transgenic strains with high-throughput proteome and metabolome screenings 
is used in order to achieve robust identification and characterisation of altered signalling 
pathways and metabolic processes associated with predisposing risk factors and 
consequences of HTN.  
The specific aims of this work are: 
• to compare, in vitro, S1PR1 expression profile in renal and vascular tissue from 21 week-
old, salt-loaded WKY, SHRSP and SP.WKYGla2a, SP.WKYGla2k congenic strains. 
• to characterise salt-sensitivity and identify putative biomarkers through metabolic 
profiling of matched urine and plasma from 21 week-old, control and salt-loaded, WKY, 
SHRSP, SP.WKYGla2k congenic and Gstm1-transgenic strains. 
• to examine, ex-vivo, MRA structure, mechanics and reactivity in vessel segments from 16 
week-old WKY, SHRSP and  SP.WKYGla2a, WKY.SPGla2a reciprocal congenic strains. 
• to study, in vitro, S1P/S1PR1-mediated mitogenic signalling in mesenteric primary VSMCs 
from 16 week-old WKY, SHRSP and SP.WKYGla2a, WKY.SPGla2a reciprocal congenic strains. 
• to extend the above study using MS-based quantitative SILAC-proteomic and 
metabolomic screenings for robust identification of S1P-mediated and genetically-driven 
changes in the global proteome and metabolome of VSMCs.  
2 Materials and Methods 
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2.1 Materials 
2.1.1 Biological Material  
Inbred colonies of the parental WKY and SHRSP, the congenic SP.WKYGla2a, 
WKY.SPGla2a and SP.WKYGla2k and the Gstm1-transgenic rat strains have been maintained at 
the University of Glasgow, by brother-sister mating and microsatellite/single nucleotide 
polymorphism genotyping, to ensure homozygosity of screened loci (Luft et al., 1988). The 
rats were housed under controlled conditions of 21°C and 12-hour light/dark cycles. The 
pups were weaned at 4 weeks and housed according to sibling group and gender thereafter. 
All rats were maintained on normal rat chow (rat and mouse No.1 maintenance diet, Special 
Diet Services, UK) and water ad libitum. The salt-loaded groups were given a salt challenge 
(1% NaCl in drinking water) at 18 weeks of age, for 3 weeks. The research was conducted in 
conformity with Public Health Service policy on the humane care and use of laboratory 
animals.  
Primary VSMCs previously isolated from thoracic aorta of the WKY and SHRSP rats, 
were grown in complete growth medium (section  2.1.4). Cell cultures were maintained for 
10-12 passages. 
2.1.2 Reagents 
General chemicals, enzymes and any reagents used in this study were of the highest 
available grades. Handling of all hazardous reagents was in accordance with Control of 
Substances Hazardous to Health regulations. The reagents were obtained from the following 
suppliers: 
• Avanti Polar Lipids Inc, Alabama, USA 
- VPC23019 sphingolipids 
• AMS Biotechnology Ltd, Europe 
- Detachin cell detachment solution 
• BD Biosciences, Oxford, UK 
- Cell nylon filter 100μm 
• BioRad Laboratories Ltd, Hertfordshire, UK 
- Ready gel tris-HCl 12%, Ready gel tris-HCl 10% 
• Dundee Cell Products Ltd, Dundee, UK 
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- DMEM-14 media (R0K0), DMEM-11 SILAC media (R6K6), DMEM-15 SILAC 
media (R10K8), dialysed FBS (MWCO 10,000 Da) 
• Enzo Life Sciences Inc (Biomol), UK 
- D-erythro sphingosine-1-phosphate  
• Fisher Scientific Ltd, Loughborough, Leicestershire, UK 
- Hepes, DMSO, Histoclear 
• GE Healthcare Bio-Sciences Ltd, Buckinghamshire, UK 
- Full-range markers RNP800E, Amersham Hybond-P polyvinylidene fluoride 
(PVDF) membrane 
• Invitrogen Ltd, Paisley, UK 
- Gibco high-glucose Dulbecco’s modified Eagle medium (DMEM), Gibco Ham’s 
F-12 nutrient mix, penicillin/streptomycin solution, gentamicin, L-glutamine, 
sodium pyruvate solution, trypsin-EDTA (0.5%-0.2%) solution, Prolong Gold 
• Lonza, Cambridge, UK 
- Calcium and magnesium free Dulbecco’s phosphate buffered saline (DPBS) 
• National Diagnostics, GA, USA 
- Histomount 
• PAA Laboratories Ltd, Somerset, UK 
- Foetal calf serum (FCS) 
• Promega Ltd, Southampton, UK 
- Sequencing grade modified trypsin 
• Roche Diagnostics Ltd, Burgess Hill, UK 
- Complete protease inhibitor cocktail 
• Sigma-Aldrich Company Ltd, Dorset, UK 
- 30% acrylamide/bis-acrylamide solution 37.5:1, bovine serum albumin (BSA), 
ponceau S, elastase (≥4 ui/mg), soybean trypsin inhibitor, N(G)-nitro-L-
arginine methyl ester hydrochloride (L-Name), carbamoylcholine chloride 
(carbachol), L-(-)-noradrenalin bitatrate (+)salt monohydrate, sodium 
nitroprusside (SNP), fasudil dihydrochloride, IgG mouse / goat / rabbit  
• Vector Laboratories Inc, Burlingame, USA 
- Vectashield, rabbit serum, goat serum 
• Worthington Biochemical Corp, Lakewood, UK 
- Collagenase type I (>200 IU/mg) 
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2.1.3 Kits 
The kits used in this study were obtained from the following suppliers: 
• Thermo Scientific, Waltham, MA, US 
- Pierce BCA Protein Assay kit 
• GE Healthcare Bio-Sciences Ltd, Buckinghamshire, UK 
- RPN2106 ECL Western Blotting Detection Reagents  
• AMS Biotechnology Ltd, Europe 
- CNM Compartmental Protein Extraction kit 
• Vector Laboratories Ltd, Peterborough, UK  
- Vectastain Universal Elite ABC kit  
- DAB Peroxidase Substrate Kit, 3,3’-diaminobenzidine  
2.1.4 Solutions & Media 
In all the solutions used in this study high purity sterile water was used as dissolving 
agent, unless otherwise stated. Laboratory glassware was autoclave-sterilised and sterile, 
disposable plastic-ware was used.  
• 6x SDS-PAGE sample buffer: 260mM Tris-HCl pH 6.8, 10% (w/v) SDS, 30% (v/v) 
glycerol, 0.012% (w/v) bromophenol blue, 6% (v/v) β-mercaptoethanol 
• SDS-PAGE resolving buffer: 10-12% (v/v) acrylamide/bis-acrylamide, 375mM Tris 
pH 8.8, 0.1 % (w/v) SDS 
• SDS-PAGE stacking buffer: 4% (v/v) acrylamide/bis-acrylamide,  125mM Tris pH 
6.8, 0.1 % (w/v) SDS 
• SDS-PAGE running buffer: 0.1 % (w/v) SDS, 25mM Tris, 192mM glycine 
• SDS-PAGE transfer buffer: 25mM Tris, 192mM glycine, 20% (v/v) methanol 
• Coomassie stain solution: 0.025% (w/v) Coomassie brilliant blue R-250, 40% (v/v) 
methanol, 10% (v/v) acetic acid 
• Coomassie de-stain solution: 40% (v/v) methanol, 10% (v/v) acetic acid 
• Ponceau S: 0.5% (w/v) Ponceau S in 1% (v/v) acetic acid 
• Tris-buffered saline / Tween (TBST): 140mM NaCl, 20mM Tris pH 7.6, 0.1% (v/v) 
Tween-20 
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• Blocking buffer: 5% (w/v) BSA in TBST 
• 10x Phosphate-buffered saline: 1.37M NaCl, 27mM KCl, 0.1M Na2PO4, 18mM 
KH2PO4, pH 7.4 
• Citrate buffer: 8mM trisodium citrate, 2mM citric acid, pH 6.0 
• Stripping Solution: 0.2M glycine in 1% (w/v) SDS, pH 2.2 
• Krebs / Physiological salt solution (PSS): 119mM NaCl, 4.7mM KCl, 0.6mM 
MgSO4.7H20, 25mM NaHCO3, 1.18mM KH2PO4, 11mM D-glucose, 2.5mM 
CaCl2.2H20, pH 7.4 
• Calcium-free PSS: 23µM EDTA in PSS free of CaCl2 
• Potassium PSS (KPSS): 123mM KCl in PSS free of NaCl  
• Paraformaldehyde (PFA) 4%:  12.5mM NaOH 1N, 4% (w/v) PFA in DPBS 
• Metabolite extraction buffer: Chloroform : Methanol (100% v/v) : ddH2O (1:3:1) 
All cell culture media were supplemented with 10% FCS and 5% 100 IU/ml Penicillin - 
100μg/ml Streptomycin and were sterilized through a 0.2μm pore size filter, unless 
otherwise stated. 
• Wash media: Ham’s F-12 nutrient mix, 10mg/ml Gentamicin, 2mM L-glutamine, 
4.8g/ml Hepes, serum free 
• Complete growth media: DMEM with 4mmol/L L-glutamine, 4.5g/L D-glucose, 110 
mg/L sodium pyruvate 
• SILAC complete media: SILAC DMEM media containing unlabelled arginine and 
lysine amino acids (R0K0) / SILAC DMEM media containing 13C labelled arginine 
and lysine amino acids (R6K6) / SILAC DMEM media containing 13C and 15N labelled 
arginine, and 13C and 15N labelled lysine amino acids (R10K8). Media were 
supplemented with 10% (v/v) dialysed FBS. 
• Cryo-preservation media: 10% (v/v) DMSO in complete growth media  
• Pre-digestion media: 3mg/ml Collagenase II in wash media 
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• Digestion media: 2mg/ml BSA, 2mg/ml Collagenase II, 0.12mg/ml Elastase, 
0.36mg/ml soybean trypsin inhibitor in wash media 
• Cell lysis buffer: Buffer A: 50mM Na4P2O7, 50mM NaF, 50mM NaCl, 5mM Na2EDTA, 
10mM Hepes, 0.5% (v/v) triton X-100, pH 7.4; Buffer B: 1mM Na3VO4, 1mM PMSF, 
2 tablets of complete EDTA-free protease inhibitor cocktail per 50ml 
2.1.5 Primary Antibodies 
Primary antibodies were purchased from the following suppliers and are listed in Table 
 2-1:  
• Abcam, Plc., Cambridge, UK 
• Cell Signaling Technologies, Inc., MA, USA - New England Biolabs, Ltd, UK 
• Santa Cruz Biotechnology, Inc., CA, USA 
Table  2-1. List of primary antibodies used in the experiments 
Primary 
antibodies
Description Company Reference Dilution Method
1/200 - 
1/500 WB
1/100 - 
1/1000 IHC
HMOX1
IgG1 monoclonal antibody raised in mouse 
immunised with synthetic peptide corresponding to 
aa 1-30 of human HMOX1
Abcam ab13248 1/250 WB
CAV1
IgG polyclonal antibody raised in rabbit immunised 
with synthetic peptide corresponding to aa 1-17 of 
human CAV1
Abcam ab2910 1/500 WB
NPR3
IgG polyclonal antibody raised in rabbit immunised 
with synthetic peptide corresponding to aa 400-500 of 
human NPR3
Abcam ab79164 1/500 WB
NQO1
IgG polyclonal antibody raised in rabbit immunised 
with synthetic peptide from within residues 200 to C-
terminus of human NQO1
Abcam ab34173 1/500 WB
ACTA1
IgG polyclonal antibody raised in rabbit immunised 
with synthetic peptide from N-terminus of human 
ACTA1
Abcam ab11317 1/500 WB
IgG polyclonal antibody raised in rabbit immunised 
with synthetic peptide from C-terminus of mouse 
GSTM1
Provided by 
professor John D. 
Hayes
1/5000 WB
GAPDH
IgG1 monoclonal antibody raised in mouse 
immunised with rabbit muscle GAPDH
Abcam ab8245 1/5000 WB
GSTM1
1µg/ml WB
EDG1
IgG polyclonal antibody raised in rabbit immunised 
with synthetic peptide corresponding to aa 241-253 of 
human EDG1
Abcam ab23695
IgG polyclonal antibody raised in rabbit immunised 
with synthetic peptide from C-terminus of mouse 
EDG1
Provided by Dr. Tim 
Palmer (PA1-1040)
 
Sofia Tsiropoulou Chapter 2 64 
Primary 
antibodies
Description Company Reference Dilution Method
ICC
AQP2
IgG polyclonal antibody raised in goat immunised 
with synthetic peptide corresponding to C-terminus 
of human aquaporin 2
Santa 
Cruz
sc-9882
1/100 - 
1/2000 
IHC
ACTA2
IgG2a monoclonal antibody raised in mouse 
immunised with synthetic peptide corresponding to 
N terminal amino acids 1-10 of alpha smooth muscle 
actin 
Abcam ab18147
1/100 - 
1/1000 
IHC
IgG polyclonal antibody raised in rabbit immunised 
with synthetic peptide corresponding to N-terminus 
of human SMCα-actin
Abcam ab5694 1/100
beta-Actin
IgG1 monoclonal antibody raised in mouse 
immunised with synthetic peptide corresponding to 
N-terminus of the beta isoform of actin
Abcam ab6276 1/10000 WB
p38 MAPK
IgG polyclonal antibody raised in rabbit immunised 
with synthetic peptide derived from the sequence of 
human p38 MAPK
Cell 
Signaling
#9212 1/1000 WB
WB
ERK1/2
IgG polyclonal antibody raised in rabbit immunised 
with synthetic peptide derived from a sequence in 
the C-terminus of rat ERK1
Cell 
Signaling
#9102 1/400 WB
phospho-     
p38 MAPK
IgG polyclonal antibody raised in rabbit immunised 
with synthetic phospho-peptide corresponding to 
residues surrounding Thr180/ Tyr182  of human p38 
MAPK
Cell 
Signaling
#9211 1/1000
WB
SAPK/JNK
IgG polyclonal antibody raised in rabbit immunised 
with GST/human JNK2 fusion protein
Cell 
Signaling
#9252 1/1000 WB
phospho-
ERK1/2
IgG polyclonal antibody raised in rabbit immunised 
with synthetic phospho-peptide corresponding to 
residues surrounding Thr202/Tyr204 of human ERK1
Cell 
Signaling
#9101 1/400
WB
Vimentin
IgG1 monoclonal antibody raised in mouse 
immunised with cytoskeletal vimentin extract of calf 
lens
Abcam ab8978 1/500 WB
phospho-
SAPK/JNK
IgG polyclonal antibody raised in rabbit immunised 
with synthetic phospho-peptide corresponding to 
residues surrounding Thr183/Tyr185 of human 
SAPK/JNK
Cell 
Signaling
#4668 1/1000
WB
Na-K 
ATPase
IgG1 monoclonal antibody raised in mouse 
immunised with full length native protein from 
rabbit renal outer-medulla
Abcam ab7671 1/5000 WB
histone 
H1.0
IgG1 monoclonal antibody raised in mouse 
immunised with ox liver histone H1.0
Abcam ab11079 1/500
WB
S1PR3
IgG monoclonal antibody raised in mouse immunised 
with synthetic peptide corresponding to C-terminal 
of human EDG3
Abcam ab12254 1/5000 WB
VCAM1
IgG monoclonal antibody raised in rat immunised 
with glycoprotein fraction from cerebellum of  8-10 
days old mice
Abcam ab78712 1/100
WBS1PR2
IgG polyclonal antibody raised in goat immunised 
with synthetic peptide corresponding to C-terminus 
of human EDG5
Santa Cruz sc-16085 1/100
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2.1.6 Secondary Antibodies 
Secondary antibodies were purchased from the following suppliers and are listed in 
Table  2-2: 
• Dako-Cytomation, Denmark  
• Abcam, Plc., Cambridge, UK 
• Vector Laboratories Ltd, Peterborough, UK 
Table  2-2. List of secondary antibodies used in the experiments 
Secondary antibodies Description Company Reference Dilution Method
Anti-mouse IgG
Horseradish peroxidase-
conjugated, polyclonal 
antibody, raised in rabbit
Dako #P0260 1/1000 - 1/2000 WB
Anti-rabbit IgG
Horseradish peroxidase-
conjugated, polyclonal 
antibody, raised in swine
Dako #P0399 1/1000 - 1/2000 WB
Anti-goat IgG
Horseradish peroxidise-
conjugated, polyclonal 
antibody, raised in rabbit 
Abcam ab6741 1/200 IHC
Anti-mouse/rabbit IgG
Biotinylated polyclonal 
antibody, raised in horse
Vector
#BA-1400 
(Universal 
ABC kit) 
1/200 IHC
 
2.1.7 Software 
• Image J V1.42, National Institutes of Health, Bethesda MD, USA 
• LabChart 6.1.1,  ADInstruments Ltd, Oxford, UK 
• MyoView 1.1, DMT, Denmark 
• Xcalibur 2.2.0 Thermo Fisher Scientific, Inc., MA, USA 
• MaxQuant 1.1.1.25, 1.2.0.18, 1.2.2.6, Max Planck Institute, Martinsried, Germany 
• Perseus 1.2.0.17, 1.2.7.4 Max Planck Institute, Martinsried, Germany 
• Scaffold 3.2.0, Proteome Software, Inc., Portland, USA 
• Mascot Server 2.3, Matrix Science Ltd, London, UK 
• IDEOM V11 – V19, Glasgow Polyomics Facility, Glasgow, UK 
• PeakML Viewer, Glasgow Polyomics Facility, Glasgow, UK 
• Wallac Work-Out, Turku, Finland  
• GraphPad Prism 4 for Windows, GraphPad Software, San Diego California USA 
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2.2 General Primary Cell Culture Methods 
All cell culture was performed under sterile conditions in vertical laminar flow 
cabinets. Cells were cultured in 100mm x 20mm culture dishes or T25, T75 and T150 culture 
flasks with vented cups (Corning, UK) and were maintained in the appropriate media as sub-
confluent cultures (70-80% confluence) at 37°C in a 5% CO2 humidified incubator. Media was 
replaced every other day. 
2.2.1  Isolation of Mesenteric Primary Rat VSMCs 
Rat primary vascular smooth muscle cells derived from mesenteric arteries of 16 week-
old male WKY, SHRSP, SP.WKYGla2a and WKY.SPGla2a rats were isolated by standard 
collagenase / elastase enzymatic digestion based on a modified version of the protocol 
described by Yogi and colleagues (Yogi et al., 2011). In summary, 1-3 animals were sacrificed 
by cervical dislocation and their mesenteric beds were excised and pooled in ice-cold wash 
media. Maximum storage time was 1h, on ice. Arteries were gently washed off of remaining 
blood with wash media and then incubated in pre-digestion media (10ml/mesenterium) for 
15min, at 37˚C under agitation. Excess fat, connective tissue and adventitia were stripped off 
in petri dishes containing cold wash media. Clean mesenteric beds were incubated in 
digestion media (7ml/mesenterium) for 60-90min, at 37˚C under agitation. The digested 
vessel fragments were subsequently passed through a 21-gauge needle, to obtain a 
homogeneous suspension, and filtered through a 100μm nylon filter to remove debris. Cell 
suspension was centrifuged for 2-3min at 800g, re-suspended in 5ml complete growth 
media, distributed in a T25 flask and kept in a 5% CO2 humidified incubator, at 37°C (passage 
0). Media was replaced after 24h. Cells were cultured up to passage 8.  
2.2.2 Culture and Passage of Primary Rat VSMCs 
Cultures of primary cells were passaged at approximately 70-80% confluence, ensuring 
they were not subject to stress by over or under-confluence. Media was removed and cells 
were washed in DPBS. Trypsin-EDTA (700µl / 25cm2) or Detachin (1ml / 25cm2), a mild 
enzymatic solution, were added to the cells and incubated at 37°C for 5min or until the 
majority of cells were detached. In the case of trypsin-EDTA the enzymatic action was 
subsequently suspended by the addition of a triple-volume of complete media. Cells were 
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pelleted by centrifugation at 800g for 3min and re-suspended in either fresh growth media 
for plating or ice-cold lysis buffer for protein extraction. 
2.2.3 Cryo-preservation of Primary Rat VSMCs 
Cells were harvested as described in section  2.2.2, and re-suspended in cryo-
preservation media at a density of approximately 2 x 106 cells/ml. Cell suspension was 
aliquoted into sterile 1ml cryogenic vials and cooled at a constant -1°C / min down to -80°C, 
using isopropanol containers. After 24h vials were stored in liquid nitrogen. 
For resuscitation, vials were quickly thawed at 37°C until culture was liquefied. Cells 
were carefully added into pre-warmed complete media and plated in a T25 flask. DMSO-
containing medium was replaced the following day. 
2.2.4 Characterisation of Mesenteric Primary Rat VSMCs 
The purity of primary VSMC cultures (% VSMC) was assessed by positive 
immunofluorescent staining (ICC) for the SMC type-specific marker SMC-α-actin (ACTA2, 
polyclonal rabbit-anti human; ab5694).  
At passage 2, cells were harvested and seeded onto sterile coverslips in 6-well plates 
and allowed to attach overnight. Media was then removed and cells were rinsed twice with 
DPBS, fixed in 4% PFA for 15min at rt and washed another three 5min times in DPBS. Cell 
permeabilisation with TritonX-100 (0.1% in DPBS) for 15min at rt was followed by three 5min 
DPBS washes. Cells were then incubated with 20% (v/v) serum/DPBS from the appropriate 
species that the secondary antibody was raised in, which was goat in this case, for 30min at 
rt, with one further DPBS wash. This was followed by incubation with the primary antibody 
(1:50 ACTA2 in 20% goat serum/DPBS) or an equivalent dilution of rabbit IgG used as a 
negative control, for 1h at rt. Excess primary antibody was removed by three 5min DPBS 
washes. Next, cells were incubated with secondary FITC-conjugated antibody (1:200 goat 
anti-rabbit IgG in 20% goat serum/DPBS), for 45min at rt. From this point on, coverslips were 
kept in the dark at all times to prevent photo bleaching of samples. Following a further three 
5min DPBS washes to remove excess secondary antibody, coverslips were mounted onto a 
glass slide using Vectashield supplemented with propidium iodide (PI) for nuclei counter-
staining. Coverslips were sealed with nail-varnish and left to dry overnight at rt, then stored 
at 4˚C. Cells were imaged under a Zeiss LSM 510 Meta confocal microscope (Carl Zeiss Ltd, 
Hertfordshire,UK) with compatible objectives, at x40 and x100 magnifications. 
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2.2.5 S1P-stimulation of Mesenteric Primary Rat VSMCs 
At sub-confluence (~80%), complete growth media was washed off three times with 
DPBS. Cells were starved overnight (~16h) in serum-free regular DMEM media to induce 
growth arrest and synchronise cell cycles to the G0 phase. Next day, starvation media was 
refreshed 30min prior to stimulation. Subsequently, cells were stimulated for 30min, at 37°C, 
with S1P (10-6mol/L) or an equivalent amount of 4mg/ml BSA in ddH2O (S1P solvent: 
vehicle), used as a negative control. Stimulation was terminated by washing off the media 
three times with cold DPBS. After removing DPBS completely, dishes were left upturned to 
dry and kept temporarily in dry ice or stored at -80˚C until used for whole cell lysate 
preparation. 
 In one set of experiments, prior to S1P stimulation, cells were exposed for 30min to 
VPC23019 (S1PR1/S1PR3 antagonist, 10-5mol/L) or equal amount of the VPC solvent [vehicle: 
DMSO/1N HCl (95:5 v/v) diluted (1:20) in 3% BSA (in ddH2O)], used as a negative control.  
2.2.6 SILAC Labelling of Mesenteric Primary Rat VSMCs 
Comparison of the whole proteome of the mesenteric primary VSMCs from WKY, 
WKY.SPGla2a, SP.WKYGla2a and SHRSP, was performed using stable isotope labelling with 
amino acids in cell culture (SILAC).  
At passage 3, the complete growth media was washed off twice with DPBS and 
replaced by regular DMEM medium supplemented with 10% dialysed serum. After cells 
being adapted for 24h, media was washed off and replaced by differentially labelled SILAC 
media. WKY cells were grown in the control “light”- R0K0 condition, with 12C6
14N4 L-arginine 
(Arg0) and 12C6
14N2 L-lysine (Lys0). SHRSP were “heavy”- R10K8 labelled with 
13C6
15N4 L-
arginine (Arg 10; 10Da heavier) and 13C6
15N2 L-lysine (Lys8; 8Da heavier). The 2a congenic 
strains were “medium heavy”- R6K6 labelled with 13C6 L-arginine (Arg6; 6Da heavier) and 
13C6 
L-lysine (Lys6; 6Da heavier). Cells were grown in the labelled media for 6 divisions, to ensure 
uniform incorporation of isotopic amino acids into proteins. At passage 7, cells were 
stimulated with S1P (10-6mol/L) as outlined in section  2.2.5 and harvested (section  2.2.2) to 
be used for proteome profiling. 
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2.2.7 Preparation of Whole Cell Lysates 
For protein extraction, cells were harvested as described in section  2.2.2, washed in 
DPBS and centrifuged for 5min at 800g, 4°C.  The pellet was then re-suspended in ice-cold 
lysis buffer (500µl / T150).   
In stimulation experiments (section  2.2.5), after washing off media, petri dishes were 
left inverted to dry. Two 10cm dishes were used per condition (e.g. vehicle, S1P-stimulated). 
Dishes were placed on an ice-tray and cells were scrapped off in ice-cold lysis buffer (120µl / 
dish) and collected into an Eppendorf tube.  
The suspension was incubated under rotation at 4°C for 30min and subsequently 
homogenised by 50 passes through a 25-gauge needle. Cell homogenates were centrifuged 
at 13,000 x g and 4°C for 15min and supernatant was stored at -80°C until required. Total 
protein concentration was measured using a BCA-based method as outlined in section  2.3.1. 
2.2.8 Compartmental Protein Extraction from Cells 
Enrichment of cellular compartments in protein was achieved using an Amsbio CNM 
Compartmental Protein Extraction Kit according to the manufacturer’s instructions. Briefly, 
cells were harvested, counted using a haemocytometer and lysed in an ice-cold hypotonic 
buffer (C-provided) by passing the suspension through a needle base for approximately 70 
times, while on ice. Lysate was compartmentalised in cytoplasmic, nuclear and membranic 
fractions by serial incubations (20min, 4°C) and centrifugations (20min, 15,000g, 4°C) in 
respective compartment extraction buffers. Hypotonic buffers C and N were used to break 
the cytoplasmic and nuclear membranes, respectively, whereas for extraction of membrane 
proteins the M buffer contained NP-40 detergent. Protein concentration of fractions was 
measured by BCA assay (section  2.3.1) and samples were stored at –80°C until required. 
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2.3 General Protein Methods 
2.3.1 Determination of Protein Concentration 
Protein concentrations were determined using a Pierce bicichoninic acid (BCA) Protein 
Assay kit according to the manufacturer’s instructions. Serial dilutions of albumin protein 
standard (provided), ranging from 25μg/ml to 2000μg/ml, was prepared (in lysis buffer) to 
generate a concentration standard curve for each assay. BCA reagent was prepared by 
mixing reagents A and B (provided) at a ratio of 50:1. 5μl of the albumin standards / protein 
samples / lysis buffer (blank) were added to a 96-well plate, in duplicate. Volume in each 
well was adjusted to 25μl with lysis buffer. BCA reagent (copper sulphate and bicinchonic 
acid) was then added at a ratio of 8:1 (BCA : sample/standard). Plates were subsequently 
incubated in dark at 37°C for 15min. At this temperature, protein peptide bonds reduce 
copper ions in the BCA reagent (Cu2+→ Cu1+). Each Cu1+ reacts with 2 molecules of BCA to 
produce a purple-coloured product detectable at 562nm. The optical density (OD) of the 
colour is directly proportional to the amount of protein in a sample. Absorbance at 562nm 
was determined using a Wallac Victor2 plate reader (Wallac, Turku, Finland). An average 
value of the two replicates was calculated. Concentration of protein in each sample was 
estimated from the linear equation of the standard curve by Work-Out software (Wallac) 
and the degree of dilution.  
2.3.2 SDS-PAGE  
In each experiment, equal amounts of protein samples (30-100µg) were diluted to an 
equal final volume, using ddH2O. Proteins were then denatured by exposure to 1% v/v β-
mercaptoethanol (1x sample buffer) and incubation at 70˚C, for 10mins. Samples were 
resolved by SDS-PAGE on gels of 4 % (w/v) acrylamide stacking buffer and 10-12 % (w/v) 
acrylamide resolving buffer, depending on the molecular weight of the proteins of interest. A 
30% acrylamide / bis-acrylamide mixture was used to form the gels, which were polymerised 
by addition of APS and TEMED. Full range (10 - 250 kDa) Amersham Rainbow or See Blue 
Plus2 molecular weight markers were resolved alongside samples to allow size estimation of 
immunoreactive proteins. Electrophoresis was performed in 0.1 % (w/v) SDS running buffer, 
at a constant electric potential of 150 volts. 
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2.3.3 Coomassie Staining / De-staining 
Following SDS-PAGE, gels containing the resolved proteins (section  2.3.2) were 
carefully stained in Coomassie solution for at least 30min, under gentle shaking. Gels were 
then de-stained in Coomassie de-staining solution, until protein bands become clearly 
visible. 
2.3.4 In-gel Trypsin Digestion of Coomassie-stained proteins 
All steps were performed in a laminar flow hood. Surfaces were cleaned with 70% (v/v) 
ethanol before use. Gloves were worn at all times to avoid keratin contamination. HPLC 
grade solvents were used to avoid polymers contamination. 
Coomassie-stained gels were rinsed in dH2O for 10min and placed on a light-surface 
inside a fume hood. Each lane was divided in 6 subsequent pieces from higher to lower 
molecular weights. Excised gel pieces were placed in Eppendorf tubes and washed first in 
100mM ammonium bicarbonate (NH4HCO3 - Sigma) and then in 50% (v/v) ACN/100mM 
NH4HCO3, pH 8, for another 30min at each stage, on shaker. To reduce peptides, treatment 
with 100mM NH4HCO3 / 45mM DTT (fresh) was performed at 60˚C for 30min. Samples were 
cooled down to rt and alkylated with 100mM iodoacetamide (IAA) (fresh) for 30min in the 
dark. In-gel reduction of disulphide bonds on cysteine by the mild agent DTT and alkylation 
of sulphydryl (SH) groups by IAA to prevent re-formation of disulphide bridges, before 
trypsin digestion, allows for wider protein coverage (Shevchenko et al., 1996). An extra 
30min wash was performed in 50% (v/v) ACN/100mM NH4HCO3, on shaker. Gel pieces were 
subsequently de-hydrated in 100% (v/v) ACN for 10min and completely dried off in a vacuum 
centrifuge. Sufficient amount of sequencing grade trypsin (in 25mM NH4HCO3) was added to 
re-hydrate each gel piece at a protease/protein ratio of 1:100 to 1:20 (w/w). Protein was 
digested overnight at 37˚C. Next day, supernatant was transferred to a 96 well-plate. Gel 
pieces were washed initially with 5% (v/v) formic acid and then with 100% (v/v) ACN for 
20min at each stage, at rt. Solvent was transferred to the respective well from the first 
extraction in the 96 well-plate. Combined extracts were completely dried off in a Speedvac 
and plate was stored at -20 ˚C until used for LC/MS. 
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2.3.5 Semi-dry Protein Transfer 
Proteins separated by SDS-PAGE (section  2.3.2) were subsequently electro-transferred 
from the gel onto a Hybond-P PVDF membrane by semi-dry transfer. Briefly, gels, filter paper 
and the PVDF membrane were equilibrated in transfer buffer for 10mins. Then, they were 
placed on a semi-dry transfer apparatus in the following order: 3 layers of filter paper, then 
the PVDF membrane, followed by the gel and a further 3 layers of filter paper. Air bubbles 
from in-between the layers were removed, apparatus lid was placed on and constant current 
of 180mA was applied for 30-45min. Time of transfer was determined by the number, 
percentage and thickness of the gels, as well as by the size of the protein(s) of interest. To 
check the efficiency of the electro-transfer, membranes were finally stained with Ponceau-S 
for 5min and de-stained with dH2O and TBST. 
2.3.6 Western Immunoblotting  
Following transfer, PVDF membranes were washed in TBST for 5min prior to 
incubation with blocking buffer for at least 1h, at rt. Membranes were then probed with 
primary antibody overnight, at 4°C, under gentle shaking. Primary antibodies were diluted to 
appropriate concentrations (section  2.1.5) in blocking buffer. After six 5min washes in TBST, 
membranes were incubated with the appropriate HRP-conjugated secondary antibody 
diluted in blocking buffer (section  2.1.4), for 2h, at rt. A further six 5min washes in TBST were 
performed. Immunoreactive proteins were detected using Amersham ECL Western Blotting 
Detection reagents, as per the manufacturer’s instructions. X-ray films were exposed to 
membranes for 1sec-30min, and developed using a Kodak X-OMAT 2000 developer. Band 
densitometric quantification (arbitrary units) was performed using ImageJ V1.42 and protein 
expression levels were normalised to expression levels of housekeeping/control proteins 
(GAPDH, β-actin). 
2.3.7 Membrane Re-probing 
After film exposure, membranes were washed off ECL buffer twice, for 5min in TBST. 
Bound antibodies were stripped off by incubation in stripping buffer for 30min, at rt, under 
mild shaking. Three 5min washes in TBST were followed by a 30min incubation in blocking 
buffer, at rt. Membranes were re-probed with new primary antibodies and the subsequent 
steps of immunodetection were performed as described in section  2.3.6.  
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2.4 Immunohistochemistry 
Expression levels of S1PR1 in thoracic aortas and kidneys from 21 week-old, salt-
loaded, WKY and SHRSP rats were detected by immunohistochemistry (IHC). Tissue 
collection and fixing (10% v/v formalin) was performed by Dr Caline Coh-Tan. Preparation of 
paraffinised sections was performed by Mr Andy Carswell. 
Prior to histological staining, paraffin was removed from the cut sections by two 7min 
washes in Histoclear and rehydrated through an ethanol gradient of 100%, 95% and 70% for 
7min at each stage and a final 7min rinse in dH2O. Endogenous peroxidase was quenched by 
incubating slides for 15min in 0.3% (v/v) H2O2 in methanol, at rt. After two 10min washes in 
dH2O, antigen was retrieved by heating at 95°C in citrate buffer for 15min, followed by two 
further 10min washes. Sections were incubated in 2% normal blocking serum (derived from 
the appropriate species that the secondary ab was raised in) in PBS, for 1h. Subsequently, 
primary antibodies against S1PR1 (ab23695; IgG rabbit polyclonal) and the positive controls 
AQP2 (sc-9882; IgG goat polyclonal) and ACTA2 (ab18147; IgGa2 mouse monoclonal), as well 
as equivalent IgGs (derived from same species primary ab was raised in - used as negative 
controls) were probed overnight. Antibodies and IgGs were diluted in the appropriate 
blocking serum at a range of 1/100 to 1/2000. Three 5min washes with PBS were followed 
by incubation with either biotinylated anti-mouse/rabbit (ABC universal kit) or HRP-
conjugated anti-goat secondary antibody, diluted in blocking serum (1/200), at rt, for 30min 
or 1h, respectively. When ABC universal secondary antibody was used, sections were 
subsequently incubated with ABC complex for 30min, at rt. Sections were then washed three 
times in PBS and incubated with the chromogen diaminobenzidine hydrochloride with 
hydrogen peroxide (DAB substrate kit) for 5min, at rt. Sections were then counterstained 
with heamatoxylin for 2min, washed in cold running tap water for 5min and dehydrated 
through a reverse ethanol gradient of 70%, 95% and 100% for 7min at each stage with two 
final 7min washes in Histoclear. Histomount was used to mount the sections before 
observation under Olympus BX40 transmitted light microscope, at several magnifications. 
Positive immunostaining was seen as a dark brown and nuclei appeared blue/purple. 
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2.5 General Ex-Vivo Drug Interventions 
Mesenteric resistance arteries (MRA) were isolated from WKY, SHRSP, WKY.SPGla2a 
and SP.WKYGla2a rats to investigate vascular reactivity by wire myography and vascular 
remodelling by pressure myography. Animals were sacrificed at 16 weeks of age under 
terminal anaesthesia with isoflurane. Mesenteries were excised and placed in ice-cold 
physiological salt solution (PSS). Third order MRAs (2–3 mm in length) were dissected of 
adherent connective tissue, and stored in PSS at 4˚C, overnight. Tissue collection as well as 
myograph set up, vessel mounting and normalisations were performed by Mrs Elisabeth 
Beattie. 
2.5.1 Wire Myography 
Vessel segments were suspended on two stainless steel wires on a four-channel small 
vessel myograph (DanishMyoTech (DMT), Atlanta, GA). Changes in isometric tension of 
vessels were detected by a force transducer and recorded by the LabChart (v6.1.1) data 
acquisition package. Segments were maintained in organ bath chambers filled with PSS pH 
7.4, at 37˚C and gassed with 95% O2 - 5% CO2. To achieve maximal contraction, vessels were 
first allowed to stabilize for 30min at resting tension and then exposed for a further 30min to 
a predetermined optimal active tension for rat MRAs (lumen diameter normalised to 90% of 
the diameter expected at transmural pressure of 100 mmHg) (Falloon et al., 1995). Viability 
of vessels was assessed by a contractile response to treatment with high potassium PSS 
(KPSS) and maximal active tension between vessels was calculated. Following three PSS 
washes, vessels were left to rest for 30min. Contractile responses to cumulative doses of the 
α-adrenergic receptor agonist, noradrenalin (NA, 10−9 to 3x10−5 M), were measured first in 
the absence and again after two PSS washes, in the presence of the Rho-kinase (ROCK) 
inhibitor Fasudil (3μM) (Asano et al., 1987). Changes in tension in the presence of Fasudil 
provided a measure of the contribution of Rho kinase pathway on the basal tone. The 
degree of contraction was calculated and expressed as percentage of the maximal response 
at 3x10-5 NA without Fasudil. Similarly, relaxation in response to cumulative doses of the 
cholinergic agonist carbachol (10-8 to 10-5 M) was assessed in the absence and presence of 
the endothelial nitric oxide synthase (eNOS) inhibitor, L-NAME (100μM). Changes in tension 
in the presence of L-NAME indicated effect of endothelial NO on the regulation of basal 
tone. Relaxation was calculated and expressed as a percentage of sub-maximal (~80%) 
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contraction to NA at 3x10-6M. Finally, MRAs were washed 3 times with PSS and allowed to 
stabilize for 10min. Endothelium-independent vasorelaxation was assessed using cumulative 
doses of an external donor of NO, the sodium nitroprusside (SNP, 10-8 to 10-5M) in a similar 
manner. Dose response curves were plotted on GraphPad Prism 4. Relaxation and 
contraction responses were expressed as percentages of the maximal response and 
statistical analysis was performed using two-way analysis of variance (ANOVA) followed by 
Bonferroni’s multiple comparison test, on GraphPad Prism 4. Differences were considered 
statistically significant at P<0.05. 
 
Figure  2-1. Myography systems. (A) Wire myograph. The vessel segment is mounted on two steal 
wires. The adjustable jaw is connected to a micrometer screw and the fixed jaw to the force 
transducer.  (B) Pressure myograph. The vessel is mounted onto two glass cannulas. Inflow and 
outflow pressures are controlled by adjusting the height of Ca-free PSS reservoirs on a tower and 
are continually recorded by two in-line pressure transducers. 
2.5.2 Pressure Myography 
Pressure myography is the method of choice for studying structure and mechanics of 
small vessels, which under exposure to intraluminal pressures assume a physiological shape 
(Halpern and Osol, 1986; Mulvany and Aalkjaer, 1990). 
Vessel segments were tied on the two glass cannulas of a pressure myograph (DMT 
p100 pressure system, Denmark) using nylon ties. Two in-line pressure transducers 
continually recorded inflow and outflow pressures, which were controlled by adjusting the 
height of Ca-free PSS reservoirs on a tower. A Zeiss Axiovert 25 inverted microscope 
equipped with a CCD Sony XC-75CE monochrome video camera was used to capture a real 
time video image of the vessel, displayed on a PC monitor by MyoView 1.1 software (DMT, 
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Denmark). Lumen (internal) and vessel wall (external) diameters were measured at a x200 
magnification. Within the bath chamber, MRAs were maintained in Ca-free PSS, pH 7.4, at 
37˚C and gassed with 95% O2 - 5% CO2. Vessel lumen was flushed to remove any remaining 
debris or blood and the segment was straightened without any stretching, by adjusting the 
micrometer. Vessels were subjected to gradually increasing intraluminal pressure from 10-
110 mmHg at 10 and 20 mmHg intervals, lasting 10min each. Internal (Di; lumen width) and 
external (De) diameters of vessels were measured and used to calculate structural and 
mechanical parameters. Structural parameters included cross sectional area (CSA = (π / 4) x 
(De
2 - Di
2)) and wall to lumen ratio (Wall / lumen = (De - Di) / 2Di). Mechanical parameters 
were calculated as previously described by Baumbach and Heistad (Baumbach and Heistad, 
1989) and included: Circumferential wall strain = (Di – D0) / D0, where D0 is the diameter at 
the lowest intraluminal pressure of 10 mmHg and Di is the observed internal diameter for a 
given pressure. Circumferential wall stress = (P x Di) / De - Di where P is the intraluminal 
pressure. Response curves were plotted on GraphPad Prism 4. Statistical analysis of 
structural and mechanical parameters was performed using two-way analysis of variance 
(ANOVA) followed by Bonferroni’s multiple comparison test. The strain-stress relation was 
fitted to an exponential curve for each vessel and the slope of the curve was determined. 
The slopes were compared between groups using unpaired Student’s t-test. Differences 
were considered statistically significant at P<0.05. 
2.6 Proteomic Profiling 
2.6.1 Sample Preparation 
Comparisons of whole proteome from 16 week-old WKY, SHRSP, WKY.SPGla2a and 
SP.WKYGla2a were performed on 30min S1P-stimulated primary VSMCs (section  2.2.6). To 
optimise the experimental design (comparison of 3 experimental groups at a time) triple 
SILAC labelling (section  2.2.5) was performed, allowing comparison of the proteome from all 
four groups in just two experiments: (A) WKY - WKY.SPGla2a - SHRSP and (B) WKY - 
SP.WKYGla2a - SHRSP. After differential labelling cells from each strain were harvested and 
mixed at 1:1:1 ratio, based on cell number counted with a haemocytometer (Hausser 
Scientific, US). Following cell lysis (section  2.2.7), the mixed-lysates were processed using 
SDS-PAGE (section  2.3.2), gel was stained with Coomassie (section  2.3.3) and each lane was 
divided into 6 gel slices to reduce the complexity of samples for LC separation. Subsequently, 
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each slice underwent in-gel trypsin digestion (section  2.3.4) and the eluates were stored as 
individual samples at -80˚C, until used for proteome profiling. The sample preparation 
procedure is illustrated in Figure  2-2A.  
2.6.2 Liquid Chromatography – Tandem Mass Spectrometry Analysis 
For proteomic profiling, the chemically identical and isotopically distinct SILAC tryptic 
peptides were distinguished by polarity and mass using reversed-phase rapid separation 
liquid chromatography (RSLC) operated on a nano-HPLC flow system (Ultimate 3000, Dionex, 
Camberley, UK), which provides ultrafast, ultrahigh-resolution LC separations using high flow 
rates.  Initially, samples were loaded onto a Dionex 100μm x 2cm, 5μm/100Å pore size, C18 
nano trap column, in ACN (98:2) and 0.1% formic acid solution. Samples were then washed 
off into an Acclaim PepMap C18 nano column 75μm x 15cm, 2μm/100Å pore size at a flow 
rate of 0.3μm/min. The nano-system was maintained at 35 °C in a column oven. Elution of 
samples was carried out for 100min, using a gradient of solvent A: 0.1% formic acid versus 
solvent B: acetonitrile, starting at 5% B and rising to 50% B. Eluted peptides were 
electrosprayed into an Orbitrap Velos Fourier Transformation mass spectrometer via a 
Proxeon nanoelectrospray ion source (2.5kV ionisation voltage, 200 °C capillary 
temperature, Thermo Fisher Hemel, UK). These mass spectrometers enable faster and more 
reliable detection and identification of proteins in complex mixtures and were operated in 
positive ion and MS-MS mode, scanning from 380 to 2000 amu. Top 20 most intense ions 
from each full scan, depending on signal intensity, were isolated for MS/MS fragmentation 
by collision-induced dissociation (CID) at 35% collision energy. The resulting fragments were 
detected at ion resolutions of 60,000 for MS scans and 7,500 for MS/MS scans. This work 
was done by Prof H. Mischak’s laboratory. 
2.6.3 Proteomic Data Processing 
Raw MS/MS Orbitrap Velos spectra were extracted using Xcalibur (version 2.2) and 
processed on MaxQuant software (versions 1.1.1.25, 1.2.0.18 or 1.2.2.6) specific for MS-
based quantitative proteomics (Cox et al., 2009). MaxQuant 'Quant' interface initially 
detected three-dimensional peak and isotope patterns and assembled them into SILAC 
triplets for quantification. Peptide fragment spectra were filtered through Andromeda, a 
peptide search engine integrated into the MaxQuant environment (Cox et al., 2011), being 
unique in accurately distinguishing and identifying co-fragmented peptides from mixture 
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spectra. Derived peak lists were searched using the Mascot search engine against the mouse 
and/or rat International Protein Index (IPI version 3.68; minimally redundant but maximally 
complete combined database) or SwissProt Rodentia peptide sequences database (2011; 
best annotated database). Cysteine carbamidomethylation was selected as the fixed 
modification; methionine oxidation, N-terminal protein acetylation, phosphorylation of 
serine, threonine and tyrosine sites and heavy isotopes of lysine and arginine (Lys6, Lys8, 
Arg6, Arg10) were selected as variable modifications. MS/MS ion data were searched with a 
relative peptide mass tolerance of 20ppm. Minimum required peptide length was 6 amino 
acids. A maximum of two missed cleavages was allowed per tryptic peptide. MaxQuant 
'Identify' interface allowed statistical filtering and quantification of identified 
peptides/proteins (Cox and Mann, 2008). Data extraction and processing through MaxQuant 
were performed by Dr D. Sumpton, Dr S. Lilla and Dr S. Zanivan (The Beatson Institute). The 
output of the MaxQuant/Mascot workflow was subsequently submitted to the Perseus 
platform (version 1.2.0.17 or 1.2.7.4) for bioinformatics analysis and visualisation 
(http://www.perseus-framework.org). Proteins were filtered for differential expression, 
using a fold change cut-off of 1.3 (FC=±1.3). To explore relevant biological pathways, 
networks and processes, all differentially regulated proteins with SwissProt/IPI identifiers, 
corresponding expression values and FC were imported into Ingenuity Pathway Analysis 
(Ingenuity®Systems, www.ingenuity.com). Each identifier was mapped to the corresponding 
protein in the Ingenuity® Knowledge Database. A cut-off of FC=±1.3 was set again to filter for 
significance. These so called Network Eligible molecules were then overlaid to biological 
canonical pathways, functions and diseases based on the existing information in the 
database. Also, networks of Network Eligible molecules were algorithmically generated 
based on their connectivity. The score for each network represents the degree of relevance 
of a network to the given list of Network Eligible molecules. The data analysis process is 
illustrated in Figure  2-2B. Selected differentially expressed proteins were validated by 
immunoblotting.  
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Figure  2-2 - SILAC proteome profiling of parental and congenic primary S1P-stimulated VSMC. (A) 
Experimental workflow. Primary mesenteric VSMCs from 16 week-old animals are adapted in 
DMEM supplemented with 10% dialysed serum, for 24h. Subsequently, cells are transferred into 
differentially isotope-labeled SILAC media for metabolic labeling. WKY are grown in control “light” 
condition with 
12
C6
14
N4 L-arginine (Arg0) and 
12
C6
14
N2 L-lysine (Lys0), SHRSP are “heavy” labelled 
with 
13
C6
15
N4 L-arginine (Arg10) and 
13
C6
15
N2 L-lysine (Lys8), 2a congenics are “medium” labelled 
with 
13
C6 L-arginine (Arg6) and 
13
C8 L-lysine (Lys6). After 6 divisions, to ensure isotopic amino acid 
incorporation, cells are serum-starved overnight, stimulated with S1P (10
-6
M) for 30 min, harvested 
and mixed in equal numbers (1:1:1, 10
6
): experiment A. WKYL - WKY.SPGla2aM - SHRSPH, experiment 
B. WKYL - SP.WKYGla2aM - SHRSPH. Following cell lysis the mixed-lysate (50 µg) is resolved by SDS-
PAGE and visualized by Coomassie staining. Each lane (A, B) is divided into 6 slices and digested in-
gel by trypsin before analysed by LC coupled to MS/MS. Differences in intensity of peptide peak-
ratios reflect differences in protein abundance. (B) MS/MS data analysis workflow. Tryptic 
peptides separated by rapid LC are directed to the Orbitrap Velos mass analyser, through ESI. Raw 
MS/MS spectra are extracted using Excalibur, filtered and quantified through MaxQuant and 
associated with amino acid sequences on Mascot search engine. Data is uploaded to Perseus 
platform for further bioinformatics analysis, and to IPA database for association with relevant 
biological pathways. 
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2.7 Metabolomic Profiling 
2.7.1 Sample Preparation 
Mesenteric primary VSMCs from 16 week-old WKY, SHRSP and the two 2a congenic 
strains were treated for 30mins with S1P or vehicle (section  2.2.5), harvested (section  2.2.2) 
and lysed in metabolite extraction buffer, as described below. Four biological replicates of 
each strain were analysed. 
Matched urine and plasma samples were collected from 21 week-old male WKY, 
SHRSP, SP.WKYGla2k congenic and Gstm1-transgenic rats fed normal or high-salt (1% NaCl in 
drinking water) diet as described in section  2.1.1. At 21 weeks of age, rats were housed 
individually in metabolic cages for 24 hours prior to sacrifice. Urine samples were collected 
over a 24h period, while stored at 4˚C. Aliquots were snap frozen into liquid nitrogen (N2(l)) 
and stored at -80˚C until use. Blood samples were collected in EDTA at sacrifice, immediately 
placed on ice and centrifuged within 1h at 1000g, for 10min. Plasma was extracted, 
aliquoted, snap frozen into N2(l) and stored at -80˚C. Metabolites were extracted from a 
maximum of 4 biological replicates of matched urine and plasma from each strain, as 
described below. Salt intervention and sample collection was done by researchers at the 
Glasgow Cardiovascular Research Centre (BHF/GCRC).  
Metabolites were extracted using a slightly modified version of Folch method (Folch et 
al., 1957). Chloroform was used as the non-polar and methanol as the polar extracting 
solvents along with water, at a ratio of 1:3:1 (v/v), allowing the extraction of both non-polar 
and polar, water-soluble and organic-soluble metabolites. Samples were vortex-mixed in 
metabolite extraction buffer for 1h, at 4°C and then centrifuged at 13.000 g for 3min, at 4°C. 
Supernatant was stored at -80˚C until metabolomic profiling was performed. 
2.7.2 Hydrophilic Interaction Liquid Chromatography – Mass 
Spectrometry 
Metabolites were separated by polarity and hydrophilicity using a ZIC-HILIC 4.6mm x 
15cm column (Merck SeQuant, Sweden) running at 300µl/min, on a UltiMate 3000 Rapid 
Separation LC system (Thermo Fisher, UK). Separation is based on weak electrostatic 
interactions (hydrogen bonds and polar-polar interactions) occurring between hydrophilic 
metabolites and the zwitterionic stationary phase. Mobile phase gradient ran from 20% H2O-
80% ACN to 80% H2O-20% ACN in 30min, followed by a wash at 5% ACN-95% H2O for 6min 
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and equilibration at 20% H2O-80% ACN for 8min. HILIC column is much more efficient (peaks 
up ~38% of molecules) compared to other columns, especially in highly complex samples 
such as urine. Eluted metabolites were directed via heated electrospray ionisation (ESI) to an 
Orbitrap Exactive mass analyser (Thermo Fisher), which exhibits ultrahigh mass accuracy and 
resolution and was operated in both positive and negative detection ion modes. The work 
was done by researchers at the Glasgow Polyomics Facility. 
2.7.3 Metabolomic Data Processing 
Raw MS data, from positive and negative modes, generated in Orbitrap Exactive was 
processed using version11/version19 IDEOM Excel interface tools, a standard pipeline 
suitable for metabolomic LC/MS data analysis (Creek et al., 2012). In specific, raw data was 
converted into a functional format by msconvert, XCMS library (R-package) was then used 
for peak picking (Smith et al., 2006a) and mzMatch for related peak annotation, filtering and 
grouping of samples (Scheltema et al., 2011). IDEOM further allowed for metabolite 
identification by mass and retention time (RT), using several comprehensive metabolomic 
and metabolic pathway databases (e.g. HMDB, KEGG, Metacyc) and RT lists of standards 
(authentic metabolites), as well as for relative quantification using internal standards. 
IDEOM also enabled advanced visualisation and multivariate statistics by exporting data to R. 
PeakML Viewer was used for rapid inspection of data quality (peak shape, intensity, 
confidence levels) and dataset comparisons (Scheltema et al., 2011). Metabolite intensities 
were corrected for total MS intensity (TIC: total ion current). Student’s unpaired t-test was 
employed to filter for significance, using a p-value (p-val) threshold of 0.05. Datasets 
containing KEGG identifiers, corresponding expression values and p-val were then uploaded 
onto Ingenuity Pathway Analysis (IPA) software (Ingenuity®Systems, www.ingenuity.com). 
Each identifier was mapped to the corresponding metabolite in the Ingenuity® Knowledge 
Database. A cut-off p-value<0.05 was set to identify significantly changing molecules, called 
Network Eligible molecules. When overlaid to a global molecular network generated by 
Ingenuity® Knowledge Database, networks of Network Eligible molecules were 
algorithmically generated based on their connectivity. Individual metabolites and networks 
were associated with metabolic processes/pathways and biomarker search. The data 
analysis pipeline is illustrated in Figure  2-3. 
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Figure  2-3 - Metabolomic analysis: sample processing and MS data analysis pipeline. Analytes 
extracted from cell lysates or biofluids, by methanol/chloroform for 1h at 4°C, are separated by 
zwitterionic - hydrophilic interaction liquid chromatography (ZIC-HILIC) according to their 
hydrophilicity, eluted and directed to the Orbitrap Exactive mass analyser through heated 
electrospray ionisation (H-ESI). Peaks are extracted from raw MS spectra using the XCMS library 
and processed through the mzMatch/IDEOM pipeline for metabolite identification and further 
bioinformatics analysis. The number of detected peaks is remarkably reduced along the extensive 
filtering process. Metabolites reaching statistical significance are finally uploaded to Ingenuity 
Pathway Analysis (IPA) database for association with metabolic processes and biological 
interpretation. 
2.8 Statistical Analysis 
In vitro experiments were performed in triplicate on 3 independent occasions, unless 
otherwise stated. Ex vivo myography experiments were carried out with 4 to 12 rats per 
group. Statistical analysis was performed using Microsoft Excel and Prism Graphpad 4 
commercially available software. Results are expressed as Mean ± standard error of the 
mean (SEM). For specific two-group comparisons, unpaired Student’s t-test was used. 
Comparisons across multiple groups and conditions were made by two-way analysis of 
variance (ANOVA) followed by Bonferroni’s multiple correction test. Statistical significance 
was considered for p-values <0.05 (two-tailed).  
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Proteomic data were filtered for fold change, FC ≥ ±1.3. Metabolomic data were 
filtered for significance using unpaired Student’s t-test for p-value <0.05. Canonical pathway 
analysis identified the pathways from the IPA library that were most significantly associated 
with the datasets. Proteins/metabolites from the dataset that met the FC/p-value cut-off 
and were mapped to a pathway in the Ingenuity Pathway Knowledge Base (IPKB) were 
considered for the analysis.  
 
Figure  2-4 - IPA annotations. This table provides a key of the main features of IPA Network Explorer 
and Canonical Pathways, including molecule shapes and relationship labels and types. (Ingenuity® 
Systems, http://www.ingenuity.com).  
3 Effects of Salt Loading on S1PR1 
Expression and Signalling and on BP 
Regulation in Salt-Sensitive Rats 
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3.1 Introduction 
Essential hypertension (EH) is regularly characterised by exaggerated responses to 
increased dietary sodium, mainly due to impaired kidney function (Luft et al., 1986). SHRSP, 
a well-characterised model of human EH, also exhibits salt sensitivity (Ohtaka, 1980, 
Tesfamariam and Halpern, 1988, Yamori and Okamoto, 1974). Genome-wide linkage studies 
have identified two QTLs on rat chromosome 2 associated with BP regulation and salt 
sensitivity (Clark et al., 1996). To confirm and further dissect the genetic components of 
these QTLs, congenic strains have been generated, using WKY as the donor of chr.2 
segments and SHRSP as the recipient strain (Figure  3-1A). Two congenic strains generated by 
introgression of a 64-cM congenic interval, SP.WKYGla2a (SW2a), and of a smaller 10-cM 
segment part of the 64-cM region, SP.WKYGla2k (SW2k), exhibit significantly lower SBP to 
SHRSP, at baseline and under salt-loading. Moreover, they display similarly reduced 
sensitivity to salt, compared to responses in SHRSP (Figure  3-1B) (Graham et al., 2007). 
Microarray expression profiling in renal tissue from baseline and salt-loaded parental and 
chr.2 congenic strains has detected differentially expressed candidate genes for BP and salt-
sensitivity. At baseline, Gstm1 was identified as a positional and functional candidate for BP 
regulation (McBride et al., 2003). A Gstm1-transgenic strain has been constructed in our 
laboratory, by insertion of the WKY gene into the SHRSP background, demonstrating 
significantly reduced SBP, similar to that of SW2a and SW2k at baseline, yet upon salt 
loading an exaggerated increase in SBP is observed (Figure  3-1). Under salt-loading, Vcam1 
and S1pr1 have been identified as two candidate genes for salt-sensitive BP regulation. 
These genes demonstrated elevated mRNA levels in SHRSP compared to WKY and the SW2a 
and 2k congenic strains. However, S1PR1 protein levels were decreased in SHRSP, suggestive 
of abnormal post-transcriptional regulation or protein turnover and subsequent altered 
signalling in hypertension (Graham et al., 2007).  
Therefore, genetic alterations, as well as exogenous perturbations can lead to 
substantial alterations in the phenotype, through large and diverse impact on numerous 
metabolic processes. Comprehensive and accurate characterisation of changes in the highly 
dynamic metabolome, which represents best the actual phenotypic state of a biological 
system (Breitling et al., 2008, Kell, 2006), can be achieved by use of high-throughput 
approaches. In metabolomic studies, body fluids are of significant value because of their 
metabolite-rich content, which reflects at least in part, the actual state of each cell, tissue 
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and organ in an organism. Plasma and urine are the most commonly used biofluids, due to 
their availability and ease of collection. In comparison to plasma, urine offers the extra 
advantages of non-invasive collection, multiple sampling over a period of time and greater 
stability and resistance to oxidation or precipitation, thus generating more reproducible 
profiles (von Zur Muhlen et al., 2009). Alterations in the metabolic fingerprint of urine and 
plasma are representative of the complex pathophysiology during progression of chronic 
diseases, such as EH. The application of metabolomics in cardiovascular research is an 
emerging field aiming to define a clearer metabolic picture of CVD for improved prognosis, 
diagnosis and therapy evaluation (Giovane et al., 2008, Barderas et al., 2011). In clinical 
diagnostics, the main focus is on identification of disease biomarkers and biofluid samples 
are typically collected from control and drug treated or diseased subjects. Large-scale 
metabolomic screenings, using advanced instrumentation and bioinformatics tools, permit 
discovery of distinct and defined metabolite patterns instead of single biomarkers, which are 
more informative of the disease complex status. 
 
Figure  3-1 - Chromosome 2 congenic and transgenic strains generated by WKY (donor) and SHRSP 
(recipient) mating. (A) Schematic of chr.2 from parental, SW2a and SW2k congenic and Gstm1-
transgenic strains, showing location and size of congenic regions, as well as approximate 
integration site of the Gstm1 gene. Blue bars: regions of WKY homozygosity, red bars: regions of 
SHRSP homozygosity. (B) Averaged weekly radiotelemetry recordings of night-time and day-time 
SBP in male parental, SW2a and SW2k congenic and Gstm1-transgenic strains, under baseline and 
salt-loaded conditions. Animals were put on high-salt diet at 18 weeks of age. Edited from Graham 
et al., 2007. 
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Aims 
This work is a follow up of previous studies on rat renal tissue identifying Gstm1 as a 
candidate gene for BP regulation and S1pr1 as a candidate for salt sensitivity. We used 21 
week-old, WKY and SHRSP parental in combination with SW2a and SW2k congenic and 
Gstm1-transgenic strains aiming to: 
• characterise S1PR1 protein expression upon salt-loading, in renal and vascular tissue 
and compare the expression profiles across salt-resistant (WKY, SW2a, SW2k) and salt-
sensitive (SHRSP) strains, by the means of immunohistochemistry (IHC) and western blot 
(WB) analysis. 
• characterise the metabolic profile (signatures/patterns) of salt-sensitivity and identify 
urine and plasma biomarkers, by comparisons across salt-resistant (WKY, SW2k) and salt-
sensitive (SHRSP, Gstm1-transgenic) strains, under normal-salt (baseline) and salt-loaded 
conditions. Untargeted metabolomic screening of urine and plasma was performed (Figure 
 3-2). 
 
Figure  3-2 - Metabolomics analysis of urine and plasma from parental, SW2k-congenic and Gstm1-
transgenic rats. Matched samples were collected from 21 week-old rats, at baseline and under salt-
loading. (A) Experimental process. Metabolites were separated by ZIC-HILIC and analysed on an 
Orbitrap Exactive mass spectrometer. Raw peaks were filtered, identified, quantified and 
statistically analysed through the IDEOM v18 stringent pipeline and uploaded to databases for 
biological interpretation. (B) Experimental design. Four biological replicates for WKY and SHRSP 
and three for SW2k congenic and Gstm1-transgenic strains were analysed. 
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3.2 Results  
3.2.1 S1PR1 expression in tissues from salt-loaded rats   
3.2.1.1 S1PR1 renal expression in salt-loaded WKY, SHRSP and congenic strains 
S1PR1 expression in kidney from 21 week-old, salt-loaded WKY and SHRSP was 
assessed by IHC, as described in section  2.4. S1PR1 levels were below detection in the kidney 
medulla and cortex from both strains (Figure  3-3B and C, bottom panels). Negative IgG 
controls showed no detectable staining as expected (Figure  3-3; A: left panel, B and C: 
bottom panels) and positive immunostaining for aquaporin2 (AQP2) gave intense signal on 
the periphery of medullary collecting ducts and cortical collecting tubules, in kidney from 
WKY (Figure  3-3A; right panel). 
 
Figure  3-3 - Characterisation of S1PR1 expression in kidney (medulla and cortex) from 21 week-old, 
salt-loaded WKY and SHRSP rats, by IHC. (A) Tissue from WKY. Left panel: Isotype (goat IgG) 
negative control; right panel: positive immunostaining for AQP2, 1/1000. Tissues from WKY (B) and 
SHRSP (C). Top panels: Isotype (rabbit IgG) negative control; bottom panels: immunostaining for 
S1PR1, 1/100. Magnification x10. 
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To increase concentrations of low abundance proteins, enrichment for cellular 
compartments was performed on whole kidney homogenates from 21 week-old salt-loaded 
parental and SW2a and SW2k congenic strains. Western blot for S1PR1 (47 kDa) detected a 
single strong band in the membrane fraction and a single fainter band in the cytoplasmic 
fraction, at the expected MW (Figure  3-4; top panels). Expression levels in the membrane 
fraction were similar across all four strains. Cytoplasmic levels appeared increased in SW2k. 
Cross-contamination of cellular compartments was tested by stripping and re-probing the 
membranes for compartment specific markers. GAPDH cytoplasm specific and Na+/K+ATPase 
membrane specific markers showed considerable cross-contamination, however enrichment 
of fractions appeared to be sufficient for detection of S1PR1 (Figure  3-4; middle and bottom 
panels). 
 
Figure  3-4 - S1PR1 expression in protein enriched, cellular compartments of whole kidney 
homogenate, from 21 week-old, salt-loaded parental and SW2a and SW2k congenic strains. 
Representative immunoblots for S1PR1 (top panel). Membranes were stripped and re-probed with 
compartment specific markers: Na
+
/K
+
 ATPase membrane marker (middle panel); GAPDH cytosolic 
marker (bottom panel). Protein loaded: 80 µg (C: cytosolic, N: nuclear, M: membranic fractions). 
Results are representative of 2 experiments. 
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3.2.1.2 S1PR1 vascular expression in salt-loaded WKY and SHRSP 
S1PR1 expression in thoracic aortas from 21 week-old, salt-loaded WKY and SHRSP was 
assessed by IHC, as described in section  2.4. S1PR1 levels were below detection in the SM of 
thoracic aortas from both strains (Figure  3-5B and C, bottom panels). Negative IgG controls 
showed no detectable staining as expected (Figure  3-5; top panels) and positive 
immunostaining for α-SMactin2 (ACTA2) (Figure  3-5A; bottom panel) gave widespread signal 
in the SM of carotid artery from WKY. 
 
Figure  3-5 - Characterisation of S1PR1 expression in thoracic aorta from 21 week-old, salt-loaded 
WKY and SHRSP rats, by IHC. (A) Carotid artery from WKY. Top panel: Isotype (mouse IgG) negative 
control; bottom panel: positive immunostaining for ACTA2, 1/1000. Thoracic aorta from WKY (B) 
and SHRSP (C). Top panels: Isotype (rabbit IgG) negative control; bottom panels: immunostaining 
for S1PR1, 1/100. Magnification x40.  
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3.2.2 Urine and Plasma Metabolomics and Bioinformatics Analysis  
To further investigate the role of candidate genes in salt-sensitive HTN, and assess the 
effects of salt-loading on BP regulation and sphingosine metabolism, untargeted metabolic 
profiling was carried out in urine and plasma matched samples from 21 week-old WKY, 
SHRSP, SW2k congenic and Gstm1-transgenic strains, under baseline and salt-loaded 
conditions. Extracted metabolites from urine and plasma were processed on a ZIC-HILIC - MS 
platform, as detailed in section  2.7. Stringent filtering of extracted MS data containing 
thousands of peaks (~50.000) using IDEOM v18, led to identification of a reduced number of 
positively and negatively ionised putative metabolites (Figure  3-6A): 4849_Plasma_Pos / 
3254_Plasma_Neg; 6395_Urine_Pos / 4116_Urine_Neg. The number of metabolites 
identified in plasma samples were almost two thirds of those identified in urine. Next, 
metabolites' intensities were corrected to the summed MS intensity (TIC: total ion current) 
to minimise the uncontrollable effect of exogenous factors (quantification errors). 
Identification lists of positive and negative modes were then combined (PosNeg) to give the 
list of putative metabolites to be further analysed: 820_Plasma_PosNeg and 
1336_Urine_PosNeg (Figure  3-6A). 
The quality of urine and plasma filtered data was assessed by generation of principal 
component analysis (PCA) plots, which represent the profile of a linear combination of the 
metabolites identified for each sample. Two representative PCA score plots, where all 
plasma or urine samples (baseline and salt-loaded) have been plotted together for increased 
reliability, are illustrated in Figure  3-6B and C, respectively. In both plots, the normotensive 
and salt-resistant WKY clustered separately from the other three strains under baseline and 
salt-loading. Gstm1-transgenic strain seemed to always cluster together with SHRSP, unlike 
SW2k which generally displayed more separated clusters, especially at baseline. Moreover, 
the metabolic profiles between baseline and salt-loaded conditions appeared to be discrete 
across all strains, although in some plots WKY and WKY-salt clusters exhibited partial 
overlapping, such as in plasma_positive (Figure  3-6B). Finally, cluster separation in plasma 
was clearer compared to urine profile. 
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Figure  3-6 - Orbitrap Exactive MS-data filtering and visualisation on IDEOM v18. (A) Peaks were 
picked using XCMS, filtered using mzMatch and matched to a set of databases for metabolite 
identification. The table summarises numbers of putative metabolites identified in the positive and 
negative modes and collectively (posneg), after correcting for total intensity (TIC), across plasma or 
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urine samples, in all four stains. (B)-(C) PCA score plots for plasma_positive and urine_negative 
samples, respectively, were generated in R using data from all strains and both baseline and salt-
loaded conditions. PC1 and PC2 represent the percentages of metabolites that drive the separation 
of samples along the axes. Dashed lines indicate separation between WKY and the other strains or 
between baseline and salt-loaded groups.  
Subsequently, pair-wise comparisons were performed both across strains, under 
baseline or salt-loading (Figure  3-7), and across salt-challenged conditions (salt_v_baseline) 
(Figure  3-8), in urine and plasma. Unpaired t-test was utilised to determine significance (p-
val <0.05). Approximately one third of the identified metabolites, in each of the comparisons 
at baseline and at salt-loaded conditions, were found to be significantly changed, both in 
urine and plasma. The only exception was the plasma comparison under salt-loading 
between Gstm1-tansgenic and SW2k, which exhibited a smaller ratio of significant 
differences (610_total / 105_significant) (Figure  3-7A). In the comparisons across baseline 
and salt-loading, WKY displayed lower ratio of significant changes in plasma compared to the 
other three strains (555_total / 71_significant). However, in urine, WKY had similar ratio to 
SW2k, which was smaller than these of SHRSP and the transgenic (Figure  3-8).  
When data was uploaded onto IPA, approximately one half of the significant 
metabolites were identified by their KEGG IDs (Figure  3-7A and Figure  3-8A). These 
significant 'analysis ready' molecules were used for biological interpretation and biomarker 
analysis. Tables of original data (IDEOM v18) and of significantly changing metabolites, for all 
comparisons and intersections of interest, are included in the 'Urine' and 'Plasma' subfolders 
of the 'Chapter 3 - Urine, Plasma metabolomics' folder, in the hard copy (CD) accompanying 
this thesis. 
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Figure  3-7 - Comparisons of interest between WKY, SHRSP, SW2k congenic and Gstm1-transgenic 
strains, at baseline and salt-loading, in plasma and urine. (A) Summary table of numbers of 
putative metabolites identified collectively in positive and negative modes (posneg), of 
significantly changing metabolites (p-val <0.05) and of significant metabolites identified on IPA as 
'analysis ready', across the comparisons. (B) Venn-diagrams of 'analysis ready' metabolites for 
comparisons of interest. 
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Figure  3-8 - Comparisons of interest across baseline and salt-loaded conditions in plasma and urine 
from WKY, SHRSP, SW2k congenic and Gstm1-transgenic strains. (A) Summary table of numbers of 
putative metabolites identified collectively in positive and negative modes (posneg), of 
significantly changing metabolites (p-val <0.05) upon salt-challenge, and of significant metabolites 
identified on IPA as 'analysis ready', across different comparisons. (B) Venn-diagrams of 'analysis 
ready' metabolites for comparisons of interest.  
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3.2.2.1 Urine metabolomic profiling at baseline and upon salt-loading 
At baseline, comparison of SHRSP urine metabolic profile to the other three strains 
identified 41 common, significantly changing metabolites across the three comparisons: 
SHRSP_v_WKY, SHRSP_v_Trans and SHRSP_v_SW2k (Figure  3-7B; top venn-diagram). The 
above metabolites mapped to a variety of functions and diseases on IPA, rather than 
highlighting a few specific ones. Of the 41, 25 displayed consistent direction of change, with 
24 being constantly increased and 1 decreased in SHRSP. Table  3-1 summarises data for 
some of the metabolites. 19 out of the 24 increased metabolites were detected only in 
SHRSP and exhibited fold changes (FC) between 2.610 and 9535.108. Complete data for all 
41 metabolites can be found in the ‘Urine/Baseline/Urine_base_IC3_41_IPA’ supplementary 
table.  
Further network analysis on IPA explored potential relation of the 41 significant 
metabolites to GSTM1 and GSTM5 (rat and human homologues), in an attempt to more 
restrictively identify molecules implicated in the improved BP phenotype of Gstm1-
transgenic compared to SHRSP (Figure  3-9). N-acetyl-L-cysteine (NAC) was an interesting 
metabolite connected to GSTM5 through molecules implicated in oxidative stress, lipid 
metabolism and CVD. NAC was reduced in SHRSP compared to WKY (FC=-2.006) and SW2k 
(FC=-2.101), but its levels were highly increased in comparison to Gstm1-transgenic 
(FC=202.72).  
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Table  3-1. Subset of the 41 'in common' urine metabolites exhibiting consistent, significant change 
across the comparisons of SHRSP versus WKY, SW2k and Gstm1-transgenic, at baseline. Data were 
generated on IDEOM v18. Green: decreased and red: increased metabolite levels.  
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Figure  3-9 - Ingenuity Pathway Analysis (IPA) network associating urine N-acetyl-L-cysteine with 
GSTM1 and GSTM5 (glutathione S-transferase mu 1/5). N-acetyl-L-cysteine (NAC) baseline levels 
were significantly deceased in the SHRSP_v_WKY and SHRSP_v_SW2k comparisons (A) and 
significantly increased in the SHRSP_v_ Gstm1-transgenic comparison baseline (B).  (C) NAC was 
associated to GSTM5 through molecules implicated in ROS generation, fatty acid metabolism, 
arterial and cardiac disorders. TP53: tumour protein p53; FOXO3: forkhead box O3; NFE2L2: 
nuclear factor (erythroid-derived 2)-like 2; AKT1: serine-threonine protein kinase AKT1; PI3K: 1-
phosphatidylinositol 3-kinase; NFKBIA: nuclear factor of kappa light polypeptide gene enhancer in 
B-cells inhibitor, alpha; Gst alpha: glutathione S-transferase alpha. Colour indications: green - 
decrease, red - increase, white - not detected.  
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Subsequently, urine metabolic profiles of salt-loaded animals were compared. 
Comparison of the SHRSP and Gstm1-transgenic salt-sensitive versus the WKY and 2k salt-
resistant strains identified 21 metabolites that were changing across all four comparisons: 
SHRSP_v_WKY, SHRSP_v_SW2k, Trans_v_WKY and Trans_v_SW2k. 14 of these metabolites 
were consistently increased in the salt-sensitive strains and all but one were detected only in 
the SHRSP and Gstm1-transgenic, having FC that ranged from 3.313 to 5555.425. Table  3-2 
summarises data for some of the metabolites. Complete data for all 21 metabolites can be 
found in the ‘Urine/Salt/Urine_salt_IC4_21_IPA’ supplementary table. 
Table  3-2. Subset of the 21 'in common' urine metabolites exhibiting significant change across the 
comparisons of SHRSP and Gstm1-transgenic versus WKY and SW2k, under salt loading. Data were 
generated on IDEOM v18. Green: decreased and red: increased metabolite levels. 
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Further network analysis on IPA associated 3-hydroxyanthranilic acid (consistently 
increased), oleic acid (consistently increased), pipecolic acid (decreased in comparisons with 
WKY) and 2-deoxy-D-ribose (decreased in SHRSP) with molecules implicated in lipid 
metabolism, inflammatory response, CVD and oxidative stress (Figure  3-10).  
 
Figure  3-10 - IPA network of urine metabolites significantly changing in the salt-sensitive versus the 
salt-resistant strains, upon salt-loading. (A) Changes in the SHRSP_v_WKY. (B) Changes in the 
Gstm1-transgenic _v_WKY followed same direction as in SHRSP_v_WKY apart from 2-deoxy-D-
ribose. (C) Changes in the SHRSP_v_SW2k. (D) Changes in the Gstm1-transgenic _v_ SW2k 
comparison. The altered metabolites were associated to molecules implicated in lipid metabolism, 
inflammatory response, ROS production, CVD. VCAM1: vascular cell adhesion molecule 1; NFkB: 
nuclear factor kappa-light-chain-enhancer of activated B cells; NOS2: nitric oxide synthase 2; 
REN:renin; PPARG: peroxisome proliferator-activated receptor gamma; Na
+
: sodium. Colour 
indications: green - decrease, red - increase, white - not detected. Asterisk indicates more than one 
potential isomers. 
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Finally, assessment of peak quality for the metabolites of interest that were identified 
in the urine comparisons, was performed on peakML.Viewer. Figure  3-11 illustrates the peak 
chromatograms of selected metabolites which demonstrated relatively good peak shape and 
reproducibility. 
 
Figure  3-11 - PeakML chromatograms of metabolites of interest identified in urine comparisons 
across WKY, SHRSP, SW2k and Gstm-1 transgenic strains, at baseline or salt-loaded conditions. (A) 
N-acteyl-cysteine exhibited significant decrease at baseline in SHRSP compared to WKY and SW2k 
and was not detected in the transgenic. At salt-loading, (B) 3-hydroxyanthraniclic acid and (C) oleic 
acid were increased in SHRSP and transgenic animals compared to WKY and SW2k. The x-axis 
indicates the retention time and the y-axis the intensity. 
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3.2.2.2 Plasma metabolomic profiling at baseline and upon salt-loading 
At baseline, comparison of SHRSP plasma metabolic profile to the other three strains 
identified 19 common, significantly changing metabolites across the three comparisons: 
SHRSP_v_WKY, SHRSP_v_Trans and SHRSP_v_SW2k (Figure  3-7B; top venn-diagram). 
Association to functions and diseases on IPA did not highlight a particular process, rather, 
each metabolite was implicated in different functions. 18 out of the 19 metabolites exhibited 
consistent direction of change, with 17 showing constantly elevated and 1 diminished levels 
in SHRSP (Table  3-3). Of the 17 increased metabolites 5 were detected only in SHRSP and 
exhibited FC raging from 3.701 to 4005.273.  
Similarly to the urine analysis, further network analysis on IPA investigated potential 
relation of the 19 significant metabolites to GSTM1 and GSTM5, attempting to more 
restrictively identify plasma metabolic components implicated in the improved BP 
phenotype of Gstm1-transgenic compared to SHRSP. 5 metabolites were connected to 
GSTM5 and related to ROS and lipid metabolism (Figure  3-12). L-proline, 1-
acylglycerophosphocholine and phosphatidylethanolamine belonged to the consistently 
increased in SHRSP metabolites. Moreover, L-proline was unique to SHRSP, with 
FC=4005.273 over the other three strains. Another metabolite of interest was the linoleic 
acid, the only consistently reduced metabolite in SHRSP, having a FC of -7.176 in 
SHRSP_v_WKY, -8.207 in SHRSP_v_Trans and -7.301 in SHRSP_v_SW2k comparison (Table 
 3-3). Moreover, an interesting hit exhibiting inconsistent change was the sphingosine-1-
phosphate (S1P). S1P was significantly decreased in SHRSP compared to WKY (FC= -72.654) 
and SW2k (FC=-58.345), but did not change in comparison to transgenic animals (FC=1.504, 
p-val=0.0954).  
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Table  3-3. Subset of the 19 'in common' plasma metabolites exhibiting significant change in SHRSP 
compared to WKY, SW2k and Gstm1-transgenic, at baseline. Data were generated on IDEOM v18. 
Green: decreased and red: increased metabolite levels. 
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Figure  3-12 - IPA network associating plasma metabolites, which significantly change at baseline in 
SHRSP versus WKY, SW2k and Gstm1-transgenic, with GSTM1 and GSTM5. (A) Changes in the 
SHRSP_v_WKY comparison. (B) Changes in the SHRSP_v_SW2k and SHRSP_v_ Gstm1-transgenic 
comparisons followed a common pattern. Five metabolites were associated to GSTM5 and the 
majority of molecules in the network mapped to ROS and lipid metabolism. IL4: interleukin 4; 
CFTR: cystic fibrosis transmembrane conductance regulator; CYCS: cyctochrome C, somatic. Colour 
indications: green - decrease, red - increase, white - not detected. Asterisk indicates more than one 
potential isomers. 
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Subsequently, plasma metabolic profiles in salt-loaded animals were compared. As in 
the urine analysis, comparison of the salt-sensitive versus the salt-resistant strains identified 
44 metabolites that were changing across all four comparisons: SHRSP_v_WKY, 
SHRSP_v_SW2k, Trans_v_WKY and Trans_v_SW2k. Of the above metabolites 3 were 
consistently decreased and 19 increased in the salt-sensitive strains. Of those increased 11 
were detected only in SHRSP and Gstm1-transgenic, having FC that ranged from 1.580 to 
382.770. Table  3-2 summarises data for some of the metabolites. Complete data for all 44 
metabolites can be found in the ‘Plasma/Salt/Plasma_salt_IC4_44_IPA’ supplementary table.  
Further investigation identified glutathione disulfide (GSSH) as a potentially interesting 
metabolite, which was detected only in salt-sensitive strains. GSSH displayed increased 
concentrations in SHRSP (FC=10.718) and Gstm1-transgenic (FC=26.31) compared to WKY 
and SW2k (Table  3-4). However, in the comparison between SHRSP and transgenic the 
change was not significant (FC=-2.455; p-val=0.0562).  
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Table  3-4. Subset of the 44 'in common' plasma metabolites exhibiting significant change across 
the comparisons of SHRSP and Gstm1-transgenic versus WKY and SW2k, under salt loading. Data 
were generated on IDEOM v18. Green: decreased and red: increased metabolite levels. 
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Finally, the metabolic effect of salt-loading on plasma was assessed in each strain 
individually, by comparing profiles between baseline and salt-loaded conditions. 
Comparisons across Gstm1-transgenic and the salt-resistant strains identified 28 significant 
changes unique to the transgenic. Of these, 9 were in common with SHRSP and 6 exhibited 
consistent increase across the two salt-sensitive strains, with FC ranging from 1.439 to 
961.421 (Table  3-5). Complete data for all unique and common metabolites can be found in 
the ‘Plasma/Salt_v_Baseline/Plasma_salt_v_base_SHRSP_IC_Trans_(13)+ Trans_unique_(28) 
_IPA' supplementary table. 
Table  3-5. Subset of the plasma metabolites exhibiting significant change in SHRSP and Gstm1-
transgenic or in the transgenic alone (unique), upon salt-loading. Data were generated on IDEOM 
v18. Green: significantly decreased and red: significantly increased metabolite levels. 
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Further investigation identified sphingosine-1-phosphate to be consistently and highly 
increased in both SHRSP (FC=82.300) and the transgenic (FC=88.898), under salt-loading 
(Table  3-5). Arachdonic acid was another molecule of interest, which displayed significantly 
increased concentrations only in salt-loaded transgenic animals (FC=1.582). 'Diseases and 
Function' analysis on IPA implicated the two metabolites in several pathological processes 
known to be related to salt, including CVD and BP regulation, inflammatory response, ROS 
producion and lipid metabolism.  
 
Figure  3-13 - 'Disease and function' analysis on IPA for significantly changing metabolites upon salt-
loading, in salt-sensitive strains. Sphingosine-1-phosphate was consistently increased across SHRSP 
(FC=82.300) and Gstm1-transgenic (FC=88.898). Arachidonic acid exhibited elevated concentrations 
only in salt-loaded transgenic (FC=1.582). The two metabolites were associated on IPA with a 
number of processes and pathological conditions including, inflammatory response, ROS 
production, lipid metabolism, BP, angiogenesis and artery disorders. Red indicates increase.  
Asterisk indicates more than one potential isomers. 
Finally, assessment of peak quality for the metabolites of interest, that were identified 
in the plasma comparisons, was performed on peakML.Viewer. Figure  3-14 illustrates the 
peak chromatograms of selected metabolites which demonstrated good peak shape and 
reproducibility. 
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Figure  3-14 - PeakML chromatograms of metabolites of interest identified in plasma comparisons 
across WKY, SHRSP, SW2k and Gstm-1 transgenic strains, at baseline or salt-loaded conditions. (A) 
Linoleic acid baseline levels were significantly decreased in SHRSP compared to the other three 
strains. (B) L-proline was a 'unique' SHRSP metabolite, not detected in the other strains, at 
baseline. (C) S1P exhibited decreased baseline concentrations in SHRSP and the transgenic strain 
compared to WKY and SW2k. (D) Glutathione disulfide was detected only in SHRSP and transgenic , 
upon salt-loading and displayed increased levels in SHRSP. (E) Upon salt-loading S1P increased in 
both SHRSP and the transgenic compared to baseline levels. (F) Arachidonic acid displayed high 
levels in the transgenic, which were even more elevated under salt-loading. The x-axis indicates 
the retention time and the y-axis the intensity. 
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3.3 Discussion 
Previous microarray profiling in whole kidney from salt-loaded rats demonstrated 
differential expression of S1pr1, a candidate gene for salt-sensitivity, across WKY, SHRSP and 
chr.2 congenic strains (Graham et al., 2007). Following up from these studies, this work 
aimed to further investigate whether the effects of altered gene expression were 
represented at the protein level, in kidneys from salt-loaded parental and SW2a and SW2k 
congenic rats. The investigation was also extended to vascular tissue, since S1PR1 is known 
to play significant role in the vasculature (Spiegel and Milstien, 2003b, Fujii et al., 2012). 
The protein levels of S1PR1 in both salt-loaded kidney and thoracic aorta were below 
detection when tested with IHC. To circumvent this issue, WB analysis was performed in 
kidney enrichments for membrane fraction and demonstrated similar expression levels 
across parental and congenic animals. This inconsistency between mRNA and protein levels 
implies abnormal post-transcriptional regulation or protein turnover. In thoracic aorta 
enrichments, previous work in our lab demonstrated consistently low detection of S1PR1 
levels across the strains. 
To further investigate the role of candidate genes in salt-sensitive HTN, and assess the 
effects of salt-loading on BP regulation and sphingosine signalling, a more comprehensive, 
untargeted, metabolic profiling was carried out in urine and plasma from rats, on normal-salt 
and salt-loaded diets. In this study, apart from the parental and the SW2k congenic strains, 
the Gstm1-transgenic strain was included. The aim was to also assess the role of Gstm1, a 
chr.2 positional and functional candidate for BP-regulation (McBride et al., 2003), on the 
metabolic level and to investigate its implication in salt-sensitivity. 
Identified metabolites in plasma were almost two thirds of those identified in urine. 
This could be the result of the fact that urine samples were collected over a 24h period. 
During this space of time, while urine is exposed to the environment, further chemical 
reactions and oxidation changes of the dynamic urinary metabolome are possibly allowed to 
take place, leading to greater inter-sample variability. PCA plots for urine and plasma were 
generated to assess the variability within and across groups. In both urine and plasma, 
clustering indicated different profiles between normal-salt and salt-loaded groups, in each 
strain, with the exception of WKY in plasma. This may illustrate the fact that WKY are 
resistant to salt-loading, maintaining low BP levels. In addition, WKY and SW2k displayed 
more different profiles to the SHRSP and Gstm1-transgenic strains, which were clustering 
(
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together, and this differential clustering was consistent across urine and plasma and across 
baseline and salt-loading. It is therefore suggested that the two salt-resistant strains, WKY 
and SW2k, handle salt-loading in a different way, as opposed to the salt-sensitive strains 
which exhibit consistently similar profiles across normal-salt and salt-loaded conditions. 
However, variability within groups was large, which can be attributed to the small number of 
replicates, in combination with the highly dynamic nature of the metabolome.  
Considering time limitations, from a large number of comparisons across urine and 
plasma, across strains and across conditions, focus was placed on particular intersects 
according to the most interesting questions to be tested in each case. At baseline, SHRSP 
was compared to each of the other three strains, in order to investigate the metabolic 
components associated with increased BP in SHRSP and improved BP in SW2k and Gstm1-
tansgenic. Under salt-loading, the SHRSP and Gstm1-transgenic salt-sensitive strains were 
compared to the WKY and SW2k salt-resistant strains, in order to examine metabolic 
changes implicated in a protective or a pathogenic manner in salt-sensitivity. Lastly, 
comparisons within each strain before and after salt-loading were performed to characterise 
how each strain responds to salt-loading. 
Comparison of urine profiles under normal-salt, demonstrated that SHRSP was equally 
different to the other three strains, and therefore ‘in common’ changing metabolites, were 
further investigated as components associated with BP regulation. The most interesting 
finding was N-acetyl-cysteine (NAC), which exhibited decreased levels in SHRSP compared to 
WKY and SW2k, but was not detected in the transgenic animals. Moreover, IPA network 
analysis identified several connections between NAC and the human homologue of GSTM1, 
GSTM5. However, N-acetyl-cysteine is a synthetic derivative of cysteine, exhibiting 
antioxidant properties (Mansano et al., 2012) and being implicated in artery vasodilation and 
protection against acute renal failure in rats (de Araujo et al., 2005, Alencar et al., 2003). It 
has been and is extensively being used in clinical trials as a treatment for a wide range of 
human diseases, including HTN and renal failure (NCT00569465, NCT00736866 - clinical trial 
identifiers). Therefore, further investigation is needed into the origin of this metabolite 
(microbiota?) in our animals, which was the single isomer identified with high confidence. 
Subsequent investigation of the effect of salt-loading in urine profiles of salt-resistant 
and salt-sensitive strains, demonstrated responses of similar magnitude for the resistant 
WKY and SW2k. However, the sensitive SHRSP and transgenic seemed to respond in a 
different way to salt-loading, as indicated through the venn diagrams. Therefore, the few 
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metabolites changing ‘in common’ and in the same direction between SHRSP and the 
transgenic may include molecules implicated in salt-sensitivity. 3-hydroxyanthranilic acid and 
oleic acid were two metabolites consistently elevated in SHRSP and the transgenic, 
compared to WKY and SW2k. 3-hydroxyanthranilic acid, an intermediate of tryptophan 
degradation, has protective effects against inflammation through scavenging of free radicals, 
induction of the antioxidant HMOX1 (heme-oxygenase 1) protein expression and reduction 
of VCAM1 protein expression (Opitz et al., 2007). Therefore, increased levels in the salt-
sensitive strains imply increased tryptophan degradation, which may act in a protective 
manner against stress induced by salt-loading. Moreover, oleic acid, a monounsaturated 
fatty acid, has been implicated in increased production of ROS (reactive oxygen species) (Lu 
et al., 1998), and the up-regulation of renin transcription through the transcription factor 
PPARg (peroxisome proliferator-activated receptor-gamma) (Todorov et al., 2007). Increased 
renin transcription suggests potentially increased levels of angiotensin II, which regulates 
vasoconstriction. Furthermore, a paradigm of how angiotensin II may be implicated in the 
pathogenesis of salt-dependent HTN has been recently described (Blaustein et al., 2012). 
Hence, raised BP in salt-sensitivity may be regulated by increased levels of oleic acid. The 
above responses may be mediated by the congenic interval due to the different profiles 
between salt-sensitive and salt-resistant strains. 
Finally, comparisons across normal-salt and salt-loaded conditions within each strain 
indicated different responses across strains, as observed through venn diagramms. However, 
due to time limitations, further analysis of these urine comparisons was not performed. 
Subsequent comparisons of plasma profiles under normal-salt, exhibited a similar 
pattern to this of urine, with SHRSP having a consistently different profile to this of the other 
three strains. Focus on ‘in common’ metabolites changing consistently across the three 
comparisons, identified L-proline and linoleic acid as potentially interesting and they were 
also associated to human GSTM5 and metabolism of ROS, on IPA. L-proline is an amino acid 
that has been reported to support generation of ROS through its oxidised form (Donald et 
al., 2001) and also to reduce the antioxidant activity of SOD (superoxide dismutase) in rat 
erythrocytes (Roecker et al., 2012). Therefore, increased levels of L-proline only in SHRSP 
suggest implication in the elevated BP phenotype, as well as a protective effect of the 
congenic interval, and potentially the Gstm1, through down-regulation of L-proline levels. In 
addition, levels of linoleic acid were consistently decreased in SHRSP. Linoleic acid, an 
unsaturated fatty acid is known to down-regulate protein expression of eNOS (endothelial 
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nitric oxide synthase) in endothelial cells (Artwohl et al., 2004) and increase NAD(P)H 
oxidase activity (Lassegue and Clempus, 2003) in VSMC. Moreover, linoleic acid plasma levels 
were shown to be inherited in families with CVD (Shah et al., 2009). Thus, decreased levels 
of linoleic acid in SHRSP may imply a protective adaptation against increased oxidative stress 
in these animals, which is most likely mediated by the congenic interval, but further 
investigation is needed. Another interesting finding was the significantly reduced S1P levels 
in SHRSP compared to WKY and SW2k, but not to the transgenic strain, which suggests that 
Gstm1 does not regulate S1P levels. 
Next, the plasma metabolic profiles upon salt-loading were compared across the salt-
sensitive and salt-resistant strains. Responses between SHRSP and Gstm1-transgenic shared 
less ‘in common’ metabolites, indicating different handling of salt-loading and supporting 
similar findings in urine. An interesting metabolite that was consistently elevated in the salt-
sensitive strains was the glutathione disulfide (GSSH). GSSH is the oxidised form of 
glutathione, a known antioxidant (Pompella et al., 2003). Increased GSSH levels are 
potentially a marker of increased oxidative stress upon salt-loading in salt sensitivity. 
Furthermore, it could be suggested that although Gstm1 expression in the transgenic strain 
is beneficial at baseline causing decrease in BP, salt-loading hampers this beneficial effect. 
Finally, the plasma profiles at normal-salt and salt-loaded conditions were compared 
within each strain to assess differential responses to salt-loading. Again, the majority of 
identified metabolites were unique to each strain, suggesting different handling of salt. The 
major finding of this analysis was the consistent increase of S1P upon salt-loading, in both 
the SHRSP and Gstm1-transgenic salt-sensitive strains, which suggests regulation of S1P 
levels by salt. This increase reaches S1P levels of WKY and SW2k at baseline and can be 
interpreted as protective in the regulation of BP and oxidative stress under salt loading.  
In conclusion, urine analysis proved to be more challenging than plasma, as urinary 
metabolic profiles are known to be more susceptible to environmental factors and therefore 
more variable. However, oleic acid was identified in urine as a candidate biomarker for salt 
sensitivity. In plasma, glutathione disulfide could represent a marker of increased oxidative 
stress in salt-sensitivity. Moreover, L-proline and linoleic acid were suggested to be 
implicated in BP regulation in HTN. For the analysis to be complete, further validation of the 
findings to authentic standards by MS/MS fractionation and verification by WB and 
enzymatic activity assays, would be essential before any generation of new testable 
hypothesis. 
4 Functional and Molecular 
Characterisation of Mesenteric 
Resistance Arteries from WKY, SHRSP 
and Chromosome 2 Congenic Strains 
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4.1 Introduction 
Elevated BP in HTN is mediated by increased peripheral vascular resistance, which is 
principally determined through the myogenic tone of microcirculation, including  resistance 
arteries (Borders and Granger, 1986, Bohlen, 1986). Alterations in the structure and function 
of resistance arteries regulate blood flow and pressure, through vascular remodelling and 
modulation of myogenic tone (Mulvany and Aalkjaer, 1990).  
Adaptive changes in structure and elasticity of mesenteric resistance arteries (MRA) in 
hypertensive rat models (SHR/SHRSP) are characterised by narrowing of the lumen and 
increased wall:lumen ratio, which may increase vascular resistance, even at full dilatation, 
and vascular stiffening caused by abnormal elastin and collagen organisation (Arribas et al., 
1997, Briones et al., 2003, Briones et al., 2009, Mulvany, 1988). However, the mechanisms 
involved in vascular remodelling, are not clear. Antioxidant therapies in SHR/SHRSP have 
been shown to improve the wall:lumen ratio in MRAs (Chen et al., 2001, Park et al., 2002, 
Rizzoni et al., 1998). Therefore, oxidative stress, along with wall stress, changes in the 
extracellular matrix proteins deposition and the neurohormonal environment, have been 
suggested as potential mechanisms contributing to the vascular remodelling (Lee et al., 
1995, Touyz et al., 2003).  
In addition, alterations of function in resistance arteries occur as a result of imbalance 
between vasodilatation and vasoconstriction. The principal vasodilators are nitric oxide (NO), 
prostacyclin (PGI2) and endothelium-derived hyperpolarising factors (EDHF). EDHF is the 
main vasodilatory pathway in small resistance arteries, whereas PGI2 and NO are more 
prominent in large vessels (Shimokawa et al., 1996). Yet, NO is considered the major 
regulator of cardiovascular homeostasis (Feletou et al., 2012). The principal vasoconstrictors 
include endothelin-1, prostanoids, angiotensin II and superoxide anions (Félétou and 
Vanhoutte, 2006). Normal function of endothelium, which is the source of the vasoactive 
factors, maintains the physiological vascular tone. Imbalance in availability of vasoactive 
factors results in endothelial dysfunction, the common denominator of cardiovascular 
diseases, including hypertension (Grunfeld et al., 1995, Potenza et al., 2005, Treasure et al., 
1993). In SHRSP, EDHF-mediated responses have been reported to be impaired in resistance 
arteries (Goto et al., 2004, Sunano et al., 1999). Moreover, endothelium-dependent 
relaxation responses are diminished due to low NO bioavailability, despite the generally 
increased eNOS activity and unaffected endothelial NO production (McIntyre et al., 1997, 
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Kerr et al., 1999, Ma et al., 2001). In SHRSP, NO bioavailability is reduced due to enhanced 
levels of the NO scavenger, superoxide anion, indicating implication of ROS in endothelial 
dysfunction (Hamilton et al., 2004). Increased production of the superoxide anion has been 
mainly attributed to endothelial xanthine oxidase, NADPH oxidase (NOX) and uncoupled 
eNOS (Grunfeld et al., 1995, Kerr et al., 1999, Suzuki et al., 1998, Zalba et al., 2000, Hamilton 
et al., 2001). Inhibition of eNOS by administration of L-NAME, decreased vascular superoxide 
levels in SHRSP (Grunfeld et al., 1995, Hamilton et al., 2001, Kerr et al., 1999). In general, 
therapeutic approaches using antioxidants demonstrate an improvement in the endothelial 
function (Fennell et al., 2002, Savoia et al., 2006).  
Apart from the endothelium-dependent modulation, the contractile state of SM is also 
regulated by neurotransmitters, hormones and other chemical signals, as well as changes in 
the load or length, which affect directly the VSMCs (Webb, 2003). The contractile activity in 
SM is controlled by the balance between Ca2+/calmodulin-dependent MLC kinase (MLCK) 
and MLC phosphatase (MLCP) activity, whereby de-phosphorylation of MLC promotes 
relaxation. MLCP activity is controlled by the RhoA small G protein and its downstream 
effector Rho kinase (RhoK), which de-activates the phosphatase, maintaining the contracted 
state of MLC in VSMCs (Seko et al., 2003, Webb, 2003). Inhibition of RhoK using 
pharmacological antagonists, such as Fasudil, has been shown to induce relaxation hence 
reduction in BP (Tsounapi et al., 2012, Uehata et al., 1997, Yang et al., 2011) and correct 
SMC hypercontractions (Mukai et al., 2001, Tsounapi et al., 2012) in in vivo and ex vivo 
studies on animal models of HTN, suggesting that inhibition of RhoK improves endothelial 
dysfunction in HTN in the SHR model. Recent publications also support a potential 
antioxidant role of fasudil, which is partly exerted through elevation of NO production (Guan 
et al., 2012, Ma et al., 2011), potentially leading to further inhibition of RhoA, in VSMC 
(Sauzeau et al., 2000, Wu et al., 1996). 
In addition, vasoactive compounds can also be produced and secreted by platelets, as 
in the case of sphingolipids, which are known to impact on vascular remodelling and 
endothelial dysfunction in HTN (Bolz et al., 2003, Ohanian et al., 2012, Spijkers et al., 2011). 
Sphingosine-1-phosphate (S1P) is an important bioactive lipid that influences vascular tone 
and VSMC function through selective binding of S1PR1, S1PR2 and S1PR3 receptors (Coussin 
et al., 2002, Lee et al., 1998, Murakami et al., 2010) (subtypes present in the 
vasculature)(Peters and Alewijnse, 2007). S1P signalling has been related to inflammation in 
HTN; specifically, it has been suggested to regulate pro-inflammatory vascular signalling 
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through receptor tyrosine kinases (RTK) (Tanimoto et al., 2004). Moreover, RTK 
transactivation has been shown to further trigger activation of MAP kinases, including 
p38MAPK and SAPK/JNK, known mitogenic signal transducers implicated in pro-
inflammatory pathways and VSMC inflammation (Eguchi et al., 2001, Linseman et al., 1995, 
Yogi et al., 2011). These S1P/S1PR1-mediated pro-inflammatory effects were upregulated in 
mesenteric VSMCs from hypertensive SHRSP (Yogi et al., 2011). Furthermore, it has been 
demonstrated that the S1pr1 (Edg1) receptor is a candidate gene implicated in salt-sensitive 
HTN in the SHRSP model, exhibiting elevated mRNA expression in kidney from these animals 
(Graham et al., 2007).  Taken together the above data signify the potential importance of 
altered S1P/S1PR1 signalling in vascular remodelling and endothelial dysfunction in HTN. 
 
4.1.1 Aims 
Previous construction of chr.2 congenic strains, both on the WKY and SHRSP genetic 
backgrounds, resulted in improved BP phenotypes (Graham et al., 2007) (Figure  4-1). This 
series of experiments used 3rd order-mesenteric resistance arteries (MRA) from 16-week-
old normotensive WKY, hypertensive SHRSP and the WKY.SPGla2a (WS2a) and SP.WKYGla2a 
(SW2a) reciprocal congenic strains aiming to: 
• to compare the structure, mechanics and vascular function of MRAs across the strains, 
as well as to assess the effect of the chr.2 congenic interval on these phenotypes.  
• to investigate the underlying regulatory mechanisms of MRA vascular reactivity across 
the strains and their association with the congenic interval.   
• to establish mesenteric primary VSMC cultures, in order to examine S1P/S1PR1 
signalling across the strains.  
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Figure  4-1 - Chromosome 2 reciprocal congenic strains generated by WKY and SHRSP  mating. (A) 
Schematic of chr.2 from parental, WKY.SPGla2a and SP.WKYGla2a congenic strains, showing location 
of the congenic interval. Blue bars: regions of WKY homozygosity, red bars: regions of SHRSP 
homozygosity. (B) Averaged weekly radiotelemetry recordings of night-time and day-time SBP in 
male parental and WKY.SPGla2a and SP.WKYGla2a congenic strains, under baseline and salt-loaded 
conditions. Animals were put on high-salt diet at 18 weeks of age. Edited from Graham et al., 2007. 
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4.2 Results  
4.2.1 Structural and mechanical properties of MRAs from WKY, SHRSP and 2a 
congenic strains 
Vascular structure and mechanics of MRAs from 16 week old WKY, SHRSP and the 
SP.WKYGla2a and WKY.SPGla2a congenic strains were assessed by subjecting vessel segments 
to a stepwise increase of intraluminal pressure (from 10 to 110 mmHg) on a pressure 
myograph, as described in section  2.5.2.  
MRAs from SHRSP exhibited smaller, yet not significantly, external diameter at 
pressures greater than 60mmHg (De; Figure  4-2A), compared with the other three strains. 
SHRSP internal diameter (Di; Figure  4-2B) also appeared slightly diminished relative to WKY 
and SP.WKYGla2a, and significantly smaller to WKY.SPGla2a, at high pressures (80-120mmHg, 
P<0.05). Wall : lumen ratio, wall thickness and cross-sectional area (CSA) (Figure  4-2C,D and 
E) tended to decrease in SHRSP and both the 2a congenic strains compared with WKY, but 
only reached significance in WKY.SPGla2a versus WKY arteries (P<0.05; 10-20mmHg for wall : 
lumen ratio, 10-20 and 80-110mmHg for wall thickness, 100-110mmHg for CSA). SHRSP and 
SP.WKYGla2a demonstrated intermediate phenotypes for these three parameters. The above 
data are summarised in Table  4-1. 
Table  4-1. Morphometric parameters of pressurised MRAs.  
Group External 
diameter (µm) 
(110mmHg) 
Lumen 
diameter (µm) 
(110mmHg) 
Wall/lumen  
ratio (%) 
(20mmHg) 
Wall thickness 
(µm)  
(110mmHg) 
Cross-section 
area (µm
2
) 
(110mmHg) 
WKY 436 ± 15.0 314 ± 10.8 0.196 ± 0.02* 61 ± 5.2* 72486 ± 7518* 
WS2a 438 ± 12.3 348 ± 12.7 0.132 ± 0.011 45 ± 2.5 55450 ±  3266 
SW2a 443 ± 10.1 328 ± 13.0 0.181 ± 0.019 58 ± 4.1         
(40-60mmHg)* 
69333 ± 4730 
SHRSP 402 ± 13.9 294 ± 18.6* 0.197 ± 0.025 55 ± 3.5 58907 ± 2847 
Values are means ± SEM        *p<0.05 vs WS2a 
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Figure  4-2 - Comparison of structural properties of MRAs from 16 week old parental WKY and 
SHRSP and congenic WKY.SPGla2a and SP.WKYGla2a strains. (A) External diameter, (B) internal 
diameter, (C) wall : lumen ratio, (D) wall thickness and (E) cross-sectional area (CSA) in dependency 
to applied intraluminal pressure, on fully relaxed MRA, as measured by pressure myography. Data 
are expressed as mean ±SEM; n=number of animals is indicated in parenthesis; P-values indicate 
statistical difference between strains calculated by two-way ANOVA (rat strain – pressure), 
followed by Bonferroni test. 
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Subsequently, vascular stiffness of MRAs was assessed by measuring stress and strain 
of the arterial wall. Wall stress was significantly enhanced only in WKY.SPGla2a, at high 
pressures (80-110mmHg), in comparison to all other strains (Figure  4-3A). Wall strain was 
significantly lower in SHRSP relative to WKY as well as WKY.SPGla2a, at pressures between 60 
and 110mmHg (P<0.001 and P<0.01, respectively) (Figure  4-3B). Incremental distensibility, at 
low pressures (10-40mmHg), followed a similar pattern between strains sharing genetic 
background, with SHRSP-background strains (SHRSP and SP.WKYGla2a) exhibiting smaller 
values than WKY-background strains (WKY and WKY.SPGla2a) (Figure  4-3C). Finally, wall 
stiffness, described by the stress - wall strain relationship, was increased in SHRSP compared 
with WKY and the congenic strains, however it did not reach significance (p=0.055) (Figure 
 4-3D). Increased stiffness is indicated by the leftward shift of the curve and the higher β 
value, which represents the curve slope. Data are summarised in Table  4-2. 
Table  4-2. Mechanical parameters of pressurised MRAs. 
Group Stress                   
(x 10
6
 dynes/cm
2
) 
(20mmHg) 
Wall strain 
(110mmHg) 
Incremental 
distensibility                        
(% mmHg
-1
) 
(20mmHg) 
β-slope         
WKY 0.041 ± 0.004 *** 0.870 ± 0.106
 ### 0.901 ± 0.162 4.053 ± 0.376   
WS2a 0.058 ± 0.004 0.755 ± 0.076 ## 0.942 ± 0.189 4.497 ± 0.278  
SW2a 0.044 ± 0.004 *** 0.669 ± 0.071 0.599 ± 0.128 5.310 ± 0.828  
SHRSP 0.042 ± 0.005 *** 0.468 ± 0.066 0.602 ± 0.123 7.221 ± 0.928  
Values are means ± SEM                                                                                                                                
*** P<0.001  vs WS2a        ###, ## P<0.001, 0.01  vs SHRSP 
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Figure  4-3 - Comparison of mechanical parameters of MRAs from 16 week old parental WKY and 
SHRSP and congenic WKY.SPGla2a and SP.WKYGla2a strains. (A) Stress, (B) wall strain and (C) 
incremental distensibility in dependency to applied intraluminal pressure, on fully relaxed MRA. 
(D) Stress-strain relationship. Data are expressed as mean ±SEM; n=number of animals is indicated 
in parenthesis; *,**,*** P< 0.05, 0.01, 0.001 indicate statistical difference between strains 
calculated by two-way ANOVA (rat strain – pressure), followed by Bonferroni test. 
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4.2.2 Vascular reactivity and endothelial function of MRAs from WKY, SHRSP 
and 2a congenic strains  
Vascular reactivity and endothelial function of MRAs from 16 week old WKY, SHRSP 
and SP.WKYGla2a and WKY.SPGla2a congenic strains were assessed by exposing vessels to 
cumulative doses of a vasodilator / vasoconstrictor, and measuring the responses on a wire 
myograph, before and after pharmacological inhibition of certain relaxation / constriction 
pathways, as described in section 2.5.1.  
To evaluate alpha-adrenergic-induced contractile responses of MRAs, isolated arteries 
were treated with increasing doses of noradrenalin (NA) (10-9 to 3x10-5M). Responses were 
measured before and after RhoK inhibition with fasudil (3μM, 30min before NA stimulation) 
to assess the involvement of RhoA/Rho kinase pathway on the basal tone. Inhibition of RhoK 
decreased similarly NA-induced contraction in WKY, WKY.SPGla2a and SP.WKYGla2a, without 
reaching significance (Figure  4-4A, B and D). On the contrary, in SHRSP, the fasudil-induced 
decrease in contraction to high NA doses was significantly greater compared to untreated 
MRAs (3x10-6M, P<0.01). Moreover, the contraction curve was slightly shifted to the right, 
indicating a lower sensitivity to NA in fasudil-treated versus untreated arteries from SHRSP 
(Figure  4-4C). Further, comparison of responses across strains, in untreated MRAs, 
demonstrated significantly enhanced contractility in SHRSP versus WKY and the two 
congenic strains (3x10-6 to 10-5M). SP.WKYGla2a NA-induced contraction was also increased 
relative to WKY, whereas WKY.SPGla2a exhibited similar responses to WKY. Finally, a small 
leftward shift of the SHRSP curve indicated higher sensitivity to NA (Figure  4-4E). After RhoK 
inhibition, SHRSP high contractile responses to NA remained significantly different to the 
other three stains (3x10-6 to 10-5 M), despite the corrected levels as described above (Figure 
 4-4F). The above data are summarised in Table  4-3. 
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Table  4-3. Contractile responses to noradrenalin in untreated and fasudil-treated MRAs.  
Group Noradrenaline                    
Active effective pressure (kPa)      
(3 x 10
-6
 M) 
Noradrenaline + Fasudil                                                 
Active effective pressure (kPa)                 
(3 x 10
-6
 M) 
WKY
 
23.18 ± 2.54  *** 
, #  17.38 ± 2.17  *** 
, ##, § 
WS2a 25.92 ± 3.89  *** 20.90 ± 5.87  
SW2a 32.85 ± 2.22  ** 27.10 ± 2.02 
SHRSP 41.45 ± 1.85  ## 31.26 ± 3.42 §§ 
 Values are means ± SEM                                                                                                                   
***,** P < 0.001, 0.01  vs SHRSP          ##, # P < 0.01, 0.05  vs SW2a                              
§§,§ P < 0.01, 0.05  vs untreated                                                                                                                 
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Figure  4-4 - Contractile responses to noradrenaline (NA) in MRAs from 16 week old parental WKY 
and SHRSP and congenic WKY.SPGla2a and SP.WKYGla2a strains. Concentration-response curves of 
(A) WKY, (B) WKY.SPGla2a, (C) SHRSP and (D) SP.WKYGla2a to NA (10
-9
 to 3x10
-5
M) before and after 
acute treatment with fasudil 3μM, using wire myography. (E) Comparison of contraction curves of 
untreated MRAs. (F) Comparison of contraction curves of fasudil-treated MRAs. Data are expressed 
as mean ±SEM; n=number of animals is indicated in parenthesis; *,**,*** P< 0.05, 0.01, 0.001 
indicate significant statistical difference calculated by two-way ANOVA (treatment - [NA] or rat 
strain - [NA]), followed by Bonferroni test. 
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Endothelium-mediated relaxation to cumulative doses of carbachol (3x10-8 to 10-5 M) 
was measured in NA-pre-contracted MRAs, at baseline and after eNOS inhibition with L-
NAME (100μM, 30min before stimulation with agonists), to evaluate function of 
endothelium and contribution of endothelial NO on relaxation, in each strain.  
In the first series of experiments, fully (100%) pre-contracted arteries (3x10-5M NA) 
from SHRSP and SP.WKYGla2a relaxed in a similar manner to carbachol (3x10
-7 to 10-5M) and 
significantly less compared to WKY and WKY.SPGla2a, under basal conditions (Figure  4-5). 
Data are summarised in Table  4-4.  
 
Figure  4-5 - Endothelium-dependent relaxation to carbachol, in fully (100%) pre-contracted MRAs 
with noradrenaline, from 16 week old parental WKY and SHRSP and congenic WKY.SPGla2a and 
SP.WKYGla2a strains. MRAs were pre-contracted with 3x10
-5
M NA and concentration-response 
curves to carbachol (3x10
-8
 to 10
-5
M) were generated using wire myography. Data are expressed as 
mean ±SEM; n=number of animals is indicated in parenthesis; *,**,*** P< 0.05, 0.01, 0.001 indicate 
statistical difference calculated by two-way ANOVA (rat strain - [carbachol]), followed by 
Bonferroni test. 
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In a following set of experiments MRAs were pre-contracted to approximately 80% 
(2x10-6M NA) before treatment with L-NAME. Untreated arteries relaxed completely in all 
four strains (Figure  4-6A). Inhibition of eNOS significantly decreased carbachol-induced 
relaxation of MRAs from SHRSP compared to WKY and the two congenic strains (3x10-7 to 10-
5 M). Responses of SP.WKYGla2a were affected to a lesser extent, without reaching 
significance against WKY and WKY.SPGla2a (Figure  4-6B). Looking specifically into each strain, 
L-NAME treatment partially reduced relaxation to carbachol in MRAs from WKY (10-7 to 
3x10-7 M), but had no significant effect on WKY.SPGla2a (Figure  4-6C and D). On the contrary, 
inhibition of eNOS highly impaired vasodilatation in MRAs from SHRSP and SP.WKYGla2a (10
-7 
to 10-5 M) (Figure  4-6E and F). Moreover, upon treatment sensitivity to carbachol was 
reduced in all four strains, however to a different extent, as indicated by the rightward shift 
of the curve. Data are summarised in Table  4-4.  
Table  4-4. Relaxation responses of MRAs  
Group Carbachol                  
% Relaxation     
(3x10
-6
 M)          
(100% pre-
contracted) 
Carbachol              
% Relaxation         
(3 x 10
-6
 M)      
(80% pre-
contracted) 
Carbachol  + L-NAME    
% Relaxation                      
(3 x 10
-6
 M)               
(80% pre-      
contracted) 
SNP                    
% Relaxation    
(3 x 10
-6
 M) 
(80% pre-
contracted) 
WKY 83.50 ± 6.43***
, ##
 98.36 ± 0.77  84.21 ± 10.53 * 100 ± 0.26  
WS2a 70.76 ± 6.57 * 95.05 ± 2.83 93.41 ± 2.56 ** 98.3 ± 1.67 
SW2a 52.34 ± 7.10 95.12 ± 3.63     63.11 ± 12.25 §§ 94.6 ± 2.77 
SHRSP 44.53 ± 5.88 88.33 ± 3.05  47.21 ± 10.85 §§§ 97.6 ± 0.66 
Values are means ± SEM                                                                                                                       
***,**,* P < 0.001, 0.01, 0.05  vs SHRSP             ## P < 0.01  vs SW2a                                                          
§§§,§§ P < 0.001, 0.01  vs untreated                                                                                                                 
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Figure  4-6 - Endothelium-dependent vasodilatation responses to carbachol, in 80% NA pre-
contracted MRAs from 16 weeks old parental WKY and SHRSP and congenic WKY.SPGla2a and 
SP.WKYGla2a strains. (A) Comparison of relaxation curves of untreated MRA. (B) Comparison of 
relaxation curves of L-name-treated MRA. Concentration-response curves of (C) WKY, (D) 
WKY.SPGla2a, (E) SHRSP and (F) SP.WKYGla2a to carbachol (3x10
-8
 to 10
-5
M) before and after 
treatment with L-name (100μM), using wire myography. Data are expressed as mean ±SEM; 
n=number of animals is indicated in parenthesis; *,**,*** P< 0.05, 0.01, 0.001 indicate statistical 
difference calculated by two-way ANOVA (treatment - [carbachol] or rat strain - [carbachol]), 
followed by Bonferroni test. 
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Endothelium-independent relaxation of NA-pre-contracted vessels (2x10-6M) was 
assessed in response to cumulative doses of the external nitric oxide (NO) donor, sodium 
nitroprusside (SNP; 3x10-8 to 10-5 M). Relaxation curves did not differ between the four 
strains (Figure  4-7). Data are also summarised in Table 4. 
 
Figure  4-7 - Endothelium-independent vasodilatation responses to the external nitric oxide donor, 
sodium nitroprusside (SNP) in noradrenaline pre-contracted (80%) MRAs. Concentration-response 
curves of WKY, WKY.SPGla2a, SHRSP, and SP.WKYGla2a, to SNP (3x10
-8
 to 10
-5
M), using wire 
myography. Data are expressed as mean ±SEM; n=number of animals is indicated in parenthesis. 
Statistical difference between treatment groups was calculated by two-way ANOVA (rat strain - 
[SNP]). 
 
 
 
 
 
 
Sofia Tsiropoulou Chapter 4 130 
4.2.3 Isolation of primary VSMCs from MRAs and culture establishment 
To investigate whether differences in physiology of MRAs are represented at the 
cellular and molecular level, primary VSMCs from MRAs of 16 week old WKY, SHRSP and 2a 
congenic strains were isolated and cell cultures were established (sections  2.2.1 and 2.2.2). 
Purity of primary VSMC cultures was assessed by positive immunofluerescent staining (ICC) 
for the smooth muscle cell type-specific marker SMC-α-actin (ACTA2), at passage 3, as 
described in section 2.2.4. Green fluorescent staining of actin microfilaments demonstrated 
clear domination of VSMCs (>90%) (Figure  4-8, middle). Negative species-specific IgG (rabbit) 
control showed no detectable staining (Figure  4-8, right). 
 
Figure  4-8 - Characterisation of mesenteric VSMC cultures from 16 week old rats, by 
immunocytochemistry. VSMC cell culture at passage 3, x10 magnification (left). 
Immunofluorescent staining for ACTA2 (polyclonal rabbit-anti human, 1/100, ab5694), x20 
magnification (middle). Isotype (rabbit IgG) negative control (right).  
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4.2.4 S1P-Receptors expression in primary VSMCs from MRAs  
Previous microarray and protein expression data from renal tissue and primary VSMCs, 
indicated S1PR1 as a positional candidate of salt-sensitivity and BP regulation in SHRSP 
(Graham et al., 2007). Following these observations, S1PR1 expression was investigated in 
primary mesenteric VSMCs relative to primary aortic VSMCs. Moreover, levels of S1PR2 and 
S1PR3 were tested in mesenteric primary VSMCs. WB analysis (section 2.3) was performed 
on whole cell lysates (section 2.2.7) from 16 weeks old WKY, SHRSP and the 2a congenics, 
probed with specific receptor antibodies. No bands corresponding to the size of S1PR1 
(47kDa) were detected in any of the strains, for mesenteric or aortic VSMCs. Positive control 
of transfected CCL39 cells expressing human S1PR1 gave an intense band at the expected 
size. No signal was detected in negative control of untransfected CCL39 cells. (Figure  4-9; top 
panel). Similarly, expression levels of S1PR2 and S1PR3 were beyond detection in mesenteric 
VSMCs from WKY and SHRSP (Figure  4-9 B and C; top panels). β-actin was used as loading 
control. 
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Figure  4-9 - S1P-Receptors expression in whole cell lysates of primary VSMCs from 16 week old 
WKY, SHRSP and 2a congenic strains. Top panels: (A) immunoblot for S1PR1 (PA1-1040 antibody 
provided by Dr. Tim Palmer) in: transfected CCL39 hamster lung fibroblast cells stably expressing 
human S1PR1 protein ((+) positive control), CCL39 untransfected cells ((-) negative control), 
primary aortic VSMCs from WKY and SHRSP (lanes 3,4), primary VSMCs from MRAs of WKY, SHRSP, 
WKY.SPGla2a and SP.WKYGla2a (lanes 5 to 8). (B) immunoblot for S1PR2 and (C) S1PR3 in  primary 
VSMCs from MRAs of WKY and SHRSP. Bottom panels: immunoblots for β-actin used as loading 
control. Protein loaded: 80 µg. 
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4.2.5 S1PR1 signalling in primary VSMCs from MRAs 
Despite expression levels of S1PR1 below the detection threshold of western analysis 
in mesenteric primary VSMCs from the four strains (section  4.2.4), investigation of receptor's 
downstream signalling was performed based on and in order to confirm data from previous 
studies, which demonstrated altered S1PR1 MAP kinase signalling between WKY and SHRSP 
in mesenteric VSMCs (Yogi et al., 2011). A drug agonist/antagonist intervention was applied 
to compare phosphorylation levels of signalling effectors and verify the receptor subtype 
through which S1P induces its effects, in primary VSMCs from the parental and congenic 
strains. As described in section 2.2.5, cells were either stimulated with the S1P agonist (10-
6M) for 30mins or pre-exposed to VPC23091 (10-5M), a potent S1PR1 antagonist, for 30min 
before S1P stimulation. Levels of phosphorylation of the MAP kinases SAPK/JNK, ERK1/2 and 
p38MAPK were compared by WB analysis (section 2.3) on whole cell lysates (section 2.2.7). 
Membranes were probed with specific antibodies for total and phosphorylated forms of 
SAPK/JNK, ERK1/2 and p38MAPK. β-actin was used as loading control. Responses were 
expressed as percentages of the initial phosphorylation levels during control treatment with 
vehicle. 
S1P-stimulation significantly increased SAPK/JNK phosphorylation in cells from all four 
strains. Responses were augmented in SP.WKYGla2a compared to the other three strains. VPC 
pre-treatment did not appear to have any inhibitory effects on the S1P-induced 
phosphorylation in any of the strains, but WKY.SPGla2a. However no statistics could be 
performed on the latter strain as there was only one experimental replicate. (Figure  4-10) 
Moreover, stimulation with S1P induced significant p38MAPK phopshorylation of 
similar magnitude in cells from WKY and SP.WKYGla2a, but not in SHRSP and WKY.SPGla2a. 
Treatment with VPC did not abrogate this change in phosphorylation levels. (Figure  4-11) 
Finally, S1P significantly stimulated ERK1/2 phosphorylation in parental strains as 
opposed to congenics. Effects were enhanced in cells for WKY relative to SHRSP, without 
reaching significance. VPC did not significantly block S1P-mediated ERK1/2 phosphorylation 
in any strain. (Figure  4-12) 
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Figure  4-10 - Effect of S1PR1 receptor stimulation and antagonism on S1P-induced SAPK/JNK 
phosphorylation in VSMCs from WKY, SHRSP and the 2a congenics. Mesenteric primary VSMCs 
from 16 week old WKY, SHRSP, SP.WKYGla2a and WKY.SPGla2a were stimulated with 10
-6
M S1P for 
30mins or pre-treated with 10
-5
M VPC23091 for 30min prior to S1P stimulation. Top panels, 
representative immunoblots on whole cell lysates for SAPK/JNK [Thr
183
/Tyr
185
] (top), SAPK/JNK 
(middle) and β-actin (bottom). Protein loaded: 30 µg. Bottom, corresponding densitometry bar 
graph demonstrating the effect of S1P stimulation on SAPK/JNK phosphorylation and of VPC23091 
on S1P-induced SAPK/JNK phosphorylation in VSMCs of the four strains. Results come either from 
one or are the mean ±SEM of 2 or 3 experiments and were compared by Student's t-test (unpaired, 
two-tailed). *P<0.05 vs vehicle; #P<0.05 vs S1P-stimulation in SP.WKYGla2a.  
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Figure  4-11 - Effect of S1PR1 receptor stimulation and antagonism on S1P-induced p38MAPK 
phosphorylation in VSMCs from WKY, SHRSP and the 2a congenics. Top panels, representative 
immunoblots for p38MAPK [Thr
180
/Tyr
182
] (top), p38MAPK (middle) and β-actin (bottom). Protein 
loaded: 30 µg. Bottom, corresponding bar graph demonstrating the effect of S1P (10
-6
M) 
stimulation on p38MAPK phosphorylation and of VPC23091 (10
-5
M) on S1P-induced p38MAPK 
phosphorylation in VSMCs of the four strains. Results come either from one or are the mean ±SEM 
of 2 or 3 experiments and were compared by Student's t-test (unpaired, two-tailed). *P<0.05 vs 
vehicle. 
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Figure  4-12 - Effect of S1PR1 receptor stimulation and antagonism on S1P-induced ERK 1/2 
phosphorylation in VSMCs from WKY, SHRSP and the 2a congenics. Top panels, representative 
immunoblots for ERK 1/2 [Thr
202
/Tyr
204
] (top), ERK 1/2 (middle) and β-actin (bottom). Protein 
loaded: 30 µg. Bottom, corresponding bar graph demonstrating the effect of S1P (10
-6
M) 
stimulation on ERK 1/2 phosphorylation and of VPC23091 (10
-5
M) on S1P-induced ERK 1/2 
phosphorylation in VSMCs of the four strains. Results come either from one or are the mean ±SEM 
of 2 or 3 experiments and were compared by Student's t-test (unpaired, two-tailed).  *P<0.05 vs 
vehicle; §P<0.05 vs S1P-stimulation in WKY. 
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4.3 Discussion 
Previous introgression of normotensive-WKY or hypertensive-SHRSP chromosome 2 
interval into the reciprocal genetic background generated the SP.WKYGla2a and WKY.SPGla2a 
congenic strains of increased SBP phenotypes. This study aims to further investigate the 
significance of the interval on vascular/endothelial function and remodelling in mesenteric 
resistance arteries (MRA) from 16 week old parental and 2a congenic strains. Ex vivo studies 
compared structure, mechanics and function of arteries. In vitro experiments in primary 
VSMCs from MRAs focused on investigation of S1P/S1PR1-mediated mitogenic signalling.  
Remodelling of MRAs was assessed by comparison of structural and mechanical 
vascular properties. Basic structure measurements of internal (Di) and external (Do) 
diameter, wall thickness, wall:lumen ratio and CSA were similar between WKY and SHRSP. 
Nonetheless, the decreased trends in Do, wall thickness and CSA in SHRSP, especially at high 
intravascular pressures (>60mmHg), indicate smaller vessel size and thinner walls, and imply 
a tendency of the hypertensive vessels to be stiffer. However, previous microscopic 
investigation of structure in MRAs from 8-10 month old SHRSP (Glasgow) has shown 
hypertrophic inward remodelling resulting from a reduced vessel lumen and an increased 
wall thickness and wall:lumen ratio compared to WKY (Arribas et al., 1997). This may suggest 
that structural alterations develop later in life as an adaptive response to increased BP, 
which is in agreement with studies on time course development of remodelling in MRAs 
from SHR demonstrating no structural alterations up to 1 month but present at 5 and 6 
months old animals (Gonzalez et al., 2006, Intengan et al., 1999). Further, from the two 
congenic strains, SP.WKYGla2a exhibited characteristics very similar to WKY, implying a 
potential beneficial effect of the WKY congenic interval. Such an effect has already been 
evident through the reduced SBP of SP.WKYGla2a compared to SHRSP. On the other hand, 
WKY.SPGla2a demonstrated increased Di, associated with decreased wall thickness and 
consequently lower wall:lumen ratio and CSA compared to WKY. Such alterations indicate a 
vessel of similar size but thinner walls, which could be interpreted as adaptive responses 
(reduce peripheral vascular resistance) to the detrimental effect (increased hemodynamic 
load/SBP) introduced by the SHRSP congenic interval.  
In line with the structural data, comparison of MRA mechanical properties, in SHRSP 
versus WKY, demonstrated significant decrease in wall strain, thus reduced ability to stretch 
(elasticity). This was also evident in the decreased trend of incremental distensibility (at 
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physiological intravascular pressures of 20 to 60 mmHg), which implies requirement of 
greater pressure in SHRSP to achieve similar percentage of Di change with WKY. However, 
wall stress (wall tension), which depends on the Di and wall thickness, did not differ between 
the parental stains, as expected. Nevertheless, the stress-strain relationship indicated a 
tendency of vessels from 16 week old SHRSP to be stiffer. Such observations are supported 
by previous studies on MRAs from 20-24 week old SHR that reported increased intrinsic wall 
stiffness and reduced stress and incremental distensibility compared to WKY (Intengan et al., 
1999, Briones et al., 2003). This implies that the mechanical alterations probably develop 
later in life, following vascular remodelling. With respect to SP.WKYGla2a, MRA mechanical 
properties did not differ significantly to those of the parental animals. Nonetheless, elasticity 
of arteries (strain) at high pressures, as well as their stiffness tended to improve by 
introgression of the WKY congenic interval. In WKY.SPGla2a, the ability of arteries to stretch 
(strain and incremental distensibility) was similar to the one of WKY. However, introgression 
of the SHRSP congenic interval appeared to significantly elevate wall tension, which is not 
surprising, considering the significantly reduced wall thickness observed in this strain. 
Moreover, stiffness of the vessels tended to increase. In both congenic strains, the observed 
tendencies in stiffness are in agreement with the respective changes introduced in SBP by 
the congenic interval. However, the cause and effect relationship is still not clear, despite 
the fact that the above data collectively would support that changes in SBP occur as primary 
events leading to changes in stiffness at a later stage. 
Taken together the above findings demonstrate no evident remodelling in SHRSP 
MRAs at the age of 16 weeks, despite the established hypertension. A possible explanation 
could be that structural and mechanical alterations develop later in life as adaptive 
responses to increased BP. From experiments on rat models of hypertension, it is known 
that primary structural abnormalities in distal resistance arteries (arterioles) seem to be 
responsible for increase in BP which finally leads to adaptive structural changes in proximal 
resistance arteries (small arteries) . It is also known that resistance artery structure is not 
entirely dependent on the development of hypertension, but it is also affected by 
neurohormonal (Folkow et al., 1988) and genetic factors. Data supporting this hypothesis 
showed that improvement in SHRSP vessel structure, such as reduction in wall:lumen ratio, 
did not reduce BP and vice versa (Morton et al., 1992, Hashimoto et al., 2010, Rigsby et al., 
2011). Furthermore, introgression of the SHRSP-'diseased' congenic interval into 
WKY.SPGla2a seems to introduce great alterations in MRA structural and mechanical 
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properties as an attempt of the WKY-'healthy' background to correct the increased BP. On 
the other hand, introduction of the WKY congenic interval in SP.WKYGla2a does not manage 
to significantly improve the 'diseased' phenotype. Further evaluation of differences in MRA 
structure and mechanical properties by histological staining for markers of morphological 
changes, such as elastin and collagens content, would have been more supportive of our 
data, but there was a limitation of time.  
Subsequently, assessment of contractile function in MRAs demonstrated 
hypercontractility of SHRSP arteries compared to the other strains, which could explain the 
increased BP in SHRSP at this age, in the lack of significant structural/mechanical alterations. 
In support of this observation, several studies have shown hypercontractility in hypertensive 
rat strains (Gradin et al., 2003). Moreover, the reduced contractile responses of SP.WKYGla2a 
in comparison to SHRSP imply that introgression of WKY congenic interval improves the 
hypercontratile phenotype. In contrast, insertion of the SHRSP congenic interval in 
WKY.SPGla2a did not seem to have any detrimental effect on the vascular tone of WKY. 
Therefore, it could be hypothesised that WKY control their contraction by components that 
lie both inside and outside chromosome 2 congenic interval and which could act 
synergistically or even compensate for each other's loss of functionality. Those components 
lying outside the interval seem to be predominant, as they maintain normal contractile 
function in WKY.SPGla2a, whereas in SP.WKYGla2a function is only partially improved. Further, 
acute inhibition of RhoK, to investigate the role of RhoA/RhoK signalling on contraction of 
the smooth muscle, demonstrated significant improvement of hypercontractility in SHRSP 
arteries, but had no effect on WKY and the congenic strains. Such observations are 
consistent with previous studies suggesting implication of RhoA/RhoK pathway in increased 
contractile responses of hypertensive rat models (Kitazono et al., 2002, Moriki et al., 2004). 
Moreover, reduction of hypercontractility in SHRSP could partially be attributed to 
decreased release of EDCFs, another effect of RhoK blockade. This is supported by studies on 
WKY aortas, in which inhibition of RhoK resulted in a significant decrease of endothelium-
dependent contractions (Chan et al., 2009). On the other hand, contractions in MRAs from 
WKY, WKY.SPGla2a and SP.WKYGla2a seem to only partially be mediated by RhoA/RhoK 
pathway, considering the trend of reduced responses upon RhoK inhibition. It is therefore 
suggested that alternative contraction regulatory systems are predominant in these strains, 
such as potassium channels and PKC. This explanation further supports our earlier 
hypothesis suggesting existence of components, in this case other regulatory systems, 
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present within or outside the congenic interval of WKY having a beneficial effect on 
contractile responses in 2a congenics. Further experiments, including inhibition of the other 
contraction pathways, calcium sensitivity and cyclic GMP regulation studies, measurement 
of Rho kinase activity and expression levels of RhoA/RhoK activation markers, such as ezrin 
and MLC, would enable a better understanding and verification of the above data.  
Moreover, assessment of vasodilatory responses of fully pre-contracted MRAs 
revealed significantly reduced ability of SHRSP and SP.WKYGla2a to relax in comparison to 
WKY and WKY.SPGla2a, at 16 weeks of age. Such observations indicate a predominant role of 
the genetic background over the congenic interval on regulation of relaxation. Further, 
based on the increased SBP phenotype of WKY.SPGla2a, it is implied that impaired relaxation 
is a secondary event to elevated BP in this strain. Whether this impairment is the result of 
smooth muscle or endothelial dysfunction was further examined. Endothelium-independent 
responses to an external vasodilator (SNP: NO donor) were similar in all four strains, 
indicating fully functional smooth muscle at this age. Endothelium-dependent relaxation was 
assessed by evaluating the contribution of endothelial NO bioavailability as relaxation 
mechanism in MRAs upon eNOS inhibition. A trend in WKY and WKY.SPGla2a arteries to dilate 
less than before eNOS blockade, imply that either NO is not the major vasodilator in MRAs of 
strains sharing WKY genetic background, but rather acts synergistically to alternative 
vasodilatory systems such as EDHF and prostacyclins, or that the alternative regulatory 
systems can effectively compensate for the reduced NO biovailability. Studies have 
previously demonstrated EDHF-signalling as the predominant vasodilatation mechanism in 
small resistance arteries, compensating for decreased NO availability (Ruiz-Marcos et al., 
2001, Hussain et al., 2001, Madhani et al., 2003). On the contrary, in SHRSP and SP.WKYGla2a, 
eNOS inhibition was followed by significantly reduced dilatory responses, although 
introgression of the WKY congenic interval slightly, but not significantly, improved 
relaxation. This suggests that either NO bioavailability is the predominant mechanism in 
strains sharing SHRSP genetic background, as shown previously (Kerr et al., 1999, Ma et al., 
2001, McIntyre et al., 1997), or that the predominant EDHF or prostacyclin pathway is 
impaired (Sunano et al., 1999, Goto et al., 2004, Giachini et al., 2009) and NO, as a secondary 
system, can only partially compensate for the impairment. The ability of different 
vasodilatation systems to act synergistically or substitute each other in situations of 
endothelial dysfunction has been previously shown in MRAs from hypertensive models 
(Chataigneau et al., 1999, Sofola et al., 2002). Taken together the results from eNOS 
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blockade unmasked an endothelial dysfunction in SHRSP and SP.WKYGla2a, as a combination 
of impaired and non-efficient relaxation mechanisms, which are primarily regulated by the 
genetic background rather the congenic interval. Moreover, based on the opposite 
relaxation responses of the 2a congenic strains, despite their increased-SBP phenotypes, it is 
implied that endothelial impairment is a secondary event to elevated BP. In agreement with 
this, studies on aorta from SHRSP demonstrated that only at a later stage, after hypertension 
is established, endothelial dysfunction develops (Kerr et al., 1999, Onda et al., 1994). Further 
experiments, including inhibition of alternative relaxation systems and measuring of NO 
levels in MRAs from the four strains, would elucidate the predominant vasodilatory 
mechanisms and impairments in each strain.  
In order to investigate whether the above physiological differences in MRAs from our 
strains are represented at the cellular/molecular level, cell cultures of primary mesenteric 
VSMCs were established. S1PR1 expression and mitogenic signalling were chosen to be 
assessed in these cells, based on existing data identifying S1PR1 receptor as a positional 
candidate for hypertension and implicating S1P/S1PR1 signalling in vascular inflammatory 
responses and cell growth in VSMCs (Graham et al., 2007, Yogi et al., 2011), processes that 
impact on vascular remodelling and endothelial dysfunction in hypertension. In contrast to 
previous studies from Touyz's group demonstrating similar expression of S1PR1 and S1PR2 
subtypes between WKY and SHRSP, but absence of S1PR3 in these cells (Yogi et al., 2011), 
our studies showed expression levels below detection for all three receptor subtypes in WKY 
and SHRSP. Similarly, S1PR1 levels were below detection in primary cells from 2a congenic 
strains MRAs, as well as from WKY and SHRSP aortas. These opposing results could be 
attributed to interstrain variability. Furthermore, it is known that GPCR receptors are 
generally expressed in low levels. Future studies could explore expression levels in enriched 
membrane fractions. 
Considering growing evidence on the importance of S1P/S1PR signalling in 
development and regulation of vascular system and in pathogenesis of vascular diseases 
(Bolz et al., 2003, Allende and Proia, 2002, Deutschman et al., 2003), particularly from the 
work of Yogi et al. (Yogi et al., 2011) and in order to verify them, altered S1PR1 signalling 
through MAP kinase activation was investigated in cells from our strains. Phosphorylation 
levels of SAPK/JNK, ERK1/2 and p38MAPK as downstream signalling partners were assessed 
in response to the S1P stimulus and VPC blockade of S1PR1/3 receptors. Also, the 30min 
stimulation was chosen as the optimal time for maximal responses, according to previous 
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data (Yogi et al., 2011). Differential activation of MAPKs observed upon S1P stimulation is an 
indirect indication that our cells express at least one out of the three subtypes of S1PR 
receptors, despite their low levels as assessed by WB. However, the observation that VPC 
treatment was unable to significantly abrogate phosphorylation of MAPKs in mesenteric 
VSMCs from any strain indicates that these changes are potentially not mediated by S1PR1 
or S1PR3. Such results contradict Yogi's data, and could suggest that S1PR2 may play a role in 
induction of MAPK pathways in these cells. However, no firm conclusions to support Yogi's 
data can be drawn regarding the extent of responses in each strain, due to the low number 
of repetitions of each experiment.  
However, S1P signalling is still relevant, as involvement of other signalling pathways, 
apart from MAPKs, are known to influence vascular function (vascular remodelling and 
endothelial dysfunction), such as generation of ROS, activation of transcription factors and 
stimulation of cation channels (Mochizuki, 2009). To further investigate such pathways and 
to overcome difficulties on assessing contribution of the congenic interval to phenotypic 
differences by ex vivo and in vitro studies, a broader, high-throughput approach was 
followed, involving whole proteome profiling in our parental and 2a congenic strains in 
response to S1P stimulation, described in the following chapter. The ultimate aim would be 
to compare the outputs of signalling pathways in health and disease and to identify/predict 
the best points at which to intervene to redress the balance.  
5 Proteome Profiling in S1P-Stimulated 
Mesenteric Primary VSMCs 
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5.1 Introduction 
5.1.1 MS-based quantitative proteomics: SILAC  
In the highly complex cellular environment, comprehensive characterisation of protein 
dynamic interactions and signalling networks is vital in revealing the mechanisms underlying 
biological processes. Development of high-throughput, MS-based quantitative proteomic 
approaches has enabled for large-scale mapping of interconnected protein networks 
(Aebersold and Mann, 2003).  
Considering that MS is not essentially a quantitative method, molecules are stably 
labelled to assist quantification. Direct comparison of intensity signals between differentially 
labelled isotopes correspond to peptide and protein ratios.  
Stable isotope labelling with amino acids of cells in culture (SILAC) is the most 
widespread metabolic labelling technique (Mann, 2006, Ong et al., 2002) applicable on both 
cell lines and primary cells. Combined with high-resolution LC-MS/MS and specialised data 
processing software, it provides a powerful strategy for rapid, unbiased screening of global 
proteomes  and of post-translational modifications (PTM) occurring in response to particular 
stimuli (Olsen et al., 2006). Moreover, SILAC has been successfully used to study the 
temporal dynamics of signalling pathways by exploiting phosphorylation based enrichment 
methods coupled to MS (EGFR pathway; (Schulze and Mann, 2004)), as well as in the 
identification of prognostic disease biomarkers (Geiger et al., 2012). SILAC achieves highly 
reliable quantification of hundreds to thousands of proteins, within four orders of 
magnitude in protein abundance, including low level regulatory molecules and membrane 
proteins (de Godoy et al., 2008).  
SILAC labelling is performed using media in which the normal isotopes 12C and 14N of 
arginine and lysine have been replaced by stable (non-radioactive) heavy isotopes 13C or 
13C/15N, to be incorporated into proteins. Arginine and lysine are selected as sites of trypsin 
cleavage, thus generating chemically identical tryptic peptides (Olsen et al., 2004). 
Nevertheless, tryptic peptides derived from differentially labelled populations are 
isotopically distinct and thus distinguished by a defined mass shift of the peak in the mass 
spectra. Specific software quantifies intensity ratios of heavy labelled peptides over light 
isotopic pairs as relative abundance (Figure  5-1). Usually, protein ratios of 1.3 to 2.0-fold 
have been used as cut-offs for both statistical and biological significance (Mann, 2006). SILAC 
allows further for multiplex comparisons either in a single experiment using triple labelling, 
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or by linking several SILAC experiments through a common experimental state or through a 
‘spiked-in’ labelled internal standard, without affecting quantitative accuracy (Andersen et 
al., 2005, Blagoev et al., 2004, Geiger et al., 2011, Kratchmarova et al., 2005). 
5.1.2 Quantitative proteomics sample preparation and instrumentation  
Recent advances in sample preparation strategies, instrument performance (Domon 
and Aebersold, 2006, Makarov et al., 2006) and bioinformatics tools (Mueller et al., 2008) 
have led to a spectacular progress and routine application of MS-based proteomics. 
It is common practice for highly-complex protein mixtures to be enzymatically digested 
(e.g. trypsin) into mixtures of chemically identical peptides prior to MS analysis (Olsen et al., 
2004). Further processing of digested peptides through liquid chromatography coupled to 
electrospray ionisation and high-resolution mass spectrometers (LC-ESI/MS) (Ho et al., 2003) 
has become the technique of choice for rapid analysis in shotgun quantitative proteomics 
(Aebersold and Mann, 2003, Cravatt et al., 2007). Amongst the existing mass analysers, 
linear iontrap quadrupole (LTQ) /orbitrap hybrids (Makarov et al., 2006) exhibit the highest 
resolving power and mass precision (5ppm m/z) and employ Fourier-transformation of 
peptide signals to generate MS spectra containing information on peptide mass and 
intensities. MS/MS fragmentation spectra are matched against sequence databases for 
peptide identification (Steen and Mann, 2004). 
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Figure  5-1 - Stable isotope labelling by amino acids in cell culture (SILAC). (A) Adaptation phase. 
Cells are initially adapted to complete growth media supplemented with dialysed serum, for 24h. 
Subsequently, they are transferred into differentially isotope-labelled SILAC media for metabolic 
labelling. Control “light” media contain 
12
C6
14
N2 L-lysine (Lys0) and/or 
12
C6
14
N4 L-arginine (Arg0). 
“Heavy” media contain heavy isotopes of these amino-acids (
13
C6 L-lysine (Lys6) or 
13
C6
15
N2 L-lysine 
(Lys8) and/or 
13
C6 L-arginine (Arg6) or 
13
C6
15
N4 L-arginine (Arg10)). Cells are propagated into SILAC 
media for 5-6 divisions, to ensure complete incorporation of labelled amino-acids. (B) Experimental 
phase. To quantify changes upon treatment of either cell population, labelled cells from both 
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populations (light and heavy) are harvested and combined in 1:1 ratio. Mixed cell lysate is then 
resolved by SDS-PAGE and visualized by Coomassie staining. Gel-lane slices or individual bands are 
extracted and subjected to trypsin digestion. Optional enrichment for a specific peptide fraction 
(e.g. phosphopeptides), is followed by separation of tryptic peptides by LC and 
identification/quantification by MS/MS analysis. (C) Exemplary mass spectra of isotopic peptide 
pairs. Differences in intensity ratios of peptide peaks reflect differences in relative protein 
abundance between the two states. (Adapted from Ong and Mann, 2006).  
5.1.3 Proteomic data processing and analysis:  MaxQuant - Perseus 
Large-scale proteomics analyses generate gigabytes of high-resolution MS data, 
requiring specialised software for efficient manipulation. MaxQuant is a widely applied 
computational proteomics platform (Cox et al., 2009), which uses a standardised workflow 
to process large numbers of LC-MS runs, including complex data from SILAC double or triple-
labelling experiments (Andersen et al., 2005, Blagoev et al., 2004). Its high quantification 
accuracy lies upon algorithms that perform measurements at the level of individual 
peptides. In combination with robust peptide and protein scoring results, it enables high 
peptide identification rates, that are even higher on SILAC peptide pairs (Cox and Mann, 
2008). In the case of SILAC experiments, raw data files generated by the mass analyser 
software are loaded into MaxQuant. Three-dimensional peak and isotope patterns are 
detected and assembled into SILAC pairs/triplets for quantification. SILAC-peptide ratios are 
normalised (log-ratio median = 0) to correct for unequal loading. Output files containing 
combined MS/MS fragmentation spectra from all LC-MS runs are submitted to either Mascot 
(commercial; (Perkins et al., 1999)) or Andromeda (MaxQuant-integrated; (Cox et al., 2011)) 
search engine, for peptide identification using a specified protein sequence database (e.g. 
IPI, Swissprot). Further processing in MaxQuant includes statistical validation of 
identifications, protein assembly and quantification and generation of summary tables 
containing all the information. Bioinformatics analysis and visualisation is performed on 
platforms such as Perseus, a separate module developed to complement MaxQuant 
workflow into a powerful, unified computational analysis pipeline for quantitative 
proteomics (http://www.perseus-framework.org), Scaffold (Searle, 2010) and IPA 
(http://www.ingenuity.com). 
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5.1.4 Aims 
Previous microarray profiling of salt-loaded SHRSP, WKY and SP.WKYGla2a congenic 
strain indicated differential renal expression of S1pr1, in addition to a number of SNPs in the 
promoter region (Graham et al., 2007). Moreover, signalling through S1PR1 receptor was 
found to be altered in S1P-stimulated mesenteric VSMC from SHRSP compared to WKY (Yogi 
et al., 2011). In order to overcome the difficulties on assessing outputs in situations of health 
and disease by low-sensitivity, small-scale experiments and to further investigate the impact 
of the congenic interval on phenotype, high-throughput MS-based quantitative proteomics 
were employed. Comparison of global-proteome profiles of mesenteric primary VSMCs from 
16-week-old WKY, SHRSP and 2a congenic strains (WKY.SPGla2a and SP.WKYGla2a) and 
characterisation of biological effects of a 30min S1P-stimulation on BP regulation were 
achieved using:   
•  high-throughput SILAC proteomic approach (triple-labelling) in the exploratory 
mode, to stably label global proteome for identification/monitoring of relative quantitative 
differences by LC-MS/MS analysis. 
•  bioinformatics analysis, to focus on significantly differentially expressed proteins 
and elucidate modulated biological processes, networks and pathways associated with S1P 
signalling and BP regulation.  
•  immunoblotting analysis, to validate SILAC results for significantly differentially 
expressed proteins as candidate molecules driving phenotypic changes in hypertension.  
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5.2 Results 
5.2.1 Proteomics and bioinformatics analysis 
Global proteomes of S1P-stimulated VSMCs from parental and 2a congenic strains 
were compared in two individual experiments using triple SILAC labelling (Light - Medium 
heavy - Heavy), as described in section 2.2.6: (A) WKYL - WKY.SPGla2aM - SHRSPH and (B) WKYL 
- SP.WKYGla2aM - SHRSPH. Cell growth rates did not seem to be affected upon replacement of 
normal with isotopically labelled media supplemented with dFBS, during the adaptation 
phase. MS data were filtered down a stringent pipeline, combining high accuracy 
quantitative software, search engines and protein sequences databases, visualisation 
platforms and web-based functional analysis tools (Figure  5-2). Filtering removed noise and 
contaminants, leaving a substantially reduced number of proteins to be further analysed. 
Assessment of incorporation of labelled-amino acids into peptides seemed to be efficient, 
when MS/MS spectra were previewed in Mascot. Combined MS/MS data were then 
processed through multiple versions of MaxQuant (v1.1.1.25, 1.2.0.18 and 1.2.2.6) to 
overcome re-occurring issues with the triple-labelling quantification (inconsistencies 
between the raw data - intensities of individual peptides mapping to a protein - and relative 
protein abundance). Eventually, data analysed with the latest version, v1.2.2.6, were 
searched against the rat IPI database v3.68, using Mascot Server to accurately identify 
proteins (high probability scores).  Proteins sharing a set of identified peptides were joined 
in a protein group, and protein quantification was performed based on unique and razor 
peptides (shared peptides associated with the group with the highest number of identified 
peptides). A total of 1998 proteins were identified across the two experiments, A and B. This 
number includes all isomers of each protein group which share at least half of the peptides 
with the leading protein of the group (majority isomers). Of these 1998 proteins, a small 
percentage represented highly abundant phosphorylated proteins, as visualised in Scaffold3 
(v3.2.0). As shown in Figure  5-3, only six phosphoproteins were identified with a probability 
higher than 95%, when filtered for a minimum of 99% protein probability, 90% peptide 
probability and peptide number of 2. Raw data for all proteins identified using MaxQuant 
v1.2.2.6 are summarised in supplementary table ‘PerseusDataTable_Expanded_MajorityIDs_ 
1998’, included in the hard copy (CD) accompanying the thesis. 
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Figure  5-2 – Proteomics analysis pipeline. MS/MS data from LTQ-Orbitrap Velos are extracted using 
Xcalibur, filtered and quantified through the MaxQuant workflow, associated with amino acid 
sequences on Mascot Server and uploaded to platforms such as Perseus and Scaffold for further 
manipulation and visualisation. Finally, Ingenuity Pathway Analysis (Ingenuity® Systems, 
www.ingenuity.com) is used for functional analysis and biological interpretation. Along the 
pipeline the number of detected features is remarkably reduced, allowing focus into a more 
manageable number of proteins. 
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Figure  5-3 - List of phosphorylated proteins identified at 95% probability, or higher, in Scaffold3 
proteome software. Protein list generated by MaxQuant v1.2.2.6 was filtered for minimum protein 
probability: 99%, minimum peptide number: 2 and minimum peptide probability: 90%. Columns A 
and B include the number of unique peptides on which the identification was based for 
experiments A: WKY - WKY.SPGla2a - SHRSP and B: WKY - SP.WKYGla2a - SHRSP, respectively. 
Further processing and visualisation of the identified peptides/proteins was performed 
using Perseus v1.2.7.4. Data from pair-wise comparisons between strains were represented 
in histograms. Normalised relative log-ratios (subtract median from each distribution) of all 
proteins identified were plotted against summed peptide counts (light, medium and heavy), 
in each experiment (Figure  5-4). Comparisons of SHRSP vs WKY demonstrated normal 
distribution. However, skewed distributions were identified in comparisons including any of 
the medium-labelled congenic strains, in both experiments A and B. Specifically, a leftward 
shift was observed for congenic vs WKY (M/L) comparisons, indicating down-regulation of an 
unexpectedly large number of proteins in the congenics, whereas the rightward shift for 
SHRSP vs congenics (H/M) comparisons suggested up-regulation of the majority of proteins 
in SHRSP. Groups of proteins represented by bins (columns) adjacent to log10Ratio=0 (1:1 
ratio) on the x-axis are not differentially expressed between the strains compared. In 
contrast, the longer the distance from 0, the greater the difference in expression levels.  
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Figure  5-4 - Distribution histograms of all proteins quantified per comparison in experiments A and 
B. Normalised protein ratios of each comparison (M/L: congenic vs WKY, H/L: SHRSP vs WKY, H/M: 
SHRSP vs congenic) are plotted on the x-axis using a log10 scale, against the summed peptide 
counts detected in each experiment, on the y-axis. Each bin (column) corresponds to a group of 
proteins sharing similar ratios. Proteins annotated to bins adjacent to log10Ratio=0 (on the x-axis) 
show no or very small expression changes. Proteins groups of positive ratios include up-regulated 
proteins whereas groups of negative ratios contain down-regulated molecules. Data is acquired on 
MaxQuant v1.2.2.6 and histograms are generated on Perseus v1.2.7.4. 
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Similar distribution-patterns were observed in scatterplot representation of relative 
log-ratios of all proteins identified, against summed peptide intensities (light, medium and 
heavy) detected for each protein, in each experiment (Figure  5-5). In this case proteins were 
represented by data points (coloured by density) exhibiting a colour gradient, ranging from 
light-blue to deep-red corresponding from unaltered up to high fold changes. In both 
experiments, distributions appeared shifted for comparisons including any of the medium-
labelled (M) congenic populations, as opposed to normal distributions exhibited in the 
SHRSP vs WKY (H/L) comparisons, with the majority of proteins clustering around 0 (ratio 
1:1). However, peptide distributions seemed to be slightly corrected when compared against 
analyses performed on previous versions of MaxQuant (v1.1.1.25, 1.2.0.18), but were still 
shifted compared to analysis on Mascot Distiller (Figure  5-6). 
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Figure  5-5 – Quantitative scatterplots of all proteins quantified per comparison in experiments A 
and B. Relative protein ratios of each comparison (M/L: congenic vs WKY, H/L: SHRSP vs WKY, 
H/M: SHRSP vs congenic) are plotted on the x-axis using a log10 scale. The abundance of each 
protein is indicated on the y-axis as the sum of the individual peptide intensities detected for each 
protein, in each experiment. Proteins clustering around log10Ratio=0 (light blue dots) show no or 
very small expression changes. Data points are coloured for expression change, with dots in 
yellow/red corresponding to highly regulated proteins. Few of the most regulated molecules are 
annotated in green. Data is acquired on MaxQuant v1.2.2.6 and histograms are produced on 
Perseus v1.2.7.4. 
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Figure  5-6 - Software and version comparison. Quantitative scatterplots of all peptides quantified 
for the comparison H/M: SHRSP vs WKY.SPGla2a in experiment A, as acquired on MaxQuant 
v1.1.1.25, v1.2.0.18, v1.2.2.6 and on Mascot Distiller. Scatterplots are produced on Perseus. 
Relative peptide ratios (normalised) are plotted on the x-axis using a log10 scale. The abundance of 
each peptide is indicated on the y-axis. The majority of peptides exhibit 1:1 ratio and cluster 
around log10Ratio=0. In red: peptides mapping to protein alpha actinin 4 (IPI0023463 - MaxQuant; 
Swissprot q9qxq0 - Distiller). Distiller ratio is inverted to match MaxQuant. 
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The unusual quantification pattern was also obvious when data were uploaded for 
biological interpretation onto IPA as protein lists containing SwissProt/IPI identifiers, 
expression values and FC. Specifically, from 1998 proteins (majority isomers) identified in 
total across experiments A and B by MaxQuant v1.2.2.6, 1736 had mapping IDs on IPA. 
Therefore, the primary focus during the discovery phase was on the SHRSP vs WKY (H/L) 
comparison, which was replicated in both A and B experiments. The reproducibility of the 
results in the two replicates was satisfactory (linear distribution along the diagonal axis) as 
indicated by correlation scatterplot of log-transformed normalised ratios, with no presence 
of distinct populations and the majority of hits clustering around 0 (1:1 ratio) (Figure  5-7A). 
Analysis on IPA identified 1148 proteins in union and 1056 in common (~92%) between H/LA 
and H/LB. 338 and 288, respectively, were significantly differentially expressed (FC ≥ ±1.3), 
'analysis-ready' proteins, exhibiting FC ranging from -12.18/-17.30 to 4.35/4.12 (in 
experiments A and B respectively) (Supplementary tables ‘HLA_analysis ready_338’ and 
‘HLB_analysis ready_288’ included in the hard copy). Not surprisingly, the number of 
significantly differentially expressed proteins appeared to be much larger in comparisons 
that included any of the medium-labelled strains: experiment A: WKY.SPGla2a vs WKY (M/LA): 
778, SHRSP vs WKY.SPGla2a (H/MA): 759; experiment B: SP.WKYGla2a vs WKY (M/LB): 675, 
SHRSP vs SP.WKYGla2a (H/MB): 638. Figure  5-7 illustrates Venn diagrams of these 'analysis-
ready' proteins for several comparisons of interest (Figure  5-7 B,C and D). Overlap in the 
cases of H/LA - H/LB and M/LA - H/MB was substantial, whereas any of the comparisons 
including a medium-labelled strain (M/L, H/M) exhibited low overlap with the parental H/L 
comparisons.  
Based on these outcomes, which support the unusual quantification pattern derived 
from MaxQuant, our further study focused mainly on the SHRSP vs WKY (H/L) comparison. 
From the 203 proteins that were changing significantly in both experiments A and B (Figure 
 5-7B), 141 were consistently up-regulated, 61 were consistently down-regulated 
(Supplementary table ‘common_HLA_HLB_Fold change significant_203’ included in the CD) 
and 18 (~10%) were encoded by genes mapping to chromosome 2 (Table  5-1). Ranking was 
performed on the 203 common IDs, individually in each experiment, and the mean ranks 
were calculated to prioritise proteins for further validation. Numerical data are summarised 
in Figure  5-8A. 
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Figure  5-7 - Bioinformatics analysis of data produced on MaxQuant v1.2.2.6. (A) Correlation 
scatterplot of log-transformed, normalised SILAC ratios determined in H/L A and H/L B 
independent replicates. Plot generated on Perseus v1.2.7.4. (B) Venn-diagram representing the 
overlap of differentially expressed majority proteins (FC≥ ±1.3) quantified in SHRSP vs WKY (H/L) A 
and B comparisons and identified as ‘analysis ready’ on IPA. (C) Venn-diagrams of comparisons of 
interest (M/L: congenic vs WKY, H/L: SHRSP vs WKY, H/M: SHRSP vs congenic).  
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Table  5-1. Differentially expressed proteins in SHRSP vs WKY (H/L) comparison, ‘common’ across 
experiments A and B, encoded by genes mapping to rat chromosome 2. Molecules exhibited 
consistent significant change (FC≥±1.3) and were identified on IPA as 'analysis ready'. Ranking was 
performed on the 203 'common' IDs. Green: down-regulation, red: up-regulation.  
Symbol Protein Names IPI Fold 
Change 
HLA
Fold 
Change 
HLB
Mean 
Ranks 
FC
DHFR Dihydrofolate reductase IPI00200419 -2.184 -2.428 11
HMGCS1 Hydroxymethylglutaryl-CoA 
synthase
IPI00188158 -1.698 -1.834 16
LMNA Lamin-A IPI00188879 -1.506 -1.414 37.5
HIST1H4A Histone H4 IPI00764726 -1.432 -1.439 38.5
ARHGEF2 Rho guanine nucleotide
exchange factor 2
IPI00368617 -1.311 -1.708 42
LXN Latexin IPI00211758 1.327 1.506 101.5
RAI14 Ankycorbin; Retinoic acid-
induced protein 14
IPI00372146 1.414 1.655 124.5
PDLIM5 PDZ and LIM domain protein 5 IPI00210187 1.457 1.360 95
GSTM1 
(Gstm2;Gstm3 )
Glutathione S-transferase Mu 2;
GST class-mu 3; GSTM2-2
IPI00411230 1.569 1.492 124.5
GSTM2 
(Gstm2;Gstm3 )
Glutathione S-transferase Mu 2;
GST class-mu 3; GSTM2-2
IPI00230942 1.569 1.492 123.5
GSTM5 
(Gstm1 )
Glutathione S-transferase Mu 1;
GSTM1-1; Rat glutathione S-
transferase
IPI00231639 1.584 1.400 115.5
Hist2h2aa1/        
Hist2h2aa2
H2A histone family, member X IPI00368293 1.670 1.311 107
HIST2H2AB H2A histone family, member X IPI00569279 1.670 1.311 111
HIST2H2AC H2A histone family, member X IPI00566481 1.670 1.311 109
ITGA1 Integrin alpha-1 IPI00324585 1.739 1.470 136.5
SELENBP1 Selenium-binding protein 1 IPI00208026 1.768 1.958 173
NPR3 Atrial natriuretic peptide
clearance receptor type C
IPI00195882 1.961 1.938 178.5
HEXB Beta-hexosaminidase subunit
beta
IPI00464518 2.386 2.687 196
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Subsequently, biological functions and diseases, pathways and toxicological lists 
relevant to the common (203) differentially regulated proteins (FC ≥ ±1.3) were explored on 
IPA (Figure  5-8B). The analysis revealed ~20% of the changing proteins to be associated with 
"cardiovascular disease" and the "cardiovascular system development and function", 
including regulation of BP. "Inflammation" was also highly affected by ~10% of the identified 
proteins. Oxidative stress, hypertrophy and fibrosis were amongst the top regulated tox 
functions/pathways and were upregulated in SHRSP. Canonical pathway analysis highlighted 
signalling involved in oxidative stress, myogenic tone and vascular remodelling as highly 
regulated. The degree of regulation was expressed as correlation between H/L A (338) or H/L 
B (288) datasets (FC ≥ ±1.3) with each pathway, indicated by -log(p-value). The most 
regulated pathways were "Integrin signalling" (5.72e-15 / 2.35e-10), "NRF-mediated 
oxidative stress response" (1.55e-09 / 3.19e-09), "ILK signalling" (2.46e-09 / 4.01e-08) and 
"RhoA signalling" (5.92e-09 / 3.81 e-0.8); numbers in brackets correspond to -log(p-value) in 
experiment A / B.  
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Figure  5-8 - Correlation analysis in IPA. (A) Table summarising numbers of significantly 
differentially expressed proteins (FC≥±1.3) in the SHRSP vs WKY (H/L) comparison, identified to be 
in union, in common and encoded by chromosome 2 genes across the two experimental replicates, 
H/L A and H/L B. Majority was up-regulated in SHRSP. (B) Lists of top Functions & Diseases, 
Toxicological processes and Canonical Pathways, related to the 203 ‘common’ proteins. Numbers 
in brackets correspond to mapped proteins found to be associated with the respective 
function/pathway. Bar-graphs demonstrate the degree of correlation (-log(p-value)) of the entire 
H/L A (dark blue) and H/L B (light blue) datasets (FC≥±1.3). Orange line on the bar-graphs 
represents the threshold of correlation significance. Green: down-regulation, red: up-regulation.  
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Following the basic function/pathway correlation analysis, top related proteins and 
pathways were investigated further on IPA. Out of the 18 significantly regulated (FC≥±1.3) 
proteins encoded by the chromosome 2 congenic interval (Table  5-1), glutathione S-
transferases (GSTM1, GSTM2: 1.569 / 1.492; GSTM5: 1.584 / 1.400), were up-regulated in 
SHRSP and linked to oxidative stress and free radical scavenging. On the contrary, 
dihydrofolate reductase (DHFR: -2.184 / -2.428) and Rho-guanine nucleotide exchange factor 
2 (ARHGEF2: -1.311 / -1.708) were down-regulated and related to regulation of myogenic 
tone. Lastly, levels of natriuretic peptide receptor C (NPR3: 1.961 / 1.938) and integrin alpha-
1 (ITGA1: 1.739 / 1.470) were enhanced in the hypertensive strain and associated with 
vasodilatation and hypertrophy, and vascular remodelling and fibrosis, respectively. 
(Numbers in brackets correspond to fold change in experiments A / B and data are 
summarised in Table  5-2). 
Further, altered proteins encoded by genes lying outside the congenic interval were 
mapped to pathways involved in BP regulation. In RhoA signalling, one of the regulatory SM-
contraction systems, actin (ACTA1/ACTC1: 2.097 / 2.058, ACTA2/ACTG2: 2.405 / 1.935), 
myosin light-chain (MYL12A/MYL12B: 1.641 / 1.710; MYL6B: 1.750 / 1.636) and MLC-kinase 
(MYLK: 3.316 / 3.617) levels were significantly increased in SHRSP as opposed to down-
regulated ezrin (EZR: -2.656 / -2.547) (Figure  5-9). Caveolin-1 (CAV1: 1.784 / 1.741), also 
increased in SHRSP, was implicated in a number of pathways related to hypertension, such 
as "Caveolar-mediated endocytosis signalling" (Figure  5-10A), "NO signalling in the 
cardiovascular system" (Figure  5-10B). Investigation of the "sphingosine-1 phosphate 
signalling" of interest did not demonstrate any significant regulation across WKY and SHRSP, 
with expression levels of most proteins remaining unaltered. (Figure  5-11A). However, 
assessment of the interconnection between S1P/S1PR1 and the list of differentially 
expressed proteins generated an interesting network (Figure  5-11B). Members of this 
network were implicated in hypertension phenotypes, including vascular remodelling, 
regulation of myogenic tone and oxidative stress. In specific, collagen alpha-1 type III 
(COL3A1: 2.121 / 1.988), cathepsin D (CTSD: 1.301 / 1.362) and superoxide dismutase 2 
(SOD2: 1.374 / 1.378) were up-regulated in SHRSP, as opposed to decreased levels of ezrin 
(EZR: -2.656 / -2.547) and milk fat globule-EGF factor 8 (MFGE8: -1.794 / -1.639). (Numbers 
in brackets correspond to fold change in experiments A / B and data are summarised in 
Table  5-2). 
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Table  5-2. List of highly regulated proteins identified on IPA to be related to processes and 
pathways implicated in hypertension. Proteins exhibited consistent differential expression 
(FC≥±1.3) in the SHRSP vs WKY (H/L) comparisons. Regulation is shown across all SILAC 
comparisons: SHRSP vs WKY (H/L), WKY.SPGla2a vs WKY (M/L A), SHRSP vs WKY.SPGla2a (H/M A), 
SP.WKYGla2a vs WKY (M/L B), SHRSP vs SP.WKYGla2a (H/M B). Red: up-regulation, green: down-
regulation. 
Protein name IPI 
identifier 
Fold change 
(H/L) 
 A            B 
Fold 
change 
(M/L A) 
Fold 
change 
(H/M A) 
Fold 
change 
(M/L B) 
Fold 
change 
(H/M B) 
GSTM1/GSTM2 
IPI00778234/
00230942 
1.569 / 1.492 -10.254 10.024 1.649 1.055 
GSTM5 IPI00231639 1.584 / 1.400 -1.463 1.557 1.288 -1.005 
DHFR IPI00200419 -2.184 / -2.428 -3.169 -1.034 -2.196 -1.767 
ARHGEF2 IPI00949206 -1.311 / -1.708 -1.598 -1.104 -1.842 -1.131 
NPR3 IPI00195882 1.961 / 1.938 1.695 1.143 -2.006 3.278 
ITGA1 IPI00324585 1.739 / 1.470 -2.363 3.746 1.790 -1.126 
ACTA1/ACTC1 
IPI00189813/
00194087 
2.097 / 2.058 -3.231 5.008 1.183 1.330 
ACTA2/ACTG2 
IPI00197129/
00560160 
2.405 / 1.935 -1.737 1.412 -6.556 5.025 
MYL12A/MYL12
B 
IPI00564409/
00914162 
1.641 / 1.710 1.270 1.324 1.356 1.247 
MYL6B IPI00870820 1.750 / 1.636 -6.094 8.196 -2.918 9.690 
MYLK IPI00779078 3.316 / 3.617 1.278 5.559 -1.015 3.265 
EZR IPI00948980 -2.656 / -2.547 -1.410 1.102 -1.663 -1.496 
CAV1 IPI00475476 1.784 / 1.741 -2.421 3.746 -1.812 3.731 
PDGFRB IPI00199968 1.065 / -1.216 1.401 -1.487 1.649 -1.863 
ERK1 IPI00231081 1.136 / 1.010 -1.015 1.059 1.083 1.010 
ERK2 IPI00199688 -1.074 / -1.163 -1.000 1.062 -1.039 -1.163 
COL3A1 IPI00366944 2.121 / 1.988 -2.086 5.012 1.485 2.990 
CTSD IPI00421525 1.301 / 1.362 -2.751 4.136 -1.788 5.412 
SOD2 IPI00211593 1.374 / 1.378 -12.107 11.540 -2.305 13.659 
MFGE8 IPI00188896 -1.794 / -1.639 -1.579 2.372 1.941 -2.427 
NQO1 IPI00231595 -2.711 / -2.784 -20.144 4.768 -5.684 6.748 
HMOX1 IPI00206626 -2.080 / -2.364 -1.179 -2.008 2.666 -4.067 
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Figure  5-9 - Schematic representation of RhoA signalling and mapping of differentially expressed 
proteins identified in SHRSP vs WKY (H/L) comparison. Actins (ACTA1/ACTC1, ACTA2/ACTG2) 
myosin light-chain (MLC: MYL12A/MYL12B, MYL6B) and MLC kinase (MLCK) were consistently up-
regulated in SHRSP, in both A and B experiments. Ezrin (EZR) was consistently down-regulated. The 
pathway was generated on IPA and overlaid with the H/L A dataset of the 203 'common' with H/L 
B proteins. Proteins involved in the pathway are indicated with their IPA names and FC. Colour 
key: red: up-regulated, green: down-regulated, grey: not changing, white: not identified. For 
molecule shapes and relationship labels and types see Figure 2.4 in M&M. 
 
Sofia Tsiropoulou Chapter 5 164 
 
Figure  5-10 - Schematic representation of top canonical pathways of caveolin-1 (CAV1). CAV1 was 
consistently up-regulated in SHRSP vs WKY, in both A and B experiments (FC= 1.784 / 1.741) and 
was associated with pathways related to BP regulation, such as caveolar-mediated endocytosis (A) 
and nitric oxide signalling in the cardiovascular system (B). Pathways were generated on IPA and 
overlaid with the H/L A dataset of the 203 'common' with H/L B proteins. Proteins involved in the 
pathways are indicated with their IPA names and FC. Colour key: red: up-regulated, green: down-
regulated, grey: not changing, white: not identified. For molecule shapes and relationship labels 
and types see Figure 2.4 in M&M. 
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Figure  5-11 - Schematic representation of sphingosine-1 phosphate (S1P) signalling and mapping of 
differentially expressed proteins identified in SHRSP vs WKY (H/L) comparison. (A) The S1P 
signalling pathway was not significantly regulated. (B) The network generated by S1P/S1PR and the 
list of differentially expressed proteins (203) was highly-regulated. Collagen alpha-1 type III 
(COL3A1), cathepsin D (CTSD) and superoxide dismutase 2 (SOD2) were up-regulated in SHRSP. 
Ezrin (EZR) and milk fat globule-EGF factor 8 (MFGE8) were decreased, whereas platelet-derived 
growth factor receptor (PDGFRB) and extracellular signal-regulated kinase (ERK1: 1.136 / 1.010; 
ERK2) remained unaltered. The pathway and network were generated on IPA and overlaid with the 
H/L B dataset of the 203 'common' with H/L A proteins. Proteins involved are indicated with their 
IPA names and FC. Colour key: red: up-regulation, green: down-regulation, grey: not changing, 
white: not identified. For molecule shapes and relationship labels and types see Figure 2.4 in 
M&M. 
Lastly, DHFR and NPR3 were two proteins that demonstrated significant regulation of a 
particular pattern of interest across comparisons with the 2a congenic strains (medium-
labelled). Specifically, when WKY.SPGla2a was compared to WKY (M/L A: -3.169_DHFR, 
1.695_NPR3), the differential expression followed same direction of change as in the SHRSP 
vs WKY (H/L A: -2.184_DHFR, 1.691_NPR3) comparison. Moreover, protein levels remained 
unaltered between SHRSP and WKY.SPGla2a (H/M A: -1.034_DHFR, 1.143_NPR3). In contrast, 
comparisons of the SP.WKYGla2a with the parental strains did not reveal a consistent pattern 
between the two protein levels. DHFR levels were decreased in SP.WKYGla2a compared to 
WKY (M/L B: -2.196) and increased compared to SHRSP (H/M B: -1.767). NPR3 regulation 
was down in the SP.WKYGla2a when compared to either of the parental strains (i.e. M/L B: -
2.006 and H/M B: 3.278). 
Sofia Tsiropoulou Chapter 5 167 
5.2.2 Immunoblotting validation 
To validate proteomic changes revealed by SILAC, eight of the significantly regulated 
proteins in the SHRSP vs WKY (H/L) comparisons were chosen to be analysed by WB, in the 
same VSMCs used for the proteomic analysis (section 2.3). The candidate proteins were: 
NAD(P)H quinone oxireductase-1 (NQO1) and heme oxygenase-1 (HMOX) - down-regulated 
in SHRSP in the proteomics analysis; glutathione S-transferase mu-1 (GSTM5), caveolin-1 
(CAV1), natriuretic peptide receptor C (NPR3) and alpha-SM-actin2 (ACTA2) - up-regulated in 
SHRSP in the proteomics analysis (Table  5-3). The 2a congenic strains were also included in 
the WB analysis. The experimental design of the 30min S1P-stimulation of mesenteric, 
primary VSMCs, was identical to the one used for the SILAC-proteomic analysis, excluding 
the use of isotopically labelled-media. 
The 30min S1P-stimulation did not cause any changes in the levels of the proteins 
examined, as expected (Figure  5-12). HMOX1 exhibited a trend to decrease in SHRSP vs WKY, 
unlike NQO1 which seemed unaltered. CAV1, GSTM1 and ACTA2 also showed a trend to 
increase in the hypertensive strain. Finally, NPR3 demonstrated a trend for up-regulation in 
SHRSP vs WKY. More specifically, NPR3 levels tended to be higher in the WKY-congenic 
(SP.WKYGla2a) compared to WKY and at the same levels as SHRSP. Further, the SHRSP-
congenic (WKY.SPGla2a) showed a decreased trend compared to SHRSP and similar levels to 
WKY. 
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Table  5-3. List of proteins selected for immunoblotting validation. Proteins were identified in the 
SILAC-proteomics analysis as differentially regulated (FC ≥ ±1.3) in SHRSP vs WKY (H/L), ‘common’ 
across experiments A and B. Ranking was performed on these 203 'common' IDs. 
Protein name Rank 
(FC_H/L) 
FC                 
 H/L A       H/L B 
FC 
M/L A 
FC 
H/M A 
FC 
M/L B 
FC 
H/M B 
NQO1  
NAD(P)H dehydrogenase 
quinone 1 
5.5 -2.711 / -2.784 -20.144 4.768 -5.684 6.748 
HMOX1  
Heme oxygenase 1 
12 -2.080 / -2.364 -1.179 -2.008 2.666 -4.067 
GSTM1 
Glutathion S-transferase 
mu 1 
115.5 1.584 / 1.400 -1.463 1.557 1.288 -1.005 
CAV1  
Caveolin 1 
167 1.784 / 1.741 -2.421 3.746 -1.812 3.731 
NPR3  
Natriuretic peptide 
receptor C 
178.5 1.961 / 1.938 1.695 1.143 -2.006 3.278 
ACTA2  
Alpha-actin-2, smooth 
muscle 
184.5 2.405 / 1.935 -1.737 1.412 -6.556 5.025 
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Figure  5-12 - Western blot analysis of selected proteins identified in the SILAC study. Primary 
VSMCs from WKY, SHRSP and the 2a congenics were treated with vehicle (control) or stimulated 
with S1P (10
-6
M), for 30mins in the same way as in the SILAC experiments. Protein loaded:  40-
50µg. Membranes were probed with the indicated antibodies. Top panels, representative 
immunoblots for HMOX1, CAV1, GSTM1 (left); NQO1, NPR3, ACTA2 (right) and respective β-actin 
and GAPDH loading controls. Bottom, corresponding bar graphs demonstrating the change 
(arbitrary units) in protein levels before and after stimulation, across the four strains. 
Quantification data were normalised to either GAPDH or β-actin. Results are the mean ±SEM of 2 
or 3 individual experiments, compared by Student's t-test (unpaired, two-tailed).  
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5.3 Discussion 
Previous microarray analysis and sphingosine signalling studies identified altered S1pr1 
expression and signalling profiles between WKY and SHRSP. To overcome difficulties faced 
during low-throughput characterisation of S1PR1 expression and signalling (chapter4) and to 
further investigate effects of altered sphingosine signalling on BP regulation, comprehensive 
MS-based proteomic screening was employed. By combining the power of SILAC labelling 
and reciprocal congenic strains, SP.WKYGla2a and WKY.SPGla2a, along with the WKY and 
SHRSP parental strains, we aimed to more accurately and reliably characterise traits 
underlying phenotypic differences in hypertensive rat models. Proteomic alterations 
occurring upon 30min S1P-stimulation, as well as genetically driven proteomic differences 
across the four strains were quantified in whole cell proteome of primary VSMCs from 16 
week old animals.  
Using triple-SILAC labelling, optimal comparison of four strains proteome was achieved 
in just two experiments. Moreover, the WKY vs SHRSP comparison was replicated twice 
allowing for testing of the technique reproducibility. Cell growth rate and morphology was 
not affected when cells were transferred in SILAC/dFBS media, minimising the chances that 
the observed proteome differences are the result of this treatment. Mixing equal numbers 
of differentially SILAC-labelled intact-cell populations at an early stage in the process 
minimised relative quantification errors, as an identical workflow was followed thereafter. 
The increased quantitative accuracy of this method was evident by similar abundance 
(score) of L(light), M(medium) and H(heavy) SILAC-peptides of housekeeping proteins, 
according to MS/MS spectra preview on Mascot. Extensive separation of intact proteins, 
with SDS-PAGE and subsequent LC, significantly reduced complexity of samples, permitting 
deeper proteome coverage. Trypsin digestion of protein mixtures generated chemically 
identical peptides, yet isotopically distinct, allowing for accurate identification and relative 
quantification of SILAC-peptides by MS. Finally, extensive processing of MS/MS data in 
MaxQuant removed noise, contaminants and low confidence hits, and normalised SILAC-
peptide ratios to further correct for any cell-mixing errors, while assuming that the majority 
of proteins were not deferentially expressed.  
Despite the initial objective of the experiment to detect effects of the 30min S1P-
stimulation, expressed mainly as changes in the phosphoproteome, only a small number of 
highly abundant phospho-peptides were detected. Generally, detection of phosphoproteins 
is considered challenging as they comprise only ~10% of the entire proteome in a cell. It is 
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lately becoming common practice to perform enrichment for particular fractions of interest 
previous to digestion, in order to achieve deeper coverage of fraction specific or low 
abundance proteins (Olsen et al., 2006, Zhang and Peck, 2011). Consequently, in our 
experiment, it is expected that the majority of detected protein differences would most 
likely be driven by genetic differences across strains rather than the S1P stimulation.  
During the discovery phase of this work, we identified proteins of potential interest by 
setting the fold change (FC) threshold to ±1.3, based on literature reports (Blagoev et al., 
2003, Mann, 2006). This cut-off is stringent enough to filter out the majority of proteins with 
ratios close to 1, without however excluding potentially interesting hits with a small 
magnitude of change. Lists of differentially regulated proteins were subjected to pathway 
analysis on IPA, allowing for biological interpretation of SILAC results in the context of 
published experimental data.  
Our primary focus was on the comparison between the two extreme phenotypes of 
hypertension, SHRSP(H) vs WKY(L), which was replicated twice. Satisfactory reproducibility 
of normalised H/L ratios between A and B experiments, as well as 1:1 H/L ratios for the 
majority of proteins in each experiment indicated good performance and SILAC 
quantification accuracy. Using IPA, significantly regulated proteins, in common between H/L 
A and H/L B, were highly correlated with CVD and a number of biologically relevant 
phenotypes and processes including BP, vascular reactivity, hypertrophy, oxidative stress 
and inflammation. Moreover, canonical pathway analysis further highlighted signalling 
associated with these processes, such as NRF2-mediated oxidative stress response 
(antioxidant pathway), Rho family GTPases / RhoA signalling (vascular contractility) and 
integrin / actin cytoskeleton signalling (cytoskeletal reorganisation). Interestingly, several of 
the regulated proteins involved in these pathways and almost 10% of all significantly 
regulated proteins in the H/L comparisons, mapped to chrom.2 congenic interval, including: 
GSTM1/GSTM2, GSTM5, DHFR, ARHGEF2, NPR3 and ITGA1. However, examination of their 
direction of change across parental and congenic strains sharing the chrom.2 interval did not 
reveal any consistent patterns of interest. Such results highlight the fact that protein 
expression levels do not solely depend upon the origin of the gene, but also on the 
epigenetics and cellular state.  
• Glutathione S-transferases (GSTM1/GSTM2 and GSTM5), implicated in ROS 
detoxification, were up-regulated in SHRSP, indicating a protective role against increased 
superoxide levels observed in their vasculature (Kerr et al., 1999). However, reduced mRNA 
Sofia Tsiropoulou Chapter 5 172 
and protein levels of GSTM1 detected in their kidneys, compared to WKY (McBride et al., 
2005), most likely imply differences in renal and vascular antioxidant mechanisms.  
• Dihydrofolate reductase (DHFR), associated with oxidative stress and regulation of SM 
tone, was decreased in SHRSP. However, its role is mainly studied in endothelial cells, where 
DHFR regulates tetrahydrobiopterin (BH4) bioavailability, essential in eNOS coupling 
(Crabtree et al., 2009). Reduced DHFR levels in SHRSP are in line with increased superoxide 
in their vasculature (Kerr et al., 1999), as well as the impaired relaxation observed in our 
functional studies (chapter 4). As protein levels are consistent with the WKY.SPGla2a congenic 
data, this suggests that regulation of DHFR expression is dependent on the congenic interval 
and may directly contribute to the pathogenesis of hypertension in this model. In addition, 
increased expression in SP.WKYGla2a vs SHRSP, could support the partial correction of 
endothelial dysfunction demonstrated in chapter 4. 
• Rho-guanine nucleotide exchange factor 2 (ARHGEF2), which activates Rho proteins to 
increase formation of actin stress fibres and regulate SM tone, was decreased in SHRSP. 
According to Yu et al. (Yu et al., 2011), ARHGEF2 down-regulation imply reduced SMC 
proliferation, and it may therefore represent a protective adaptation against the 
hypertrophic phenotype of SHRSP.  
• Natriuretic peptide receptor C (NPR3), primarily expressed in the mesenterium of 
SHRSP (Nagase et al., 1997), was up-regulated compared to WKY. NPR3 mediates C 
natriuretic peptide (CNP) signalling known to be associated with lowering of BP, and exerts 
anti-hypertrophic and anti-inflammatory properties (Scotland et al., 2005a). Further, CNP 
was recently identified as an EDHF factor, therefore implicating NPR3 in regulation of 
vascular reactivity (Chauhan et al., 2003). Increased NPR3 levels in SHRSP are consistent with 
previous data demonstrating higher density in VSMCs from SHRSP vs WKY (Liao et al., 1991). 
This could be interpreted as an attempt to correct high BP, hypertrophy and inflammation 
phenotypes, as well as the hypercontractility and endothelial dysfunction observed in 
chapter 4, or even to compensate for reduced affinity and responsiveness of the receptor, as 
previously shown (Liao et al., 1991). Moreover, the direction of change in the congenic 
strains, imply that NPR3 expression is principally controlled by the interval and is a 
secondary response to the already established hypertensive phenotypes. 
• Integrin alpha-1 (ITGA1), associated with negative regulation of ROS production and 
collagen synthesis, hallmarks of fibrosis (Chen et al., 2004), was increased in SHRSP. Integrins 
are also known to participate in detection of pressure and contraction changes (Martinez-
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Lemus et al., 2005). Therefore, ITGA1 increase could be a protective response against 
pronounced oxidative stress and hypercontractility in SHRSP (chapter 4). Considering the 
direction of change in the congenic strains, it can be assumed that ITGA1 expression is 
primarily regulated by the genetic background rather the congenic interval.  
Apart from the proteins mapping to the congenic interval, differentially regulated 
proteins lying outside the interval were also associated with pathways related to 
hypertension phenotypes, BP regulation and S1P signalling.  
• RhoA/Rock pathway, a regulator of cytoskeletal re-organisation and thus vascular 
tone, was most regulated in SHRSP. Consistent with this finding, previous studies have 
shown up-regulation in mesenteric and aortic VSMC from SHRSP (Moriki et al., 2004, Savoia 
et al., 2005). Moreover, our vascular reactivity data (chapter 4) demonstrated RhoA/Rock as 
the major contraction mechanism in SHRSP MRAs which was impaired, promoting 
hypercontractility. Therefore, the up-regulation of MLC-kinase (MYLK), myosin light-chain 
(MYL12A/MYL12B, MYL6B) and actin (ACTA1, ACTA2) could imply increased contractile 
activity in SHRSP vs WKY, despite no differences in RhoA and Rock levels, which is consistent 
with previous findings in aortic VSMCs (Moriki et al., 2004). On the contrary, a downstream 
target of Rock, ezrin (EZR), an actin-binding protein, was down-regulated, perhaps as a 
defence mechanism attempting to lower the activity of the pathway. 
• Caveolin-1 (CAV1), the main component of caveolae, highly expressed in rat vascular 
SM (Voldstedlund et al., 2001), was up-regulated in SHRSP compared to WKY and 
SP.WKYGla2a. It is known to induce RhoA activation in rat MRAs (Dubroca et al, 2007), 
consistent with the hypercontractility we observed in SHRSP (chapter 4). Furthermore, CAV1 
overexpression in vascular myocytes has been shown to attenuate growth by inhibiting 
PDGF proliferative responses (Peterson et al., 2003), which is critical since PDGFR signalling 
is up-regulated in hypertension (Tabet et al., 2005, Yogi et al., 2011). In addition, CAV1 has 
been implicated in S1P/S1PR1 signalling in endothelial cells, through direct interaction with 
S1PR1 in caveolae, which is crucial for endothelial barrier integrity and eNOS activation 
(Igarashi and Michel, 2000, Singleton et al., 2009). Such findings encourage further studies 
on the role of CAV1 in VSMC of hypertensive animals. 
• The S1P/S1PR1 signalling canonical pathway was not significantly altered between 
WKY and SHRSP and the receptor levels were below detection. Moreover, PTMs mediating 
enhanced signalling in SHRSP upon 30min S1P-stimulation (Yogi et al., 2011)  could not be 
observed in global proteome screening. Nevertheless, in a broader S1P/S1PR1 interaction 
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network a number of interesting proteins were highly changing. More specifically, enzymes 
positively related to oxidative stress responses, including superoxide dismutase 2 (SOD2) and 
cathepsin D (CTSD) (Roberg, 1998, Tiwari et al., 2008), were increased in SHRSP, exerting a 
potentially protective role. These enzymes have also been implicated in attenuation of VSMC 
proliferation and migration (Wang et al., 2012a) and hypertrophy of aortic VSMC from SHR 
(Fukuda et al., 1999), respectively. Other regulated proteins of the network were also 
associated with vascular structure and mechanics. Increased mRNA levels of collagen alpha-1 
type III (COL3A1) have been related to fibrotic stiffness of MRA in aged rats (Briones et al., 
2007, Campbell et al., 1991) and the increased protein levels observed here could therefore 
explain the increased stiffness of MRAs from SHRSP observed in our functional studies 
(chapter 4). Further, up-regulated levels of ezrin (EZR) and milk fat globule-EGF factor 8 
protein (MFGE8) have been detected in proteomic screenings of pulmonary hypertensive 
mice (Veith et al., 2013) and of aortas from rats with chronic kidney disease exhibiting 
arterial stiffness (Lin et al., 2010), respectively. EZR has also been associated with SMC 
hypertrophy and increased vascular resistance in pulmonary artery of rats with induced 
inflammation (Dai et al., 2006), while MFGE8 has been shown to induce aortic VSMC 
proliferation in aged rats (Wang et al., 2012b). Hence, the decreased levels observed in our 
SHRSP may reflect protective adaptations. Interestingly, the above proteins exhibited 
consistent direction of change across the comparisons between SHRSP vs WKY and 
SP.WKYGla2a, reflecting regulation of their expression by the WKY congenic interval.  
• Finally, two proteins important in the protection against oxidative stress were highly 
down-regulated in SHRSP, which may contribute further to the hypertensive phenotypes. 
Heme oxygenase-1 (HMOX1) is an enzyme shown to regulate myogenic tone, reduce BP in 
SHR and counteract oxidative stress (Datla et al., 2007, Escalante et al., 1991, Sammut et al., 
1998), as well as to restore high-blood-flow-dependent remodelling and impaired 
endothelial function in MRAs from old Wistar rats (Freidja et al., 2011). The second protein, 
the detoxification enzyme NAD(P)H quinone oxireductase-1 (NQO1) (Zhu et al., 2007), is 
highly expressed in cardiovascular cells and has anti-proliferative effects on VSMCs (Kim et 
al., 2009).  
Despite the fact that several protein expression data from the congenic strains could 
be interpreted in a meaningful way, we have to be careful due to the unusual quantification 
patterns observed in the congenics' comparisons. It is highly likely that such patterns reflect 
issues of the MaxQuant version used in performing triple-SILAC quantification. This 
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assumption is supported by the fact that when MS/MS spectra of housekeeping proteins 
were previewed on Mascot, similar abundance (score) of L, M and H SILAC-peptides was 
observed. Moreover, when data were quantified using Mascot Distiller normal distributions 
were acquired for every (pair) comparison. To confirm our assumption a control, 'cross-over' 
experiment with inverted SILAC labels between the strains could be performed, had there 
not been time limitations. 
Validation of changes observed with MS was performed for some proteins of interest, 
which were identified as single isoforms and exhibited FC>1.5, to enable more accurate and 
easier detection by WB. As expected, levels of these proteins were not changing upon the 
30min S1P-stimulation, consistent with the hypothesis that the observed differences were 
genetically driven. However, WB results did not provide any solid confirmation of the 
proteomic data. Possible explanations could be the small number of WB replicates, the small 
magnitude of protein FC or the sensitivity and specificity of the antibodies. Generally, due to 
inherent variability in a WB, which makes the technique less accurate and reliable, only 
'dramatic' changes can be confirmed. 
In conclusion, identification of proteins previously known to be related with the 
disease, as well as expression changes consistent with the literature validate our workflow 
design, giving more confidence to our data. On the other hand, changing proteins not 
previously reported to associate with the disease, could provide novel knowledge and the 
motive for generation of new testable hypothesis. To further investigate the effect of S1P-
signalling on hypertension and assess contribution of the congenic interval, metabolomic 
screening was conducted on the S1P-treated VSMC used in our proteomics analysis, 
described in chapter 5. 
  
6 Metabolome Profiling in S1P-stimulated 
Mesenteric Primary VSMCs  
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6.1 Introduction 
One of the major strategies in systems biology is integration of data from high-
throughput 'omics' analyses, which promises valuable insights into cellular biology and a 
more holistic and accurate characterisation of the living systems. In the past, such 
approaches were prevented due to the high-complexity of such datasets and the lack of 
powerful analytical software. However, the recent advances in high-resolution and accuracy 
instrumentation, in combination with developed quantitative and statistical platforms and 
databases have opened the way to large-scale integrating studies. To date, the majority of 
such studies come from the areas of plant biology and microbiology (Kromer et al., 2004, 
Maier et al., 2013), primarily due to the lower complexity of such systems. So far, there are 
many less studies integrating data from different platforms for highly complex biological 
systems (Ly-Verdu et al., 2013, Geiger et al., 2010, Zhang et al., 2013). Yet, the number of 
'omics' analyses on complex organisms, including animal models of human diseases as well 
as on biofluids and tissues from human subjects, grows exponentially. This provides the 
potential for a rapid rise of 'omics'-integrating studies in the near future, towards a better 
understanding of the pathophysiology and treatment of chronic diseases, such as EH.  
Upon perturbations of a biological system, response of its homeostatic mechanisms 
results in alterations on its proteome and metabolome. Therefore, comprehensive analysis 
of dynamic changes in the molecular characterisation of living systems should include both 
proteomic and metabolomic profiling. Variations in the metabolic profile, represented by 
changes in metabolites levels, comprise a useful complementary analysis to proteomic 
studies, which identify changes in protein levels, protein-protein interactions and PTMs. 
6.1.1 Aims 
Following the global proteomic profiling of mesenteric primary VSMCs, conducted in 
chapter 5, and studies demonstrating altered sphingosine signalling in VSMCs from SHRSP 
(Yogi et al., 2011), an untargeted metabolomic profiling of these cells was performed in this 
chapter. Metabolome from mesenteric primary VSMCs from 16-week-old WKY, SHRSP and 
the SP.WKYGla2a (SW2a) congenic strains was subjected to HILIC/MS and IDEOM 
bioinformatics analysis aiming to:  
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• investigate metabolic differences under basal conditions (vehicle), across the 
hypertensive SHRSP, the normotensive WKY and the SW2a congenic strain of improved 
BP phenotype (Figure  3-1A),  
• elucidate the metabolic effects of sphingosine signalling (30min S1P-stimulation) within 
each strain and compare the effects across the three strains (Figure  3-1C).  
 
Figure  6-1 - Metabolomics analysis in S1P-stimulated mesenteric primary VSMCs isolated from 16-
week-old WKY, SHRSP and SP.WKYGla2a-congenic strains. (A) Averaged weekly radiotelemetry 
recordings of night-time and day-time SBP in male animals, under baseline and salt-loaded periods 
(high-salt diet at 18 weeks of age) (Edited from Graham et al., 2007). (B) Experimental process. 
Metabolites were separated by ZIC-HILIC, ionised by ESI and directed to Orbitrap Exactive mass 
analyser. Raw peaks were filtered, identified, quantified and statistically analysed through IDEOM 
v18, visualised on PeakML.Viewer and finally uploaded to databases for biological interpretation. 
(C) Experimental design. Four biological replicates of each strain were analysed at basal conditions 
(vehicle) and upon 30min stimulation with spingosine-1-phosphate (S1P).  
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6.2 Results  
Metabolites were extracted from mesenteric primary VSMCs, which had been treated 
with vehicle or S1P for 30min (section 2.2.5), and processed on a ZIC-HILIC/MS platform, as 
detailed in section 2.7. Stringent processing of raw MS data containing thousands of peaks 
(~50.000) using IDEOM v18, led to identification of a relatively small number of positively 
(691_Pos) and negatively (374_Neg) ionised putative metabolites (Figure  6-2A). Correction 
for total MS intensity (TIC; metabolite intensity / sum of all metabolite intensities) was then 
performed to minimise the uncontrollable effect of exogenous factors (quantification 
errors). Identification lists of positive and negative modes were then combined (PosNeg) to 
give the list of putative metabolites to be further analysed: 920_PosNeg (Figure  6-2A). 
The quality of filtered data was assessed by generation of principal component analysis 
(PCA) plots (Figure  6-2B), which represent the profile of a linear combination of the 
metabolites identified for each sample. In the PCA for the PosNeg dataset, in which all 
samples (vehicle and S1P-stimulated) were plotted together, the percentage of PC1 was 
13.9% and of PC2 was 12.7%. Clustering of samples according to strain or to differential 
treatments was not clear. 
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Figure  6-2 - Orbitrap Exactive MS-data filtering and visualisation on IDEOM v18. (A) Peaks were 
picked using XCMS, filtered using mzMatch and matched to a set of databases for metabolite 
identification. The table summarises numbers of putative metabolites identified in the positive and 
negative modes and collectively (posneg), after correcting for total intensity (TIC), across all 
samples and stains. (B) PCA score plots for PosNeg list of putative metabolites, was generated in R 
using data from all strains and both vehicle and S1P-stimulated samples. PC1 and PC2 represent 
the percentages of metabolites that drive the separation of samples along the axes.  
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Subsequently, pair-wise comparisons were performed across strains under vehicle or 
S1P treatment, as well as within each strain before and after the S1P-stimulation. Unpaired 
t-test was utilised to determine significance (p-val <0.05). Approximately 1/10 to 1/30 of the 
identified metabolites were found to be significantly changed in each of the comparisons. 
Around one half of these had KEGG IDs and were qualified as ‘analysis ready’ molecules on 
IPA (Figure  6-3A). During further exploration on IPA, the majority of ‘analysis ready’ 
metabolites were related to ‘lipid metabolism’ and ‘small molecule biochemistry’ processes. 
When associated to canonical pathways, diseases and toxicological functions, the relatively 
few metabolites were, mostly, individually mapped to different processes rather than 
highlighting a few common ones. Therefore, an individual investigation of potentially 
interesting molecules was followed, including the significant metabolites that were not 
mapped on IPA (no KEGG ID) (Figure  6-3B). 
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Figure  6-3 - Comparisons of interest across WKY, SHRSP and SW2a-congenic strains, under control 
and S1P-treated conditions. (A) Comparisons were performed either across the stains or within 
each stain, before and after S1P-stimulation. Table summarises numbers of putative metabolites 
identified in positive and negative modes collectively (total), of metabolites changing significantly 
(p-val <0.05), and of significant metabolites mapped on IPA (‘analysis ready’), in each comparison. 
(B) Venn-diagrams of significantly changing metabolites for comparisons of interest. Data acquired 
on IDEOM v18. 
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6.2.1 Metabolic differences across strains at basal conditions 
To investigate the metabolic components that are potentially implicated in BP 
regulation the metabolome of VSMCs was compared across the three strains, under basal 
conditions (vehicle). The ratio of significantly changing metabolites to total metabolites 
identified for each of the comparisons was: SHRSP_v_WKY (20/778); SHRSP_v_SW2a 
(25/782); SW2a_v_WKY (12/776) (Figure  6-3A). Most changes were observed between 
SHRSP_v_WKY (16 unique) and SHRSP_v_SW2a (17 unique) (Figure  6-3B; top left venn-
diagram). The main focus was on intersects between comparisons, as they are likely to 
include metabolites regulated by the congenic interval and be beneficial on the VSMC 
phenotype. When SHRSP or SW2a were compared to WKY, no 'in common' metabolites 
were identified. In the comparisons between SHRSP versus WKY or SW2a, four metabolites 
were found to be changing 'in common', consistently decreased in SHRSP. In addition, 
potentially protective metabolites could be included in the 17 unique metabolites identified 
in SHRSP versus SW2a comparison, from which 10 were decreased and 7 increased in SHRSP. 
The decreased metabolites were implicated in nucleotide, amino acid and carbohydrate 
metabolism. Of similar interest were the 16 unique metabolites identified to be changing in 
SHRSP compared to WKY, from which 15 were reduced and one raised in SHRSP. From the 
decreased metabolites, 8 were related to lipid metabolism. Table  6-1 summarises data for 
some of the above significant metabolites. Full data are included in ‘vehicle comparisons; 
venns’ supplementary table. 
Additional checking of peak quality for the above metabolites on peakML.Viewer, in 
order to exclude false-positives (e.g. present only in 'standards' or 'quality control' samples, 
peak reproducibility), directed the focus on the four metabolites, whose peaks are illustrated 
in Figure  6-4. [SP (16:0)] N-(hexadecanoyl)-sphing-4-enine-1-phosphocholine was found to 
be consistently decreased in SHRSP compared to WKY and SW2a: FC= -1.314 and -1.242, 
respectively. Homoarginine was reduced in SHRSP versus WKY: FC= -2.040. L-ornithine and 
inosine were also decreased in SHRSP in comparison to SW2a: FC= -14.974 and -1.581, 
respectively. 
Network analysis on IPA mapped few of the metabolites changing significantly in 
SHRSP versus WKY and SW2a to a network implicating molecules related to vascular tone 
modulation and BP regulation. The network included nitric oxide synthase (NOS), tumor 
necrosis factor (TNF), xanthine dehydrogenase (XDH), calcium, cAMP and hydrogen peroxide 
(Figure  6-5). 
Sofia Tsiropoulou Chapter 6 184 
Table  6-1. Subset of metabolites exhibiting significant change in the comparisons across WKY, 
SHRSP and SW2a, under basal conditions. Data were generated on IDEOM v18. Green: decreased 
and red: increased metabolite levels. 
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Figure  6-4 - Levels of significantly changing metabolites in the comparisons across WKY, SHRSP and 
SW2a, at basal conditions (vehicle). PeakML chromatograms illustrate significant (p<0.05) decrease 
of: (A) [SP (16:0)] N-(hexadecanoyl)-sphing-4-enine-1-phosphocholine, in SHRSP versus WKY and 
SW2a; (B) homoarginine, in SHRSP versus WKY; (C) L-ornithine and (D) inosine, in SHRSP versus 
SW2a. The x-axis indicates the retention time and the y-axis the intensity. 
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Figure  6-5 - Ingenuity Pathway Analysis (IPA) network of metabolic changes in SHRSP versus WKY 
and SW2a, in VSMCs under basal conditions. Significantly changing molecules from the two 
comparisons are related to TNF (tumor necrosis factor), NOS (nitric oxide synthase), SMAD3 
signalling protein, calcium (Ca
2+
), xanthine dehydrogenase (XDH), hydrogen peroxide and cyclic 
AMP. (A) Metabolites changing in the SHRSP_v_WKY comparison. (B) Metabolites changing in the 
SHRSP_v_SW2a comparison. Colour indications: green - decrease, red - increase, gray - no change, 
white - not detected. Asterisk indicated more than one potential isomers.  
Sofia Tsiropoulou Chapter 6 187 
6.2.2 Metabolic differences across strains upon S1P-stimulation 
To investigate the metabolic effect of sphingosine stimulation across the strains and its 
association with processes and pathways related to BP regulation, the metabolome of S1P-
stimulated VSMCs was compared across the three strains. The ratio of significantly changing 
metabolites to total metabolites identified in the three comparisons was: SHRSP_v_WKY 
(45/784); SHRSP_v_SW2a (11/784); SW2a_v_WKY (22/786) (Figure  6-3A). The majority of 
changes were observed between SHRSP_v_WKY (36 unique), with SHRSP_v_SW2a exhibiting 
the fewest (9 unique). The main focus was on intersects between comparisons, as they are 
likely to include metabolites affected by the congenic interval and having protective or 
detrimental effect on BP regulation (Figure  6-3B; top right venn-diagram). In the 
comparisons between SHRSP versus WKY or SW2a, one metabolite was found to be 
consistently decreased in SHRSP and it was involved in lipid metabolism. When SHRSP and 
SW2a were compared to WKY, 8 'in common' metabolites were identified. All 8 displayed 
reduced levels in SHRSP and SW2a and they were mapping to different metabolic pathways. 
Moreover, the 36 unique metabolites changing in SHRSP versus WKY were further 
investigated. 20 of them were related to lipid or amino acid metabolism, 22 were decreased 
and 14 increased in SHRSP. Table  6-2 summarises the data for some of the above significant 
metabolites. Full data are included in ‘S1Pcomparisons; venns’ supplementary table. 
Further inspection of peak quality for the above metabolites on peakML.Viewer, 
brought up the three metabolites illustrated in Figure  6-6 as potentially interesting. (S)-3-
methyl-2-oxopentanoic acid was found to be consistently decreased in SHRSP and SW2a 
compared to WKY: FC= -1.649 and -1.362, respectively. Inosine and tyramine displayed 
increased concentrations in SHRSP versus WKY: FC= 2.777 and 5.487, respectively. 
Generation of S1P-network on IPA involved significantly changing metabolites from the 
SHRSP versus WKY comparison, including inosine and tyramine. The metabolites were 
associated with S1P through calcium, cAMP and hydrogen peroxide (Figure  6-7). 
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Table  6-2. Subset of metabolites exhibiting significant change in comparisons across S1P-
stimulated VSMCs from WKY, SHRSP and SW2a. Data were generated on IDEOM v18. Green: 
decreased and red: increased metabolite levels. 
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Figure  6-6 - Levels of significantly changing metabolites in the comparisons across S1P-stimulated 
VSMCs from WKY, SHRSP and SW2a. PeakML chromatograms demonstrate significant (p<0.05) 
decrease of (S)-3-methyl-2-oxopentanoic acid in SHRSP and SW2a compared to WKY (A) and 
increase in the levels of inosine (B) and tyramine (C) in SHRSP versus WKY.  The x-axis indicates the 
retention time and the y-axis the intensity. 
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Figure  6-7 - IPA comparison of S1P-network across S1P-stimulated VSMCs from SHRSP, WKY and 
SW2a. (A) Significantly changing metabolites in the SHRSP_v_WKY comparison are associated to 
sphingosine signalling, involving hydrogen peroxide, cAMP and calcium. These metabolites are 
unique to the comparison and are not changing in (B) SHRSP_v_SW2a and SW2a_v_WKY 
comparisons. Colour indications: red - increase, gray - no change, white - not detected. Asterisk 
indicates more than one isomers. 
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6.2.3 Metabolic effects of S1P-stimulation within strains 
The metabolic effect of sphingosine stimulation was assessed in each strain 
individually, by comparing metabolic profiles under basal conditions and upon S1P-
stimulation. The number of significantly changing metabolites compared to the total number 
of metabolites identified in each strain was: WKYS1P_v_WKYveh (32/783); 
SHRSPS1P_v_SHRSPveh (20/780); SW2aS1P_v_SW2aveh (26/784) (Figure  3-7A). The majority of 
changed metabolites were unique to each strain: union (75); WKYS1P_v_WKYveh (31); 
SHRSPS1P_v_SHRSPveh (19); SW2aS1P_v_SW2aveh (22), with no molecules identified 'in 
common' (e.g. Figure  6-3B; bottom venn-diagram). In WKY the number of metabolites 
exhibiting reduced levels (12) upon stimulation was similar to those with elevated levels 
(19). Many of the decreased metabolites (5) mapped to lipid metabolism, whilst most of the 
increased (8) were related to amino acid and carbohydrate metabolism. In stimulated SHRSP 
the larger number of metabolites was increased (14 out of 19) and related to lipid 
metabolism. Lastly, in stimulated SW2a most metabolites were decreased (17 out of 22) and 
also mapped to lipid metabolic pathways.  The 30 unique metabolites in WKY comparison, 
along with the two common between SW2a and WKY comparisons, were further 
investigated as potentially protective in the sphingosine-related BP regulation. Likewise, the 
19 SHRSP unique metabolites and the one common metabolite between SW2a and SHRSP 
comparisons were examined as potentially deleterious upon S1P-stimulation (Table  6-3). Full 
data are included in ‘S1P_v_veh_comparisons; venns’ supplementary table. 
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Table  6-3. Subsets of metabolites exhibiting significant change upon S1P-stimulation in VSMCs 
from WKY, SHRSP and SW2a. Data were generated on IDEOM v18. Green: decreased and red: 
increased metabolite levels. 
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Subsequent assessment of peak quality for the above metabolites was performed on 
peakML.Viewer. Figure  6-8 illustrates selected peaks of potential interest. Myo-inositol 
(FC=1.477) was increased in S1P-stimulated WKY as opposed to reduced levels of 
homoarginine (FC=-1.908) (Figure  6-8A). In SHRSP, S1P-stimulation caused significant 
increase in inosine (FC=17.152) and N,N-dimethylsphing-4-enine (FC=1.894) concentrations 
(Figure  6-8B). The significance in inosine reduction in S1P-stimulated SW2a (FC=-2.775) 
appeared to be a 'false positive' indication, driven by outliers (Figure  6-8C).    
Generation of S1P-network on IPA involved significantly changing metabolites from 
stimulated WKY, SHRSP and SW2a strains, including homoarginine, N,N-dimethylsphing-4-
enine and inosine (Figure  6-9). In WKY the metabolites were connected to S1P through 
calcium, L-glutamic acid, NOS (nitric oxide synthase) and SMAD3 protein. In SHRSP the 
connections were either direct or involved cAMP-adenosine. Finally, in SW2a the network 
implicated the inflammatory molecules, TNF (tumour necrosis factor), IFNG (interferon 
gamma) and IL6 (interleukin 6). 
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Figure  6-8 - Levels of significantly changing metabolites upon S1P-stimulation of the three strains, 
illustrated as peakML chromatograms. (A) S1P-stimulated WKY demonstrate significant (p<0.05) 
increase of myo-inositol (FC=1.477)) and decrease of homoarginine (FC=-1.908). (B) In S1P-
stimulated SHRSP, inosine (FC=17.152) and N,N-dimethylsphing-4-enine (FC=1.894) exhibit 
increased concentrations. (C) S1P-stimulation in SW2a did not affect inosine levels, despite the 
achieved significance (p=0.0499) due to poor reproducibility of peaks. The x-axis indicates the 
retention time and the y-axis the intensity. 
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Figure  6-9 - Metabolic changes induced by S1P-stimulation of VSMCs in SHRSP, WKY and SW2a and 
mapping to S1P-network. (A) Significantly changing metabolites in stimulated WKY are related to 
NOS (nitric oxide synthase), calcium (Ca
2+
), L-glutamic acid and SMAD3 protein. (B) Changing 
metabolites in stimulated SHRSP are either directly associated with S1P or through cyclic AMP-
adenosine, NOS, (Ca
2+
) and L-glutamic acid. (C) In SW2a the changes are mediated through cyclic 
AMP-adenosine or mainly through inflammatory components (TNF: tumour necrosis factor; IL6: 
interleukin 6; IFNG: interferon gamma). The network was generated on IPA.  Colour indications: 
red - increase, gray - no change, white - not detected. Asterisk indicates more than one isomers.  
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6.3 Discussion 
To complement previous proteomic profiling of primary mesenteric VSMCs across 
WKY, SHRSP and reciprocal 2a-congenic strains, and in order to further investigate the 
altered sphingosine signalling in HTN (Yogi et al., 2011), untargeted metabolomic profiling 
was conducted in primary VSMCs from WKY, SHRSP and SW2a, under basal and S1P-
stimulated conditions. 
Initially, data quality was assessed by PCA plots, where all samples (vehicle and S1P-
stimulated) were plotted together for increased reliability. Relatively low percentages of PC1 
and PC2 as well as not clear clustering of samples imply small differences across and within 
strains, before and after S1P-stimulation. This is further supported by the relatively small 
ratio of significantly changing metabolites to total metabolites identified, across all 
comparisons. However, such a result could be attributed to the small number of replicates 
(N=4) and the dynamic nature of metabolome, which can compromise reproducibility. 
Alternatively, the fact that metabolome is a highly diverse entity which may not be entirely 
characterised by a single analytical platform, may suggest that more significant differences 
exist in a different component of the metabolome that were not identified in this analysis. 
Further investigation of this assumption would be worthwhile by conducting analysis on a 
different platform, or a more specified lipidomic analysis. 
Considering time limitations, from a large number of comparisons across strains and 
conditions, we focused on particular intersects according to the most interesting questions 
to be tested in each case. 
At basal conditions, the SHRSP had more different profile to SW2a and WKY, than the 
SW2a to WKY. This suggests that the congenic interval is having a profound effect on the 
SW2a metabolic profile, which is likely to contribute to their improved BP phenotype. 
Specifically, the majority of changes in SHRSP compared to SW2a indicated decreased 
nucleotide, amino acid and carbohydrate metabolism, whereas comparison with WKY 
showed altered lipid metabolism. This demonstrates that metabolic processes are 
genetically regulated in a different manner across the strains, which are likely to also 
regulate BP. Therefore, the main focus was to identify 'unique' metabolites changing in 
SHRSP versus SW2a and in SHRSP versus WKY, and more importantly to identify 'in common' 
metabolites between these two comparisons, changing in the same direction. These 
molecules were investigated as potentially deleterius against high BP. On an IPA-generated 
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network, several of the altered metabolites were connected, directly or indirectly, to NO, 
Ca2+, cAMP and H2O2, indicating potential association with pathways implicated in vascular 
tone regulation and oxidative stress.  
Inosine and hypoxanthine, two sequential products of the adenine-adenosine (purine) 
metabolic pathway, mapped to the above network through association with NO, uric acid 
and xanthine dehydrogenase (XDH), and were significantly reduced in SHRSP versus SW2a. 
The purine degradation pathway has been implicated in oxidative stress and enzymes such 
as XDH, which uses hypoxanthine as substrate, are known drug targets for CVD (Rekhraj et 
al., 2013, Feig et al., 2008). Moreover, both hypoxanthine and inosine have been identified 
as plasma metabolic biomarkers for myocardial injury (Lewis et al., 2008). The observed 
decreased levels in SHRSP imply increased XDH activity and elevated oxidative stress, which 
is corrected in SW2a by introduction of the congenic interval. Another interesting 
metabolite, which exhibited small but significant reduction in SHRSP compared to SW2a, was 
L-ornithine. In VSMCs arginase hydrolyses L-arginine to produce L-ornithine, which is further 
metabolised into polyamines to promote SMC proliferation and collagen synthesis (Morrison 
and Seidel, 1995, Durante et al., 1998, Durante et al., 2001). Decreased levels in SHRSP may 
imply increased polyamine synthesis and vascular remodelling of MRAs, which is attempted 
to be prevented by the congenic interval in SW2a. In addition, homoarginine, an aminoacid 
derived from lysine and known to inhibit arginase (Hrabak et al., 1994), was decreased in 
SHRSP compared to WKY. Low levels could suggest increased arginase activity influencing 
vascular remodelling in SHRSP. Moreover, low homoarginine concentrations, in plasma, have 
been associated with myocardial dysfunction and increased risk of fatal cardiovascular 
events in human studies (Pilz et al., 2011). Finally, [SP (16:0)] N-(hexadecanoyl)-sphing-4-
enine-1-phosphocholine, also known as palmitoyl sphingomyelin, was an interesting 
metabolite displaying slight, yet significant decrease in SHRSP compared both to WKY and 
SW2a. Not much is known about the specific role of palmyitoyl sphingomyelin in cell 
function and disease. However, the family of sphingomyelins are known to be metabolised 
in ceramide and bioactive lipids, which mediate VSMC proliferation, apoptosis and 
constriction in a number of cardiovascular diseases (Pavoine and Pecker, 2009). Therefore, 
the observed low concentrations in SHRSP could reflect potentially increased levels of 
ceramides in SHRSP, which have not been detected on this analytical platform. 
Upon S1P-stimulation, metabolic profiles of the parental strains exhibited the larger 
number of differences, supporting Yogi’s data (Yogi et al., 2011) on significantly altered 
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signalling induced by S1P between the two strains. Further, SHRSP and SW2a displayed the 
most comparable profiles, which imply similar responses to stimulation. Such result is in 
contrast to the findings under basal conditions, which demonstrated greater similarities 
between SW2a and WKY. Therefore, it becomes obvious that S1P signalling is most likely 
regulated by components lying outside the congenic interval. For this reason, the most 
interesting metabolites to be further examined were those changing 'in common' between 
SHRSP versus WKY and SW2a versus WKY. (S)-3-methyl-2-oxopentanoic acid was one of the 
above metabolites having a consistently decreased trend across SHRSP and SW2a. It is 
known to participate in isoleucine degradation, and has not been related to any other 
processes or diseases. Therefore further investigation on its potential association to BP 
regulation processes is needed. The rest of the 'in common' metabolites presented low 
confidence due to either noisy peakML chromatograms or significance driven by one outlier, 
and they were not pursued further. Subsequently, focus was on the 'unique metabolites 
changing between SHRSP and WKY. Tyramine, a trace amine derived from tyrosine and 
involved in the release of catecholamines, displayed increased concentrations in SHRSP 
versus WKY. Tyramine has been reported to induce vasodilatation in raised-perfusion-
pressure MRAs from Sprague-Dawley rats (Anwar et al., 2012), in contrast to its 
vasoconstrictive effects on mesentery from Wistar (Elliott et al., 1989) and on rat aortic rings 
(Fehler et al., 2010). Consequently, addressing the effects of tyramine on SHRSP 
mesenterium would aid the interpretation of its increased levels in SHRSP. Lastly, inosine 
concentration was elevated in SHRSP compared to WKY but not SW2a. S1P is known to 
regulate accumulation of cAMP in VSMCs (Damirin et al., 2005), which in turn is involved in 
the purine metabolism and can be associated with observed increases in levels of AMP and 
inosine. Considering the significantly decreased levels of inosine in SHRSP versus SW2a at 
baseline, it is obvious that S1P stimulation causes an increase in SHRSP to reach SW2a levels. 
This effect seems to be dependent on the congenic interval and is a priority finding for 
further investigation. 
The last set of comparisons examined changes in the metabolic profiles of each strain 
before and after S1P-stimulation. The majority of changed metabolites were unique to each 
strain, with very few 'in common' metabolites identified. This finding demonstrates 
differential responses of each animal to the stimulation and suggests a combined effect of 
the genetic background and the congenic interval in S1P-signalling. Indeed, on a network 
generated on IPA, with S1P at the apex, metabolites identified in the three comparisons 
Sofia Tsiropoulou Chapter 6 199 
were connected to S1P through intermediate molecules associated with different processes.  
Nonetheless, all three strains appeared to respond to S1P-stimulation mainly through 
alterations in their lipid profile. However, the lack of a larger number of common consistent 
changes between SHRSP and SW2a limits identification of potentially interesting metabolites 
implicated in the altered sphingosine signalling in HTN. This finding may suggest further that 
filtering through SW2a and WKY for identification of candidates for S1P-mediated BP 
regulation is not the most appropriate strategy, at least for the metabolite profile, or that 
another analytical platform is needed to capture these metabolic changes.  
In WKY, S1P-stimulation induced increase in myo-inositol levels. This carbohydrate, 
apart from being the structural component in the synthesis of inositol phosphates, it has 
been reported to prevent and reverse endothelial dysfunction in rat mesenteric vessels, 
through scavenging of superoxide (Nascimento et al., 2006). Therefore, further 
characterisation of its relation to S1P signalling in VSMCs would be of interest. Moreover, 
stimulated WKY exhibited diminished levels of homoarginine, which may impact on arginase 
activity towards VSMC proliferation and collagen synthesis (Hrabak et al., 1994). In SHRSP, 
S1P-stimulation elevated concentration of N,N-Dimethylsphing-4-enine, which is a 
sphingosine kinase inhibitor (Edsall et al., 1998). This metabolite has been implicated in 
reduction of MAPK and NADPH oxidase activities, VCAM1 expression, intracellular calcium 
and formation of actin stress fibres (Wu et al., 2004, Ibrahim et al., 2004, Xia et al., 1998, 
Meyer zu Heringdorf et al., 1998, Hanna et al., 2001). Thus, increased levels upon S1P 
stimulation could be potentially beneficial on VSMC function and structure and consequently 
on BP regulation. Furthermore, inosine was considerably elevated in stimulated SHRSP, 
which suggests that in this strain sphingosine signalling significantly affects purine 
metabolism. This could be mediated by cAMP, which participates in purine metabolism and 
its intracellular levels are known to be regulated by S1P (Damirin et al., 2005, Van Brocklyn 
et al., 1998).  
In conclusion, the effect of the congenic interval on the metabolic profile appears to be 
more profound under basal conditions, whereas S1P signalling may be predominantly 
regulated by components lying outside the interval. However, metabolic responses to 
stimulation seem to be, not surprisingly, a combined effect of the genetic background and 
the congenic interval. Further investigation by use of complementary analytical platforms 
would allow more comprehensive capturing of metabolic changes. Moreover, the putative 
metabolites identified in this analysis, will have to be validated to authentic standards by 
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MS/MS fractionation and verified by WB and enzymatic activity assays, on control and S1P-
stimulated cells, before generation of new testable hypothesis.  
 7 General Discussion 
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 The growing problem of elevated blood pressure (BP) over the last decades has 
become one of the major contributors to the present pandemic of cardiovascular disease 
(CVD) (Levenson et al., 2002b, Carretero and Oparil, 2000). Hypertension (HTN) is a trait of 
large phenotypic variance with a clear genetic predisposition (Franceschini et al., 2011). By 
2025, approximately 1.56 billion adults are predicted to suffer from essential hypertension 
(EH), which makes the need for better understanding of its pathophysiology and genetics 
highly pressing. Over the past few years, an increasing number of large scale-genetic studies 
in human, including several GWAS (Levy et al., 2009, Ehret, 2011, Johnson et al., 2011), has 
accelerated the current understanding of the polygenic nature of BP regulation. However, 
only in few cases the reported SNPs implicate a specific gene of high effect (Padmanabhan et 
al., 2010) and, collectively, they represent, only a small fraction of BP heritability and have 
small size effects that do not explain BP phenotypic variance. This could be attributed to 
multifactorial upstream regulation of the candidate gene expression, as well as downstream 
regulation of the protein levels and activity, which would be reflected on the metabolic 
profiles of cells, tissues, organs and ultimately on the phenotype. 
To further dissect the genetic components of EH, the present study employed high-
throughput, untargeted proteomic and metabolomic profiling, on a well characterised 
animal model of human EH, the SHRSP. These high-resolution powerful approaches were 
combined with chr.2 congenic stains, which had been previously generated in our laboratory 
using the SHRSP and WKY parental strains and had confirmed that the congenic interval is 
involved in BP regulation. Our results demonstrate that the chr.2 congenic interval affects BP 
phenotype through regulation of vascular reactivity and mechanics of resistance arteries, 
and that these events are primary to vascular remodelling. Alterations in vascular reactivity 
are confirmed at the molecular level in the proteomic and metabolomic screenings, along 
with highly de-regulated antioxidant responses. Finally, proteomics analysis identifies up-
regulation of NPR3 in SHRSP, a protein which is correlated to a GWAS discovery in humans.  
Below are discussed in more detail the aims of this work, the results in association to 
existing knowledge as well as the potential and limitations of our studies.  
The SHRSP is an experimental rat model resembles the human pathophysiology of HTN 
and has been used extensively in high-throughput genomic studies, offering the advantage 
of increased genetic homogeneity. Previous genetic linkage studies have identified QTLs 
associated with BP regulation and salt-sensitivity on chr. 2, 3 and 14 (Luft et al., 1988, 
McBride et al., 2005, McBride et al., 2003). Construction of chr.2 reciprocal congenic stains 
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in our laboratory, using SHRSP and WKY as the parental stains, combined with microarray 
gene expression profiling in kidney from salt-loaded rats, identified positional candidate 
genes for salt-sensitive hypertension. Sphingosine-1-phosphate receptor 1 (S1pr1) and 
vascular adhesion molecule (Vcam1) lie on the chr.2 congenic interval implicated in salt-
sensitivity and were differentially expressed across the strains (Graham et al., 2007). 
Additionally, glutathione S-transferase mu 1 (Gstm1) was identified as another chr.2 
positional and functional candidate for BP regulation, lying outside the region implicated in 
salt-sensitivity (McBride et al., 2003). Construction of congenic strains has been widely used 
for the dissection of QTLs and identification of candidate genes underlying complex, 
multifactorial diseases (Wallace et al., 2004, Kumarasamy et al., 2011, Ariyarajah et al., 
2004). 
However, as differential expression profiling of candidate genes at the mRNA level, 
does not always correlate with phenotypic variance, alterations at the protein and 
metabolite levels need to be investigated in order to obtain a clearer picture of 
multifactorial traits such as HTN. Use of large-scale proteomic and metabolomic screenings 
are becoming essential for comprehensive characterisation and comparison of phenotypic 
alterations induced by genomic changes, at health and disease (Geiger et al., 2010, Mittler et 
al., 2009). Such high-resolution, system-wide, (semi)-quantitative approaches offer new 
potential in post genomics and systems biology. However, analysis and interpretation of 
such gigabyte-large datasets remain challenging.  
The present study combined shotgun proteomics and metabolomics, with chr.2 
congenic and Gstm1-transgenic strains, aiming to identify potential biomarkers for EH and 
salt-sensitivity, as well as altered processes in HTN related to S1P/S1PR1 signalling and 
regulated by the congenic interval. Comparison of the parental WKY and SHRSP strains, 
exhibiting two extreme BP and salt-sensitivity phenotypes, with the SW2k-congenic, the 
SW2a and WS2a reciprocal-congenic and the Gstm1-transgenic strains of intermediate BP 
and salt-sensitivity phenotypes, offered the potential of more restrictive identification of 
components underlying these differences. Moreover, during these studies, 3 major 
disciplines were combined: biology for sample preparation, analytical chemistry for sample 
processing and bioinformatics for data analysis.  
Initially, untargeted metabolomic profiling was performed in urine and plasma from 
normal-salt and salt-loaded parental, SW2k-congenic and Gstm1-transgenic rats. Given the 
different BP phenotypes, the aim was to assess the role of the congenic interval and Gstm1 
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on salt-sensitivity and BP-regulation and identify putative biomarkers. The rich metabolic 
content of urine and plasma, consisting of building blocks and by-products of processes 
occurring throughout the organism, classifies them as biological samples of high prognostic 
and diagnostic value in the biomarker research (Giovane et al., 2008, Barderas et al., 2011). 
Moreover, recent untargeted metabolomic studies were able to associate distinct urine 
metabolite signatures to specific QTLs, suggesting a global impact of genetic loci on 
metabolic pathways (Cazier et al., 2012). In our study, quantitative changes of L-proline and 
linoleic acid in plasma, under normal-salt, were unique to SHRSP, indicating regulation of 
their metabolic pathway by the congenic interval and potential association with Gstm1. 
Upon salt-loading, oleic acid in urine and glutathione disulfide and S1P in plasma, exhibited 
different pattern of change in salt-sensitive versus salt-resistant strains. This demonstrates a 
regulatory role of the congenic interval in salt-loaded conditions, but not of Gstm1, which 
was expected, as this gene is not a candidate for salt-sensitivity. The majority of altered 
metabolites were associated with lipid metabolism, inflammatory response and free radical 
scavenging processes previously shown to be altered in salt-sensitive rats and associated 
with cardiovascular disorders (Spijkers et al., 2011, Liu et al., 2012).  
Subsequently, due to the importance of the resistance vasculature in BP regulation, 
the effect of the congenic interval on structure, mechanical properties and vascular 
reactivity of MRAs was investigated, in parental and 2a-reciprocal congenic strains. 
Remodelling of vessels at 16 weeks of age was not observed across the strains, suggesting 
that structural alterations develop later in life as an adaptive response to increased BP. 
However, MRAs from SHRSP exhibited a tendency to be stiffer, whereas the congenic strains 
displayed an intermediate phenotype, implicating the congenic interval. The above data are 
supported by studies in 24-week-old animals, which demonstrated no significant alterations 
in vessel structure but increased intrinsic wall stiffness in SHRSP/SHR versus WKY (Arribas et 
al., 1997, Gonzalez et al., 2006). However, the effect of the congenic interval was more 
obvious in the vascular reactivity studies, where it corrected for hypercontractility but not 
for the endothelial dysfunction observed in SHRSP, when introgressed into SW2a congenic 
rats. Hypercontractility in SHRSP implicated RhoA/RhoK pathway which is supported by 
studies on hypertensive rat models (Moriki et al., 2004, Kitazono et al., 2002) and is 
potentially affected by the congenic interval. Endothelial dysfunction in the SHRSP and SW2a 
was mediated by NO bioavailability, as shown previously (McIntyre et al., 1997, Kerr et al., 
1999, Ma et al., 2001) and appeared to be independent of the congenic interval. In the 
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reciprocal WS2a congenic strains detrimental effects were not identified, suggesting that 
elements outside the interval regulate these processes or compensate for the loss of the 
'healthy' genes.  
Further investigation of these differences in the vasculature between the stains was 
performed at the molecular level, through MS-based quantitative proteomic analysis of 
primary mesenteric VSMC from the parental and 2a-reciprocal congenic strains. Use of 
triple-SILAC labelling allowed for three-way comparisons across the strains. However, 
challenges in the bioinformatics analysis directed the focus on the comparison between WKY 
and SHRSP. Not surprisingly, differentially regulated proteins were associated to processes 
implicated in BP regulation and HTN, including oxidative stress, vascular tone regulation and 
remodelling. Increased GSTM1 levels in the primary VSMCs from SHRSP, as opposed to 
previously described reduced mRNA and protein levels in the kidney (McBride et al., 2005), 
suggest differences in vascular and renal antioxidant mechanisms. This is further supported 
by the observed reduction in SHRSP, of HMOX and NQO1 detoxification enzymes of the Nrf2 
(nuclear factor (erythroid-derived 2)-like 2) pathway, which has been found to be up-
regulated in the kidney antioxidant response (Wilmes et al., 2011, Zoja et al., 2013). 
Moreover, NPR3, which maps to the chr.2 congenic interval, was up-regulated in SHRSP. As a 
receptor of C natriuretic peptide (CNP), an identified EDHF factor (Laurant et al., 1997), NPR3 
increased levels could be interpreted as an attempt of SHRSP to correct for 
hypercontractility and endothelial dysfunction, which was observed in MRAs. Furthermore, 
in support of the data implicating RhoA/Rock signalling in MRA hypercontractility, this 
pathway was found to be significantly altered in SHRSP during the proteomics analysis and 
CAV1 which induces RhoA activation (Dubroca et al., 2007) was also up-regulated in SHRSP. 
Lastly, proteins related to sphingosine signalling were also differentially expressed in SHRSP, 
including down-regulated EZR, a member of the RhoA/Rock pathway, and up-regulated 
SOD2 and CTSD antioxidant enzymes, as well as COL3A1, which has been implicated in 
stiffness of MRAs and therefore supports the findings of the myography functional studies 
(Briones et al., 2007, Campbell et al., 1991).  
To further investigate the effect of S1P-signalling on HTN and assess contribution of 
the congenic interval, metabolomic screening was conducted on VSMC used in the 
proteomics analysis, at basal conditions and upon S1P-stimulation. Under basal conditions, 
the effect of the congenic interval was more profound on the metabolic profile of SW2a, 
which may be linked to their improved BP phenotype. S1P-stimulation induced more 
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differences in the metabolic profiles of SHRSP v WKY, which is supported by altered S1P 
signalling in VSMCs (Yogi et al., 2011). Differences between SHRSP and SW2a were fewer, 
suggesting that S1P signalling is predominantly regulated by components outside the 
congenic interval. However, responses to stimulation were different across all strains which 
suggests a combined effect of the genetic background and the congenic interval on S1P 
signalling regulation and implies that filtering through the SW2a congenic strain for 
identification of candidates for S1P-mediated BP regulation, may not by the most 
appropriate strategy, at least in the VSMC metabolite profiling. Two interesting metabolites 
were elevated in stimulated SHRSP compared to the other strains. Effects of S1P-signalling 
on inosine levels appeared to be mediated by the congenic interval, which suggests that in 
SHRSP, sphingosine signalling significantly affects purine metabolism potentially through 
cAMP (Damirin et al., 2005, Van Brocklyn et al., 1998). Additionally, S1P-signalling in SHRSP 
may be related to BP-regulation through tyramine, which has vasodilatory properties in rat 
MRAs (Anwar et al., 2012) and could have a protective role against the hypercontractility 
described in the myography studies.  
Collectively, this study followed a holistic approach aiming to capture a clearer picture 
of the genetic determinants underlying BP regulation in the SHRSP. Combination of high-
throughput proteome and metabolome profiling with chr.2 congenic and transgenic strains 
allowed identification of candidate metabolites and proteins whose altered quantitative 
profiles may underlie salt-sensitivity, sphingosine signalling and BP regulation in SHRSP. 
Validation and functional characterisation of these candidates and the implicated pathways 
is the essential step before any further translational studies are curried out in humans. One 
major finding of our study, which could be correlated to a GWAS discovery in humans, is the 
differential protein expression levels of NPR3 in SHRSP. The largest GWAS meta-analysis of 
>200.000 human subjects identified NPR3 - C5orf23 as one of the 29 loci harbouring 
validated SNPs associated with systolic BP (Ehret, 2011). Therefore, further work needs to be 
prioritised towards the elucidation of the pathways linking NPR3 and HTN. Particular focus 
should be placed on pathways implicated in regulation of vascular reactivity in resistance 
arteries, based on the results from our vessel-myography functional studies and the 
knowledge that CNP has been identified as a potential EDHF in vasodilation (Chauhan et al., 
2003). However, it should be kept in mind that translating results from animal models into 
human HTN has proven challenging. The best maybe example coming from GWAS studies, to 
this day, is uromodulin (UMOD), whose discovery in humans was extended to a umod KO 
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mouse model, identifying a novel pathway linking UMOD, sodium homeostasis, and HTN 
(Graham et al., 2014). Moreover, the challenge of multiple causative genes mapping to a 
single GWAS locus, making genetic dissection of the polygenic trait of HTN more complex, 
needs to be circumvented. Recent studies, have shown phenotypic contributions of the five 
out of six genes within the AGTRAP-PLOD1 GWAS locus (Johnson et al., 2011) on CVD 
phenotypes in a rat model of HTN, many of which were previously unattainable in the 
human population. The approach used was introduction of mutations to each of the genes 
within the locus. (Flister et al., 2013).  
The fact that GWAS studies have been unable to identify genetic variants of relatively 
large influence on physiologic responses in HTN, can be attributed to multifactorial 
determination of expression of such traits, as discussed above, and compensatory 
mechanisms. Transcriptional regulation, protein post-translational modifications (PTM) and 
protein-protein interactions could either alter or abolish the function of proteins encoded by 
GWAS candidate genes. Altered protein function could in turn lead to dramatic changes in 
the metabolite profile of cells, tissues, organs and to an ultimately changed phenotype. The 
potential regulatory interactions across the different layers of information in a biological 
system are illustrated in Figure  7-1A. Integration of large 'omics' datasets appears to be the 
next step in studying causal relationships between genes and phenotypic endpoints. A 
growing number of studies support the importance of this integrative approach by 
demonstrating direct functional links between GWAS variants, quantitative metabolic traits 
and an end-point of cardiovascular diseases and identifying new underlying biological 
processes and pathways (Illig et al., 2010, Suhre et al., 2011, Kettunen et al., 2012). In this 
light, the recent generation of SHRSP and WKY genome sequence (Glasgow strains) permits 
integration of transcriptomic with our proteomic and metabolomic studies, towards the 
investigation of the pathophysiology of EH in the SHRSP (Atanur et al., 2013). Rapid and 
continuous development of platforms such as Ingenuity Pathway Analysis (IPA) allow for 
quantitative data integration in cells, tissues or biofluids. Curated knowledge databases are 
used for generation of networks and pathway mapping, which improve the understanding of 
causal network connections across diseases, genes, upstream regulators and intermediate 
metabolic traits. Implementing an integrative approach of high-throughput analyses (Geiger 
et al., 2010, Maier et al., 2013) could lead to identification of genetic variants, signalling 
pathways and metabolic processes that are altered in human disease. (Figure  7-1B) 
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Figure  7-1 - Data integration across the various layers of information. (A) High-level view of 
biological information flow from expression of genes to expression of phenotypes, via the multiple 
'omics' levels of regulation. Adapted from Genomics Sciences Research Complex. (B) Simplified 
schematic of how information from our proteomic and metabolomic studies could be integrated, 
on IPA, with existing genomic and tanscriptomic data, towards identification of candidate 
gene/proteins/metabolites/pathways for further functional validation and generation of new 
hypotheses. Assessment of if and how such findings translate in human EH could lead to a better 
understanding of the disease pathophysiology and lead to generation of new therapeutic targets.  
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Using systems biology tools, data integration could feed into reconstruction of 
dynamic networks with increasing reliability. Moving from working on individual molecules 
to work on networks, which constitute functional processes that link genetic and 
biochemical incidents with biological phenotypes, provide holistic information on living 
systems. Mathematical modelling of network maps provides the means to predict the 
emergent properties of complex systems, such as biological systems, by using sets of 
mathematical rules describing interactions of molecular components (Calder et al., 2010). 
Combination of dynamic network maps with models simulating their mean behaviour allows 
rigorous predictions of the output to specific stimuli, as well as validation of experimental 
data. Applying the predicted models in patho-biological systems at the molecular, cellular, 
tissue/organ and whole animal levels facilitate discovery of novel mechanistic pathways and 
predict the best points at which to intervene to redress the balance. 
Irrespective of how informative robust 'omics' characterisations can be, they still pose 
big challenges during data analysis and interpretation, due to the high technical and 
biological variability as well as complexity of the samples. A simple, basic strategy to ensure 
reproducibility and increase confidence is the use of large numbers (>10) of replicates 
(biological, technical, analytical) in every experimental design (Jankevics et al., 2011). A weak 
point of our work was the small numbers of replicates (N=4) included in our metabolomic 
studies, which may explain the substantial variability observed within groups. Another 
challenge in the application of highly sensitive and automated technologies in 'omics' studies 
has been the identification of false-positives. To circumvent such issues, data normalisation, 
multiple testing analyses and the use of appropriate statistical tests are crucial for detection 
of statistically significant signals. However, in-house packages used in this study were under 
constant development, which made the data analysis process long and exigent. A limitation 
of IDEOM, in the case of the metabolomics analysis, was the use of t-test statistical filtering 
for such a large number of comparisons, which may have led to identification of false-
positive, as it does not account for multiple testing. Therefore, the statistically significant 
results were always confirmed through reviewing of the original raw data. A more 
appropriate statistical test for such large datasets would be the Rank Products (RP) non-
parametric statistical test (Breitling et al., 2004). RP is based on ranks of fold changes and 
multiple testing, using false discovery rate (FDR) significance cut-off, and is about to be 
implemented in the next versions of IDEOM. Furthermore, the limited ability of a single 
analytical platform to screen for the global, highly diverse metabolome makes the use of 
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multi-platform approaches demanding, towards the characterisation of complex diseases 
like EH (Mandal et al., 2012, Suhre et al., 2010, Naz et al., 2013). Moreover, due to the fact 
that several chronic diseases are characterised by altered lipid metabolic profile, including 
CVD, there is a growing interest in the area of shotgun lipidomics (Min et al., 2011, Han et 
al., 2011). In the case of proteomics analysis, the imperfect overlap of identifications from 
different search engines, which is reflected on partial overlap of results from different 
quantification algorithms (Searle et al., 2008, Yu et al., 2010), limits an even more robust 
protein identification. In addition, we still need to understand the issues MaxQuant 
presented during the processing of the triple-labelling SILAC datasets. As several new 
versions of MaxQuant have been released since our analysis, it would be worthwhile re-
processing our proteomic data. Another challenge in proteomics analysis is the validation of 
findings through western blot (WB). The fact that our SILAC-proteomics results were not 
reproducible by WB could be attributed to the small number of WB replicates, the small 
magnitude of protein FC or the sensitivity and specificity of the antibodies. However, it is 
important to stress that, despite generally increased sensitivity of antibodies, the inherent 
variability in a WB makes the technique less accurate and reliable, and only substantial MS 
changes can be confirmed. Moreover, in WB only a single signal-band is quantified, whereas 
MS methods measure several individual peptides per quantified protein and generate 
independent measurements, thus increasing the accuracy of the mean (relative) 
quantification. Therefore WB is seriously questioned as a validation method for MS results 
and maybe reproducibility and consistency of the results across multiple replicates is the 
answer to validity. 
In conclusion, this study combined MS-based (semi-)quantitative proteomics and 
metabolomics approaches with congenic strains, to improve our understanding on 
fundamental pathophysiological processes underlying HTN in SHRSP. Despite big challenges 
in the data analysis process, this work identified altered quantitative profiles of molecules 
and processes in health and disease, which once integrated with data from 'omics' studies at 
the gene level will set the basis for generation of new testable hypothesis, aiming to 
elucidate the underpinning molecular mechanisms of these processes. Furthermore, findings 
from our proteomic and metabolomic analyses that are associated with GWAS genetic loci 
could potentially identify novel pathways which would be translated into new drug therapies 
for human EH.  
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